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DEFINITIONS AND ABBREVIATIONS USED IN THIS THESIS 
Amenorrhea : the time period after the first day of the 
last normal menstrual period expressed in completed days 
or completed weeks. 
Gestational age : the duration of gestation as measured 
from the first day of the last menstrual period expressed 
in completed days or completed weeks. 
Abortion : the expulsion or extraction of a fetus or em-
bryo before the 16th completed week of amenorrhea. 
Immature delivery : delivery after 16 completed weeks and 
before 28 completed weeks of amenorrhea. 
Premature delivery : delivery after 28 completed and be-
fore 37 completed weeks of amenorrhea. 
Term delivery : delivery after 37 completed weeks and be-
fore 42 completed weeks of amenorrhea. 
Preterm : less than 37 completed weeks of amenorrhea. 
Perinatal period : period between 28 completed weeks of 
amenorrhea and the end of the seventh completed day after 
delivery. 
Hypoglycemia : plasma glucose levels lower than 1.65 
mmol/1 (term infants) or lower than 1.1 mmol/1 (preterm 
infants). 
Gestational (pregnancy) diabetes : venous plasma glucose 
levels exceeding, only during pregnancy, two or more 
following concentrations after a 100 mg glucose load. 
fasting top 2 hours 
4.4 mmol/1 8.8 mmol/1 6.6 mmol/1 
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Hyperbilirubinemia 
ceeding : 
day of birth 
day 2 
day 3 
day 4 
day 5 
day 6 
day 7 
plasma bilirubine concentration ex-
preterm infants 
85 mcmol/l 
135 mcmol/l 
170 mcmol/l 
185 mcmol/l 
200 mcmol/l 
225 mcmol/l 
240 mcmol/l 
term infants 
85 mcmol/l 
135 mcmol/l 
185 mcmol/l 
225 mcmol/l 
255 mcmol/l 
255 mcmol/l 
255 mcmol/l 
Criteria for IRDS (idiopathic respiratory distress syn-
drome: 
- grunting 
- increased respiratory rate and retraction of the supra-
sternal notch and intercostal spaces 
- rising PCO- levels 
- diffuse reticulogranular infiltrate throughout the lung 
fields with an air-filled tracheobronchial tree 
(air-bronchogram) on the chest roentgenogram. 
t - d interval : time interval between the cessation of 
treatment and delivery. 
d - s interval : time interval between the delivery of the 
infant and plasma sampling. 
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General introduction 
The specialty of obstetrics has traditionally been 
preoccupied with the mechanics of human parturition. In 
recent decades, however, this traditional approach has 
been supplemented increasingly by the knowledge gained 
from research into the physiology, biochemistry and endo-
crinology of reproduction in man and other species. As a 
consequence of these developments, one can now glimpse 
some of the secrets of human parturition. Although much 
remains to be learned about the processes involved in the 
maintenance and natural termination of pregnancy, means 
are presently available to prolong or shorten the duration 
of pregnancy, within limits, in many cases. In general it 
has been much easier to terminate pregnancy than to pro-
long it ; however, even in this latter field some progress 
has been made. In probably the majority of cases of 
threatening preterm labor, prolongation of pregnancy can 
be achieved by suppressing unwanted uterine contractions 
pharmacologically, even though the cause of the contrac-
tions remains unknown. Mechanical measures (e.g., cervi-
cal cerclage) remain useful in a small minority of pa-
tients. 
Today long-term relaxation of the uterus can be attained 
effectively with uteroselective adrenergic drugs, and 
these agents are increasingly used for indications other 
than the prevention of preterm labor. Unfortunately, 
however, this therapy is not without side effects on 
mother and fetus in the dosage levels used in obstetric 
practice. 
In this thesis, some aspects of human tocolysis with 
two different ß-2-sympathomimetic agents will be discuss-
ed. 
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Chapter 1 
Premature labor 
1.1. Introduction 
Despite tremendous improvements in treatment by neo-
natal intensive care, premature birth is by far the most 
important factor in the incidence of neonatal mortality 
and morbidity and may thus be considered one of the 
greatest problems of current obstetric and pediatric 
practice. 
If the premature infant survives the threats of the early 
postnatal period, the possibility of long-term morbidity 
such as psychomotor, intellectual and emotional deficits 
may cause great concern to doctors and parents. There-
fore, the recent advances in neonatal medicine in no way 
decrease the need for the obstetrician to prevent preterm 
deliveries or, when these are not preventable, at least to 
minimize the risk of developing respiratory distress or 
other major complications after birth by appropriate man-
agement antenatally and during labor. 
Prevention of premature delivery has become an even 
greater challenge for the obstetrician now that in-
creasingly effective drugs are becoming available to post-
pone the moment of birth. 
When referring to prematurity, not every obstetrician 
or pediatrician is referring to the same group of chil-
dren. Because of problems associated with the frequent 
uncertainty of the actual date of conception, the anam-
nestic duration of amenorrhea has often been considered to 
be an inadequate measure of fetal maturity. In the past, 
therefore, more attention has been given to the weight pa-
rameter (Cavanagh and Talisman, 1969). The following 
definition was approved by the American College of Obste-
tricians and Gynecologists (1965) : 
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- Immature infant : the fetus weighs between 500 and 1000 
grams 
- Premature infant : the fetus weighs between 1000 and 
2500 grams. 
There are a great many disadvantages inherent in any arbi-
trarily defined weight standard, for birth weight is in-
fluenced by many factors other than gestational age, in-
cluding ethnic and nutritional factors, fetal disease and 
perhaps socio-economic circumstances. Various other ob-
jective measurements, including biparietal diameter and 
crown-rump length (ultrasound techniques), analysis of the 
amniotic fluid and neurodevelopmental scoring of the new-
born, singly or in combination are used in many centres in 
assessing the maturity either pre- or postnatally. Recent-
ly there has been a tendency towards using gestational 
age, judged from the first day of the last menstrual pe-
riod, as the main criterion, in correlation with above 
mentioned ultrasonic evaluation of fetal size and amniotic 
fluid indices and regardless of birth weights. Premature 
birth is thus defined as a delivery after 28 weeks (196th 
day) of amenorrhea and before the end of the 38th week 
(266th day) , or as a birth weight over 1000 grams and an 
amenorrhea of less then 37 completed weeks (259 days) 
(FIGO) (Kloosterman, 1977). 
Although these definitions offer the possibility of 
distinguishing clearly between prematurity and dysmaturity 
at term, it must be stressed that the abandoning of the 
pseudo-exact birth weight criterion places an extra 
emphasis upon accurate recording and proper interpretation 
of the menstrual history. 
1.2. Etiology 
Until a few decades ago prematurity was largely the 
burden of the pediatrician. Obstetricians were unable to 
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play a significant role in prevention for they had very 
few tools with which to handle the problem. Now that sev-
eral pharmacological and surgical possibilities are 
available, it is essential to survey the possible causes 
of prematurity, in order to anticipate these early deliv-
eries and thus to select appropriately the patients for 
treatment. 
A wide variety of diseases and circumstances have been 
associated with an increased incidence of premature labor. 
Many comprehensive studies have been carried out to deter-
mine the relative importance of various factors which 
might contribute to the problem. 
The etiologic and epidemiologic information may be clas-
sified for purposes of discussion into two major catego-
ries : 
- factors relating to the conceptus (fetus, amniotic 
fluid, fetal membranes and placenta) ; and 
- factors outside of the conceptus (health, age and con-
stitution of the mother, uterine anomalies, socio-eco-
nomic factors, etc.). 
In many instances factors in a category may be related to 
factors in the other ; for example, the association be-
tween maternal vascular disease and placental pathology, 
or between multiple pregnancy and pregnancy-induced hyper-
tension in the mother. 
1.2.1. The conceptus 
1.2.1.1. Multiple pregnancy 
The duration of pregnancy is inversely proportional to 
the number of fetuses in utero. 
Overdistention of the uterus has long been considered to 
be a major provocative element in shortening duration of 
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pregnancy. This assumption is supported by the fact that 
in cases of multiple pregnancy with polyhydramnios, gesta-
tion is shorter than when the amount of amniotic fluid is 
normal. (Van Bilderbeek, 1960). 
1.2.1.2. Congenital abnormalities of the fetus 
Several severe congenital malformations are associated 
with a shortened duration of pregnancy (Specken, 1964). 
The association may be partly secondary to the malforma-
tion itself and partly due to the possible accompanying 
polyhydramnios, the severe degree of dysmaturity often 
present or intrauterine death. 
2 . 2 . 2 . 3 . The amount of amniotia fluid 
An excessive amount of amniotic fluid is associated 
with a shortened duration of gestation (van der Velden, 
1957) . Overdistention of the uterus has already been 
suggested as a possible trigger for premature labor. 
1.2.1.4. Early rupture of the membranes 
Rupture of the membranes may give such a strong stim-
ulus to the onset of labor that this procedure was one of 
the first methods described to terminated pregnancy. Sev-
eral explanations for this phenomenon have been proposed, 
including an unfavourable effect on the placental circula-
tion, mechanical stimulation of the lower uterine parts 
and stimulation of prostaglandin synthesis. 
1.2.1.5. The placenta 
Bleeding from the placental site in case of placental 
anomalies, premature separation or placenta praevia is 
highly correlated with prematurity as is infarction of the 
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placenta. 
In a group of pregnancies of at least 34 weeks dura-
tion, Kloosterman (1975) found a correlation between the 
size of the placenta and the chance of prematurity. Among 
the 17543 cases he reported upon the prematurity rate de-
creased with increasing placental weights. 
In some species a change in placental steroid hormone 
production precedes the onset of labor, but the evidence 
for the existence of such a relationship in man is mixed. 
Some observations suggest altered placental steroid hor-
mone production preceding the onset of labor (Turnbull et 
al., 1974). 
1.2.2. Outside the eonoeptus 
1.2.2.1. Placental perfusion 
Absolute and relative insufficiency of the maternal 
vascular bed, as in the case of hypertensive disease, 
leads to premature delivery, especially when there is 
substantial placental infarction as well. 
1.2.2.2. Cervieal insuffiaiency 
Congenital or acquired incompetence of the internal os 
of the uterine cervix, if untreated, results in the birth 
of an immature fetus because of the inability of the cer-
vix to retain the enlarging conceptus in the uterus. 
Prolapse of the conceptus usually occurs during the second 
trimester before the fetus reaches the stage of extra-
uterine viability. 
1.2.2.3. The uterus 
Both congenital and acquired (fibromatosis) abnormal-
ities of the uterus may be etiologic elements in prema-
19 
ture labor. Furthermore there might be an intrinsic 
hypercontractility of the uterus in some women (see dis-
cussion of section 5.4.3). 
1.2.2.4. Infectious diseases 
Acute infectious diseases are often attended by an 
increased contractility of the myometrium and may thus 
initiate labor ; possibly as a result of enhanced 
prostaglandin synthesis. 
Acute and chronic infections of the urinary tract, with or 
without symptomatology, are the most important causes in 
this category from a quantitative point of view. 
1.2.2.5. Endocrinologia diseases 
Diabetes mellitus (even subclinical) and thyroid 
disease bring about an increased risk of many of the 
hazards of pregnancy including prematurity. 
1.2.2.6. Other factors 
Race, parity, maternal age, reproductive history, 
emotional stress and psychogenic factors, dietary de-
ficiency, severe anemia, socio-economic circumstances, and 
cigarette smoking are among the other factors assumed to 
influence the incidence of prematurity. 
Only a minority of these conditions or diseases of 
fetus, mother or maternal genital tract have been so fre-
quently associated with the early onset of labor that they 
can be regarded conclusively as causative factors, how-
ever; so in spite of the wide variety of factors possibly 
related to the etiology of prematurity, in about half of 
the cases of imminent premature birth, no apparent cause 
can be found. 
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During recent years, research has produced several hy-
potheses regarding the initiation of human labor. 
Csapo (1956) proposed a 'progesterone block' produced 
by the placenta as a reason for relaxation of the uterus 
during pregnancy and suggested progesterone withdrawal as 
a major factor in the onset of labor (Csapo et al.r 1971, 
1974). This hypothesis was supported by Turnbull and 
associates (1974), who measured a significant fall in 
progesterone and rise in oestradiol levels in human pe-
ripheral plasma during the 5 weeks preceding labor. A 
number of other investigators have not, however, found any 
changes in these hormones prior to labor. 
Caldeyro-Barcia and Sereno (1961) believe that human 
myometrium becomes progressively more sensitive to a rela-
tive constant level of circulating oxytocin during preg-
nancy, until a critical level is attained, producing la-
bor. Kumaresan and coworkers (1974), however, found 
rising oxytocin levels in human plasma long before the on-
set of labor. 
The fetus could exert an influence on the onset of la-
bor via its own oxytocin production (Chard et al., 1971) 
or via increased adrenal corticosteroid production. 
In sheep Cortisol has been shown to cause an increase in 
estrogen production, decreased progesterone secretion, and 
release of prostaglandins by the placenta (Liggins, 1975). 
This mechanism has not been established as contributing to 
the onset of labor in human pregnancy. 
Based on studies by Klock and Jung (1973) , Csapo and 
Csapo (1974) suggested that prostaglandins, synthetized in 
response to progressive myometrial stretching, are the in-
trinsic uterine stimulants for the onset of labor. Other 
reports give support to the hypothesis that local pros-
taglandin synthesis may be involved in the onset of labor 
(Karim, 1968 ; Gustavii, 1977). 
Brotanek and associates (1969) reported that in spon-
taneous labor, uterine (cervical) blood flow decreases for 
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about 30 seconds before the onset of contractions and sug-
gested that a decrease of uterine blood flow may have a 
role in the initiation of labor. Flowmeter studies in 
monkeys, however, have not demonstrated any pre-contrac-
tion drop in uterine artery blood flow (Martin, 1972) and 
in fact an increase in myometrial blood flow during 
contractions (Lees et al., 1971). 
To date, no clear definition of the mechanism of the 
initiation of labor in man has been established. Thus we 
are presented with a variety of possible mechanisms, some 
of which may function simultaneously in bringing about the 
onset of parturition (Barden, 1974, 1977 ; Eskes, 1979). 
1.3. Diagnosis 
The diagnosis "imminent premature labor" is basically 
the same as that of the onset of spontaneous labor at 
term. In either case it is very difficult to make a posi-
tive diagnosis in an early stage of the process. 
The onset of labor is to some extent an arbitrary point, 
and only when the symptoms increase in the expected way, 
can one say retrospectively that a woman has been in labor 
for some time. 
Unlike beginning labor at term, however, it is most impor-
tant to recognize premature labor early and clearly, for 
the possibility of successfully postponing birth decreases 
very rapidly as the process of parturition proceeds. 
Several clinical criteria are employed in the diagnosis of 
threatening premature labor : 
1. recurrent, more or less painful, contractions of the 
uterus, increasing in frequency and intensity ; 
2. rupture of the membranes ; 
3. "bloody show" ; 
4. effaced or effacing cervix ; and 
5. dilatation of the internal cervical os. 
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Utérine contractions (Braxton Hicks contractions) may 
occur throughout the latter months of pregnancy, and need 
not be associated with the onset of labor. The frequency 
of these contractions is usually low, they are often hard-
ly recognized by the woman, and they do not produce 
effacement and dilatation of a normal cervix. The fre-
quency of these contractions can easily be established by 
external tocography. 
Zahn (1978) presented data on contraction frequencies. He 
observed an increase in the number of spontaneous contrac-
tions from 1/hr in the 25th week to 3/hr (primigrávida) 
and to 3.5/hr (multigravida) at term (97th percentile) 
with a remarkable incidence peak around the 32nd week. 
There is a strong correlation with the onset of labor when 
the contractions are "laborlike" : that is regular con-
tractions at intervals of less than 10 minutes, painful, 
and leading to effacement and dilatation of the cervix. 
Statistical analysis of 643 cases of threatened premature 
labor of which 27 % (172) received intensive pharmacologic 
treatment suggested that the frequency and regularity of 
the contractions was of low prognostic value. Pain asso-
ciated with the contractions, however, seemed to be cor-
related better with a difficult-to-postpone labor 
(Melchior and Bernard, 1974). 
Rupture of the fetal membranes, whether spontaneous or 
artificial, usually leads to the onset of labor after a 
varying latent period. The diagnosis of ruptured mem-
branes is usually not difficult. 
More difficulty may arise in differentiating between low 
and high sites of membrane rupture, for the latter carries 
a better prognosis with regard to successful lengthening 
of the pregnancy than does the former. The exact mecha-
nisms by which rupture of the membranes stimulates the 
onset of labor is not yet clear. A recent hypothesis, 
which is supported by a number of laboratory observations, 
is that mechanical disruption of the membranes and decidua 
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leads to increased prostaglandin synthesis (Gustavii, 
1975) . 
Mitchell and colleagues (1976) , found significantly 
greater amounts of PgF and PgFM in amniotic fluid obtained 
by amniotomy than in samples taken by amniocentesis. 
Uterine haemorrhage due to placenta praevia, abruptio 
placentae or placental anomalies can lead to labor, 
possibly due to the accumulation of blood between the mem-
branes and the uterine wall resulting in irritation of the 
myometrium, or to the release of prostaglandins from the 
damaged decidua. Loss of mucus, often mixed with blood is 
strong confirmative evidence of an effacing and dilatating 
cervix and thus of the start of parturition. 
Effacement and dilatation of the uterine cervix as a 
result of regular uterine contractions are reliable indi-
cators of the presence of labor, especially if there are 
other accompanying symptoms. According to Melchior and 
Bernard (1974), dilatation has a higher prognostic value 
than effacement. On the other hand a certain degree of 
dilatation unrelated to the onset of labor is not uncommon 
in the last trimester, especially in multiparae. 
In the second trimester, however, any cervical dilatation 
of the internal os is abnormal. In the absence of uterine 
activity, the possibility of primary or acquired cervical 
incompetence must be strongly considered. 
Laboratory aids to the diagnosis of premature labor 
are few and until now, not widely used. 
Csapo and Herczeg (1977) advocate determination of the 
peripheral plasma progesterone level. A low progesterone 
value would favor the diagnosis of premature labor, where-
as a normal value would identify patients in whom the con-
tractions would subside spontaneously. In relatively few 
hospitals, however, this determination can be made with 
sufficient rapidity to be of value in management of pos-
sible preventive labor. 
Measurement of rheobase values seems to be a promising 
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way to make the diagnosis in an early stage of premature 
labor. (Schenk et al., 1975b ; Feichtinger and Frb'lich, 
1979) . Rheobase values were found to be significantly 
lower during labor or threatening preterm delivery, than 
during pregnancy. Because of the large range of normal 
values and the corresponding overlap of the normal and 
pathologic groups, however, it is still difficult to 
interpret rheobase values in an individual gravida. 
Wolfs and van Leeuwen (1979) demonstrated with intra-
uterine electrodes and an intrauterine open tipped cathe-
ter that electrical activity of the myometrium preceding 
the uterine contraction was observed in progressive labor 
while electrical activity simultaneous with the uterine 
contraction did not result in cervical dilatation. This 
methodology using intrauterine electrodes is, however, not 
clinically attractive in cases of early labor because of 
the possibility of the induction of labor and/or intra-
uterine infection. 
1.4. Treatment 
It is of utmost importance in cases of imminent prema-
ture labor to try to determine the etiologic element and 
if possible to treat the cause. 
Although some progress has been made in recognition and 
treatment of causative factors, in many cases the precipi-
tating factors remain unexplained or incurable. Even if 
there is strong suspicion of a particular reason for the 
premature labor and curative treatment is available, the 
uterine activity as such must be arrested. Thus the 
symptomatic approach, as well as prophylactic measures, 
still form the basis of the efforts to avoid prematurity. 
Several methods of treatment of premature labor have been 
reported, with varying degrees of applicability. 
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1.4.1. Bed rest 
Psychological and physical stress may provoke or in-
crease premature uterine contractions (Newton et al., 
1979). Thus, one of the oldest measures employed in 
treatment has been absolute bed rest and, if necessary, 
sedation. Bed rest still constitutes a major part of the 
treatment in almost all cases. 
1.4.2. Anes the tics 
The general anesthetics fluothane and ether produce a 
very strong relaxation of the uterine muscle ; but for ob-
vious reasons these agents are not useful for long-term 
tocolysis (van Liere et al., 1964). 
1.4.3. Ethanol 
Since Fuchs (1965) reported on this subject, intrave-
nous ethyl alcohol has been used widely, mainly in the 
U.S.A. The relaxing effect of alcohol upon uterine activ-
ity is presumably due to inhibition of oxytocin release 
from the neurohypophysis, although an anti-prostaglandin 
effect has also been proposed. 
1.4.4. B-adrenergic drugs 
Effective inhibition of uterine contractility can be 
obtained by ^-sympathomimetic agonists (chapter 2). These 
agents also produce cardiovascular and many other effects. 
The pharmaceutical chemists have produced a series of 
so-called ß-2-mimetic agents with greater affinity for the 
ß-receptors in, for example, myometrium and bronchi and 
lesser activity upon the heart and blood vessels. Even 
with these agents, however, cardiovascular effects usually 
constitute the dose-limiting factor. 
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1.4.5. Prostaglandin synthesis-inhibiting agents 
There are reasons to believe that prostaglandins are 
involved in the process of inititation of labor, at term 
as well as prematurely. Several reports have been pub-
lished on the use of prostaglandin synthesis-inhibiting 
agents (indomethacin, acetylsalicyl acid, naproxen) for 
the treatment of premature labor (Zuckerman et al., 1974 ; 
Wiqvist et al., 1975 ; Csapo et al., 1974a). 
Besides the well-known possible side effects of indo-
methacin or aspirin upon the mother, these agents also 
present some hazards to the fetus. In animal studies 
indomethacin was found to reduce fetal renal function 
(Friedman et al., 1976 ; Winther et al., 1977), and to 
produce a dose dependent fetal neuronal necrosis in rats 
(Altshuler et al., 1979). It has been shown by Sharpe et 
al. (1975) that intrauterine closure of the ductus 
arteriosus occurs in animal fetuses given indomethacin or 
sodium salicylate shortly before term. Intrauterine 
closure of the ductus arteriosus in association with 
salicylate exposure during human pregnancy was first 
reported by Arcilla et al. (1969), and there have been 
several subsequent cases reported. Other case reports 
about this presumed association were published by Csaba 
and coauthors (1978) ; two deaths in 10 infants after 
indomethacin therapy, and Levin et al. (1978) ; two 
deaths, one each after salicylate and indomethacin 
treatment. Persistent pulmonary hypertension, 
abnormalities in blood clotting, and impairment of renal 
function in the fetus after intrauterine exposure to 
Naproxen was reported by Wilkinson and coworkers (1979) . 
Manchester and associates (1976) documented a possible 
association between maternal indomethacin therapy and 
primary pulmonary hypertension of the newborn. 
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1.4.6. Diazoxide 
Diazoxide, an antihypertensive agent, produces a re-
laxing effect upon the myometrium (Landesman et al., 
1969) . The attendant drop in blood pressure could, how-
ever, diminish maternal placental blood flow below the 
level necessary to maintain optimal fetal oxygenation. 
Diazoxide also affects carbohydrate tolerance adversely. 
1.4.7. MgS04 
Magnesium sulfate, widely used in clinical obstetrics 
for the therapy of pre-eclampsia and eclampsia, has been 
proved to have a relaxing effect on both striated and 
smooth muscle including myometrium (Hutchinson et al., 
1964) . 
The precise mechanism of magnesium sulfate action is not 
yet clear. The most likely mechanism of action in uterine 
relaxation is competition at the intracellular level of 
Mg with the Ca necessary for muscular contraction. 
There may also be an indirect influence on the contracting 
uterus through the sedative effect upon the mother. 
1.4.8. Calcium antagonists 
The effect of the calcium antagonist nifedipine in the 
excitation contraction coupling has been studied with 
promising results (Ulmsten et al., 1980). 
The tocolytic action is thought to come about via inhibi-
tion of influx into the cell of calcium necessary for con-
traction. 
1.4.9. Progesterone 
It was shown by Johnson and coworkers (1975) in a 
double blind methodology, that after prophylactic adminis-
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tration of 17-a-hydroxyprogesterone caproate to patients 
with obstetric histories of preterm deliveries or small 
for dates infants, the mean duration of pregnancy was sig-
nificantly greater (p < 0.025) than after placebo therapy. 
However, once premature labor was started, progesterone 
therapy was found to be ineffective in preventing delivery 
(Fuchs and Stakemann, I960). 
Efforts have been made to combine several forms of 
therapy, not only in the form of additional symptomatic 
treatment when a cause-directed approach is available, but 
also combinations of agents with different presumed mecha-
nisms of action. 
Thus, bed rest is an adjunct to pharmacologic treatment in 
most cases. Trials of direct inhibition of myometrial ac-
tivity by betamimetics coupled with simultaneous suppres-
sion of oxytocin release with alcohol did not prove to of-
fer a great advantage over either treatment alone 
(Bieniarz, 1971), although from a theoretical point of 
view the combination of two drugs which have completely 
different methods of action could be beneficial. In 1978 
a double-blind, placebo controlled study was carried out 
by Gamissans et al. (1978). Ritodrine and placebo were 
compared to ritodrine and indomethacin. The latter treat-
ment regimen showed to be significantly better in pro-
longing pregnancy (p < 0.05). 
Several substances have been tried in conjunction with 
tocolytic treatment to minimize undesirable side effects. 
Trials with 6-2-sympathomimetics simultaneous with 
so-called cardioselective ß-adrenergic blocking agents, a 
possibility suggested by Eskes and coworkers in 1965, have 
in the past, been unsuccessful. Not only was the heart 
frequency lowered to normal values, but the uterine con-
tractions returned in full strength (Esteban-Altirriba et 
al., 1972 ; Müller-Tyl et al., 1974). Furthermore, as 
ß-blockers cross the placenta, they might block the normal 
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fetal cardiovascular responses to hypoxia. Recently, 
however, a smaller increase in maternal heart rate was 
reported with the combined use of fenoterol and the 
cardioselective З-1-Ыоскіпд agent metoprolol, compared 
to fenoterol alone, with similar tocolytic results in both 
groups (Trolp et al., 1980). 
The Ca antagonist verapamilum has been used in addi­
tion to 8-mimetics in order to diminish the cardiovascular 
side effects. The advantage of this substance is still 
controversial from a clinical point of view (Hiltmann and 
Weidinger, 1977 ; Richter and Hinselmann, 1979), although 
from animal studies with relatively high doses (Flecken­
stein et al., 1978) and from in vitro organ cultures 
(Hofmann et al., 1977) a cardioprotective effect was 
suggested. 
As has been stressed earlier, it is of the utmost im­
portance to start treatment of premature labor in an early 
stage for the probability of successfully prolonging preg­
nancy decreases very rapidly as the process of parturition 
proceeds. 
Unfortunately, the tools for prompt and positive recog­
nition of true premature labor as opposed to "false" labor 
are still lacking. The choice thus lies between overtreat-
ment, with many patients receiving unnecessary drug thera­
py, and undertreatment resulting in a definite incidence 
of avoidable premature delivery. 
When the treatment carries no serious side effects for 
mother or fetus, this tendency to overtreatment is no 
major problem from a medical or ethical point of view. 
The inclusion of an unknown number of patients treated 
unnecessarily does, however, complicate the evaluation of 
the effectiveness of different treatment methods. And, as 
already pointed out, side effects, sometimes serious, are 
associated with essentially all treatment methods. 
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Chapter 2 
Betasympathomimetic agents In human obstetrics 
2.1. Introduction 
This chapter presents a short review of present 
knowledge about the use of 3-mimetic drugs in pregnant 
women. 
As the results of the investigations presented in chapters 
3, 4 and 5 deal with the prevention of preterm delivery, 
accent is placed upon long-term tocolysis. 
Some of the major side effects of these agents upon mother 
and fetus will also be discussed. 
2.2. History 
In 1927 Bourne and Burn reported inhibition of uterine 
activity during labor by intravenous administration of 
adrenaline. 
Two years earlier Rucker (1925) had already published his 
observation of transient relaxation of the uterus after 
small injections of adrenaline. 
Subsequent studies revealed a dose and species dependency 
of the uterine response to adrenaline ; relaxation as well 
as contraction of the uterine muscle could be achieved by 
the same drug. 
An explanation of this phenomenon was found after 
Ahlquist's (1948) suggestion that sympathomimetic amines 
could stimulate two distinct types of adrenotropic recep­
tors : α and β. 
Stimulation of α-receptors in the myometrium was thought 
to be responsible for contractions whereas relaxation of 
the uterine muscle could be achieved by stimulation of 
ß-receptors. With growing knowledge of the two types of 
adrenoreceptors and their contradictory effects, efforts 
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were made to synthesize adrenaline-like compounds with a 
more specific ß-mimetic action. 
In I960, Lish and coworkers reported on the uterine in-
hibiting effect of such a drug (Isoxsuprine hydrochloride) 
in vitro on uterine tissue from the human and the rabbit, 
and in vivo on rabbits, cats and dogs. Among the first to 
publish about human tocolysis with B-mimetic drugs were 
Bishop and Woutersz (1961) ; Hendricks et al. (1961) ; 
Stolte et al. (1965) and Eskes et al. (1965). 
Another step towards clinical applicability of 
ß-mimetic drugs was Lands' (1967) postulation of two types 
of ß-receptors on the basis of their relative response to 
adrenaline and noradrenaline : 
3-1, predominantly in myocardium and fat cells, and 
ß-2-receptors in uterus, bronchial muscle, liver and stri-
ated muscle cells. Subsequent studies have indicated that 
there is no absolute organ separation of ß-1 and ß-2 re-
ceptors, although a particular organ might contain predom-
inantly B-l but also ß-2 receptors, or the reverse 
(Carlson and Ablad, 1976) . 
Ariens and Simonis (1976) have introduced a more phys-
iological separation of adrenoceptors into receptors for 
the neurotransmitter noradrenaline and receptors for the 
adrenal medullary hormone adrenaline. The neurotrans-
mitter receptors are classified as α-T and β-Τ according 
to the response obtained with activation, and a parallel 
division into α -Η and β-Η can be made for the adrenaline 
receptors. In general, the difference in distribution of 
β-Τ and β-Η receptors parallels the empirical occurrence 
of ß-1 and ß-2 receptor sensitivity patterns. In this 
paper the terms ß-2 receptor and ß-2-mimetic (agonist) 
will be used, since these terms are still the ones most 
frequently encountered in the literature. 
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2.3. Clinioal pharmacology 
2.3.1. The effect of betamimetic stimulation on the uterine muscle 
Like other smooth muscle, myometrium is characterized 
by autogenous contractile activity. Changes in the state 
and pattern of activity occur in physiological conditions 
(menstrual cycle) as well as in response to pharmacologi-
cal substances. 
Adrenotropic compounds are prominent among the pharmaco-
logic agents effecting the myometrium as noted previously 
(section 2.2). Both a- and ß-adrenotropic receptors are 
present in the myometrium, with α-receptor activation 
leading to increased uterine contractility and ß-receptor 
stimulation, to myometrial relaxation. Further, the uter-
ine β-adrenergic receptors fall into the β-2 category 
according to Lands' (1967) classification. 
The relaxing effect of β-sympathomimetics is consid­
ered to come about by stimulation of adenylcyclase in the 
cell membrane. 
Adenyl cyclase is believed to correspond functionally with 
the ß-receptor (Robison et al., 1967). As a result of 
this stimulation, ATP is converted intracellularily into 
3-5-adenosinemonophosphate (cyclic AMP). An essential 
mechanism of intracellular cAMP is its participation in 
the absorption of intracellular calcium by the sarcoplas-
mic reticulum as well as mitochondria and microsomes, re-
sulting in a decrease in the ionized free intracellular 
calcium level. This is an active process, the energy for 
which is supplied by the decomposition of ATP. Ionized 
calcium seems to be an essential element in the contrac-
tile properties of myofibrils (Schild, 1966 ; Rasmussen, 
1970) . When an action potential occurs in the cell mem-
brane this ion mediates transmission of the activation 
from the cell membrane to biochemical systems of contrac-
tile proteins (Czekanowski, 1977). Thus the effect of a 
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decrease of free calcium within the cell is an inhibition 
of the uterine contractile activity. 
Apart from interference with cellular contractile 
activity through its effect on intracellular Ca , the 
formation of cAMP is believed to cause initiation of 
several other enzymatic processes in the cell in a manner 
which is still not fully clear, leading to glycogenolysis, 
lipolysis and, so far as the heart muscle is concerned, 
inotrophy and chronotrophy. Thus, in addition to inhibi-
tion of uterine contractions, administration of ß-sympa-
thomimetics can produce hyperglycemia, increased free 
fatty acid levels, and acceleration of the heart rate. 
These several effects are summarized in table 2.1. 
2.3.2. Pharmacokinetics 
Pharmacokinetic profiles of 4 frequently used В-adren­
ergic agonists were collected from literature by Post 
(1977). 
Fenoterol : plasma levels of the sum of the active 
agent and its metabolites were measured by Buchelt and 
Romiger (1472). Because of the extensive conversion of 
these agents to pharmacologically inactive products, the 
data presented seem of little clinical interest. 
Ritodrine : serum levels of ritodrine were determined 
by radio-immunoassay, after oral and parenteral adminis­
tration. Intravenous infusion of 150 meg per minute for 
one hour resulted in a peak serum level of about 41.0 + 
1.9 ng/ml (mean + SEM) . After the end of the infusion a 
distribution half life of 6-9 min was measured, followed 
by a second phase with a half life of about 2 hours. 
Finally a third phase with a half life of more than 15 
hours could be calculated. Oral administration of 10 mg 
gave a peak level of about 10 ng/ml in the 20- or 40- min 
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Table 2.1 EFFECTS OF ADRENERGIC RECEPTOR STIMULATION IN SOME ORGANS 
ORGAN 
Uterus 
RECEPTOR TYPE EFFECTS 
Blood vessels in uterus a 
Heart 
Coronary vessels 
Bronchi 
Pulmonary blood vessels 
Liver 
Pancreas 
Wall of gut 
Blood vessels in gut 
Bi (62) 
α 
ß2 (Si) 
62 (ßi) 
α 
ß2 (В,) 
α 
ßi 
α 
Kidney Bi (Вг) 
Blood vessels in kidney о 
Skeletal muscle ^2 
Blood vessels in skeletal a 
muscle 82 (Bi) 
Fat tissue Bi (Вг) 
Blood vessels in skin α 
ß2 
increase in contractility 
decrease in contractility 
vasoconstriction 
vasodilatation 
increase in heart rate 
increase in contractility 
vasoconstriction 
vasodilatation 
relaxation 
vasoconstriction 
vasodilatation 
glycogenolysis, increase of plasma glucose 
glycogenolysis, increase of plasma glucose 
inhibition of insulin release 
stimulation of glucagon release 
stimulation of insulin release 
relaxation 
relaxation 
vasoconstriction 
vasodilatation 
reni η release 
vasoconstriction 
tremor 
glycogenolysis, increase of plasma lactate 
vasoconstriction 
vasodilatation 
lipolysis, increase of plasma free 
fatty acids 
vasoconstriction 
vasodilatation 
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sample. 
Half lives of 1.3 hours and of 20 hours were discernible. 
(Gandar et al., 1980) . 
Salbutamol : Martin and coworkers (1976) presented 
data qn plasma levels of salbutamol determined by a gas 
chromatographic mass spectrometric technique after intra­
venous (one subject) and oral administration. After oral 
administration of 4 mg, maximum peak plasma concentrations 
of 6 - 9 ng/ml were attained in 1 to 3 hours. 
The half life seemed to be about б hours. 
Terbutaline : oral administration of 5 mg terbutaline 
resulted in maximum serum levels of 6-7 ng/ml, attained 
after 90 to 120 min (Leferink et al., 1977). 
Comparison of ritodrine, salbutamol and terbutaline 
with respect to the areas under their serum concentration 
curves after parenteral and oral administration was done 
by Post (1977) according to rough estimations of these 
curves from data available from the literature. All doses 
were converted to 1 mg/hour. With all three drugs the 
biovailability after parenteral administration was marked­
ly greater than that after oral medication, indicating a 
so called first-pass effect. 
2.4. Indieations and contraindications 
2.4.1. Threatening premature labor 
The most frequent indication for the use of ß-mimetics 
in obstetric practice is the treatment of threatening pre-
mature labor. This diagnosis is a clinical one, based 
primarily on the presence of regular, frequent, more or 
less painful uterine contractions. Other symptoms or 
findings which may support the diagnosis of premature la-
bor include expulsion of the cervical mucus plug ("bloody 
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show"), progressive effacement and dilatation of the cer-
vix, and rupture of the fetal membranes. By the time 
these findings are present, however, the premature labor 
may be well established and the chance of successful 
treatment, accordingly less. 
At present, there are no laboratory tests which bear 
directly on the diagnosis of threatening premature labor. 
Determination of serum progesterone levels (Csapo and 
Herczeg, 1977) and measurement of rheobase values (Schenk 
et al., 1975b ; Feichtinger and Frölich, 1979) have been 
suggested as useful indicators of an early stage of pre-
mature labor as opposed to a transient increase in uterine 
activity which will subside spontaneously. However, clin-
ical experience with these measurements is still limited 
and until now, there seems to be a large overlap between 
results in normal patients and those with premature labor. 
Increased uterine activity is sometimes a finding in 
other pregnancy complications besides premature labor : 
for example, with acute pyelonephritis or other acute 
febrile complications, or with partial premature separa-
tion of the placenta. Accordingly, underlying factors 
such as these should be looked for in each patient pre-
senting with pathologically increased uterine activity 
prior to term and, when detected, treated appropriately. 
The status of the fetus should also be investigated, 
with regard both to nutrition (size appropriate for 
gestational age) and oxygenation (CTG registrations). The 
presence of fetal distress is a contraindication to 
tocolytic therapy except as a temporary "resuscitative" 
measure (see section 2.4.4.1.). 
With regard to the period of amenorrhea within which 
tocolytic therapy with B-mimetics may be indicated, most 
authorities consider this to be the time from 16 to 34 or 
36 weeks corrected menstrual age. Threatened pregnancy 
termination earlier than 16 weeks is usually not treated 
because of the high incidence of chromosomal and other 
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abnormalities found in these cases. Beyond 36 completed 
weeks of gestation, prolongation of pregnancy would seem 
to offer little benefit with regard to decreasing neonatal 
morbidity and mortality. In some cases, it may become 
apparent at an even earlier time that the fetus is better 
off in the newborn nursery than in utero. 
Particularly in pregnancies complicated by intrauterine 
growth retardation or other conditions in which the risk 
of fetal distress is increased, clinical and laboratory 
information about the well-being and maturity of the fetus 
must be taken into account in the decision as to whether 
to initiate or continue tocolysis. A mature L/S ratio, if 
this is known, is not per se a contraindication to toco-
lytic therapy since, as remarked by Puyenbroek and Stolte 
(1975), "a neonate is more than a couple of lungs", and 
pulmonary maturity does not assure maturity of other organ 
systems. 
The indications for inhibition of uterine activity 
with ß-sympathomimetics are summarized in table 2.2. 
Table 2.2 
MAIN INDICATIONS FOR TOCOLYSIS WITH BETAMIMETICS IN HUMAN OBSTETRICS 
1. Excessive uterine ac t i v i t y 
2. Threatening preterm labor 
3. Inh ib i t ion of uterine ac t i v i t y : 
- during external version 
- during internal version 
- af ter intra-abdominal or uterine surgeiy 
during pregnancy 
4. Intrauterine "resuscitat ion" of the distressed fetus 
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2.4.1.1. Clinical trials of long-term toaolysis with betasympatho-
minetio agents 
Several agents are known to decrease uterine activity 
(section 1.4), however, most of them are not useful in 
treatment of preterm labor because of side-effects which 
make it impossible to administer them in adequate dosage 
for sufficient periods of time. 
Besides, even if it is possible to use a specific uterine 
relaxant in an effective dose level for a sufficient 
length of time, it may be difficult to prove the effec-
tiveness of such a drug for preventing early delivery ; 
for in some women with threatening preterm labor, contrac-
tions disappear without any treatment at all. 
Therefore, to assess the capacity of a specific tocolytic 
drug to postpone the moment of birth, one has to compare 
treated patients with a control group in a carefully 
designed study with proper statistical analysis of the re-
sults. Data should be gathered prospectively and the 
treatment and control groups must be comparable with re-
gard to relevant factors, either as a result of random-
ization of the subjects between the study groups or by 
balancing of the groups. Double blind studies are unfor-
tunately not possible because of the clinical recognition 
of the effective drug as a result of its side effects. 
2.4.1.1.1. Adam (1966) 
The first randomized placebo-controled study to inves-
tigate the suitability of a 3-mimetic agent for the pre-
vention of preterm labor was published by Adam (1966). 
Isoxsuprine was given by intramuscular injection (40 -
80 mg per 24 hours) and orally to 26 patients, whereas 24 
women were treated with a placebo preparation. 
No beneficial effect of the isoxsuprine treatment re-
gime compared to the control patients could be demon-
strated in this trial. 
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2.4.1.1.2. Wesselius-de Casparis et al. (1971) 
A multicenter placebo-controlled study was carried out 
by Wesselius-de Casparis and associates (1971) in 63 pa-
tients. Ritodrine was given for 24 to 48 hours by infu-
sion at a rate of 200 meg per minute, followed by oral 
therapy with 10 mg four times daily for 5 to 7 days. Rit-
odrine given according to this plan proved to be effective 
in arresting premature labor (p = 0.02) and in lenghtening 
the duration of gestation at delivery (p = 0.005) compared 
to placebo-treated subjects. 
However, in this trial patients in who symptoms of prema-
ture labor recurred after completion of the first course 
of treatment were considered as a new case in the study. 
Thus, the same woman could be counted several times and be 
treated with more than one type of drug. 
Moreover, the patients in this trial were given a variable 
number of other drugs. 
The results of the trial are therefore difficult to judge. 
2.4.1.1.3. Ingemarsson (1976) 
Terbutaline was compared to placebo by Ingemarsson 
(1976) in 30 patients with intact fetal membranes. Only 
women with imminent premature labor of unknown etiology 
were included. Terbutaline was infused at an initial rate 
of 10 meg per minute. The infusion rate was increased 
every 10 minutes up to a maximum of 25 meg per minute or 
until uterine contractions ceased. 
After maintaining the minimal dose necessary to achieve 
complete relaxation for one hour, the infusion rate was 
decreased by 5 meg per minute every 30 minutes until the 
lowest effective dosage was reached. 
If uterine contractions had been absent for a period of 8 
hours, intravenous therapy was followed by intramuscular 
administration (250 meg four times daily for 3 days) . 
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Thereafter 5 mg of terbutaline was given orally three 
times per day until the end of the thirty-sixth week. 
Pregnancy was maintained to the thirty-seventh week in 80% 
of the treated women whereas this was only seen in 20 % of 
the control population (p < 0.01). 
Side effects were more often seen in the terbutaline 
group, but in no case did these lead to discontinuance of 
therapy. 
2.4.1.1.4. Csapo and Herczeg (1977) 
Similar results were reported by Csapo and Herczeg 
(1977) in their clinical trial in 36 patients with 
threatening premature labor and distinct progesterone de-
ficiency. 
Only patients with intact fetal membranes were included. 
Isoxsuprine was given intravenously at an initial rate of 
0.2 to 1.0 mg per minute for ten minutes as a loading 
dose. For the next 25 hours the infusion rate was re-
duced to a maintenance level of 0.1 to 0.3 mg per minute. 
Dose levels were adjusted individually to arrest progress 
in premature labor without serious effects. 
After the initial period of intravenous medication, oral 
treatment was individually adjusted according to clinical 
symptoms and side effects. The usual dose was 20 mg four 
times daily. 
Oral treatment was given for two to three weeks. 
Labor was delayed by 46.3 + 6.6 days among treated 
patients whereas in the placebo group pregnancy was pro-
longed by only 13.6 + 5.6 days (p < 0.001). 
Similar differences were seen according to gestational age 
at birth (p < 0.001) and fetal birth weights (p < 0.01). 
As expected a greater number of side effects was reported 
by the isoxsuprine-treated patients, but in no instance 
was the discontinuation of treatment required. 
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2.4.1.1.6. Spellaay et al. (1979) 
Ritodrine (14 patients) was compared to placebo (15 
patients) by Spellacy and associates (1979) in a random-
ized methodology. 
The drug was given intravenously for only 12 hours (maxi-
mum dose 350 mcg/min). During the next 24 hours the pa-
tients were given intramuscular therapy (5 - 10 mg every 
3-8 hours, whether or not uterine contractions had been 
suppressed, and thereafter oral therapy was substituted 
(maximum 120 mg/day). 
Within 24 hours of the beginning of (parenteral) medica-
tion 73 % of the placebo-treated and 43 % of the rit-
odrine-treated patients had delivered (p = NS). 
With decreasing ritodrine serum levels (oral medication, 
see section 2.3.2) the percentage of failures became sim-
ilar in the 2 groups : 73 % verus 71 % after 7 days. 
Cardiovascular side effects were seen significantly more 
frequently among the ritodrine-treated patients than among 
the control subjects. 
2.4.1.1.6. Christensen et al. (1980) 
A placebo-controlled randomized trial to assess the 
effect of ritodrine after premature rupture of the mem-
branes, was carried out by Christensen and coworkers 
(1980). 
The study included 30 patients between 28 and 36 weeks of 
gestational age, pregnant with only one fetus, the cervix 
dilated 4 cm or less, and without pyrexia or other signs 
of uterine infection after premature rupture of the fetal 
membranes. 
Ritodrine was given by an initial infusion rate of 100 meg 
per minute. In the presence of persisting uterine activ-
ity this dose was increased by 50 meg per minute every 10 
minutes up to a maximum of 400 meg per minute. 
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After 6 hours the infusion rate was lowered to 100 meg per 
minute and after 24 hours oral treatment (20 mg, 3 times 
daily) was begun and continued until the end of the 35 th 
week of gestation if no signs of infection appeared. 
When uterine activity recurred during treatment a new se-
quence of infusions and oral medication was started. 
The two groups were comparable with regard to the relevant 
factors such as age, parity, duration of pregnancy etc. 
Only with respect to the inhibition of labor during the 
intravenous treatment period was a statistically 
significant difference (p < 0.05) in favor of the rit-
odrine treated women found. 
There were no differences between the 2 groups in the to-
tal duration of pregnancy nor in the clinical data of the 
infants. 
From these trials several conclusions can be drawn : 
1. When given by the intravenous route in high dosage 
levels and for a sufficient period of time, some 
3-mimetic agents are capable of prolonging pregnancy 
despite threatening premature labor. 
2. Better results are achieved when dosage levels and 
treatment periods are adjusted according to the pa-
tient's needs, than with fixed treatment schemes. 
3. Oral therapy, in the doses employed, is not effective 
before the uterine contractions have been completely 
suppressed and remain absent on a low parenteral con-
centration of the agents used in the mentioned trials. 
4. In 20 to 30 % of the patients, no further progress of 
the supposed labor was seen following bed rest alone. 
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2.4.1.2. Evaluation of success in treatment of threatening premature 
labor 
In order to e s t i m a t e the potency of i n h i b i t o r s of 
u t e r i n e a c t i v i t y with r e s p e c t t o t h e i r long term u t e r i n e 
r e l a x a t i o n c a p a c i t y , and for the e v a l u a t i o n of success of 
d i f f e r e n t methods of management, s e v e r a l parameters a re 
e s s e n t i a l : 
- the o b s t e t r i c s i t u a t i o n a t the s t a r t of t r e a tmen t ; 
- the number of days gained as a r e s u l t of t r e a tmen t ; 
- the amenorrhea reached a t d e l i v e r y ; and 
- the c o n d i t i o n of the i n f an t a t b i r t h and dur ing the 
e a r l y newborn p e r i o d . 
2.4.1.2.1. Tooolytic index (premature labor score) 
In an a t t empt to a s s e s s the o b s t e t r i c s i t u a t i o n a t the 
onse t of t r e a t m e n t , Baumgarten and Grüber (1974) developed 
a t o c o l y t i c index ( t a b l e 2 . 3 ) . 
Table 2.3 TOCOLYTIC INDEX (BAUHGARTEN and GRÜBER, 1974) 
1 2 3 4 
Contractions i rregular regular 
Rupt. membranes - high - low 
Bleeding spotting bleeding 
Di latat ion 1 cm 2 cm 3 cm ΐ 4 cm 
This s c o r e , in which u t e r i n e c o n t r a c t i o n s , v a g i n a l b l e e d ­
ing, c e r v i c a l d i l a t a t i o n and the s t a t u s of membranes a r e 
taken i n t o a c c o u n t , was based on the fol lowing c o n d i t i o n s : 
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- calculation must be done easily and securely ; 
- it must use only factors that can be recognized objec-
tively ; 
- it must be reproducible by different examiners within 
the same period of time ; and 
- it must be easily remembered, for use at any time neces-
sary. 
To meet these requirements, Baumgarten and Grüber were 
obliged to exclude some undoubted important parameters. 
The degree of effacement and the consistency of the 
cervix are not included directly. 
These cervical parameters, however, are closely correlated 
with the degree of dilatation and are thus involved in an 
indirect way. Moreover, Melchior and Bernard (1974) found 
cervical dilatation to correlate much more strongly to la-
bor than did effacement of the cervix uteri. 
The relative size of the uterine content was not taken 
into account in assessing the premature labor score, 
although the findings 'fundus large for dates' (twins, 
polyhydramnios) and 'fundus small for dates' (placental 
insufficiency, chromosomal disorders) are known to corre-
late with the outcome of pregnancy in terms of gestational 
age at birth and condition of the neonate. 
An important shortcoming of the tocolytic index is 
that not every element of the index is of equal prognostic 
significance, nor will each element change in the same way 
during successful treatment. The symptoms of uterine con-
traction and bleeding may decrease or even disappear 
completely, while ruptured fetal membranes and dilatation 
of the cervix uteri usually will not. For example con-
sider 2 patients, each with a tocolytic index of 4. In 
one patient, however, the points have been awarded for 
regular uterine contractions and vaginal bleeding, whereas 
the other patient received her score on the basis of high 
rupture of the fetal membranes and 2 cm cervical dilata-
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Figure 2.1 
Scatterdiagvam of the aorvelation between tooolytio index and relative 
gain in the patients included in the aliniaal trial described in 
chapter 3. 
The relative gain is defined in section 2.4.1.2.2. 
Each circle represents one subject. 
(¡represents > 9 subjects. 
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tion. After 1 week of treatment the index in the first 
patient could have reverted to 0, whereas in the second 
example, the index will remain 4. Thus the latter situ-
ation presents a considerably more serious threat to the 
outcome of pregnancy than the former, especially at low 
gestational age, but the initial tocolytic indices were 
equal. 
Another important shortcoming of the index is the fact 
that the week of amenorrhea is not included ; for con-
tractions occuring at 30 as opposed to 34 weeks of amenor-
rhea may make only a slight difference in the outcome of 
pregnancy, but rupture of the membranes in the 30th week 
is a much more severe threat than the same event at 34 
weeks of pregnancy. 
Even so, we found the tocolytic index to be a suitable 
parameter in the clinical judgement of the prognosis of 
treatment (fig. 2.1). 
2.4.1.2.2. Judgement of success 
Considering threatening premature delivery as reason 
for tocolysis, the most rational success-criterion would 
be the amenorrhea at delivery, for prematurity is defined 
by the duration of amenorrhea. Thus successful tocolysis 
should result in a mature (^. 38 weeks = 266 days (former 
WHO definition) or >, 37 weeks = 259 days (FIGO)), live 
born neonate. However, to look at gestational age as the 
only criterion would be inadequate as may be illustrated 
by the following considerations : 
- an individual fetus may be mature even before the 37th 
week of pregnancy ; 
- in some cases of placental dysfunction the condition of 
the neonate and the prognosis for healthy development is 
favoured by premature delivery instead of artificial 
prolongation of pregnancy to term. In such cases post-
ponement of labor from early to late premature may be a 
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better result than exceeding the 37th or 38th week. 
Also when membranes are ruptured after 34-35 weeks of 
amenorrhea during or before tocolysis, accepting or even 
inducing labor could be the better alternative, espe-
cially if the L/S ratio in the amniotic fluid indicates 
lung maturity, because of the possibility of ascending 
intrauterine infection ; 
- treatment resulting in a term delivery may be considered 
a greater success (at least, less easily achieved) when 
the threat of labor occurs in an early stage of preg-
nancy compared to a later phase. 
These objections can be partly met if success is 
measured by judging the condition of the neonate only. 
Several parameters such as Apgar scores, umbilical cord 
blood analysis, incidence of hyperbilirubinemia, hypogly-
cemia and abnormal neurologic scores can be used in this 
respect. Morbidity of neonates, however, will be strongly 
influenced by factors unrelated to maturity as such ; for 
example, placental dysfunction and complications during 
labor. 
Success could be related to the number of days preg-
nancy is prolonged after administration of a tocolytic 
agent. However, it is clear that the earlier in pregnancy 
tocolysis is started, the more days can be gained. There-
fore it could be more appropriate in this respect to ex-
press the number of days that pregnancy was prolonged as a 
percentage of the number of days that could be gained till 
the 40th week. 
As tocolysis is seldom continued after the 37th complete 
week of amenorrhea, it would be even better to express the 
number of days that pregnancy was prolonged as a percent-
age of the number of days that was aimed at, i.e., the 
days remaining until the beginning of the 38th week. 
Another important element is the time in pregnancy at 
which labor first threatens to occur, for the length of 
time between the moment the premature threat becomes mani-
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fest and the expected date of delivery is inversely cor re-
lated with the chance of delivering a healthy mature in -
fant . 
So when evaluating the success of a therapeutic regime i t 
is e s sen t i a l to take the amenorrhea on admission into ac-
count e i ther when assessing the obs te t r i c s i tua t ion at the 
s t a r t of treatment or when measuring the r e su l t s of t r e a t -
ment at del ivery . 
In an attempt to meet th i s requirement Richter (1977) 
introduced a so called prolongation index which is calcu-
lated by taking 100 times the value of the time interval 
between the onset of the ß-mimetic treatment and del ivery, 
divided by the ges ta t ional age on admission (f ig. 2 .2) . 
Estimation of the effect of longterm betamimetic drugs by means 
of the prolongation index (Richter, 1977) 
Formula : 
At 
PI = . 100 
to 
t = gestational age at onset of uterine relaxant treatment 
At = lag time between onset of treatment and delivery 
Figure 2.2 
In a series of 135 patients with signs of threatening pre-
mature labor ?nd intact fetal membranes on admission, 
treated with various drugs, he could find good correla-
tions between the prolongation index and the clinical 
signs as well as the neonatal outcome. 
In a series of 372 consecutive patients treated for 
threatening early labor, including patients with ruptured 
fetal membranes, Eskes and Essed (1979) also found the 
prolongation index to correlate well with the tocolytic 
index of Baumgarten. 
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2.4.2. Possible usefulness of betamimetic therapy in chronic 
placental insufficiency 
2.4.2.1. Introduction 
The syndrome of placental insufficiency is a very 
complex oner for this organ is responsible for a great 
variety of functions. These functions of the placenta can 
be grouped under the general headings : maternal - fetal 
exchange and pregnancy maintenance. That functional 
performance in these 2 categories does not always follow a 
parallel course is easily seen from 2 examples : progres-
sive fetal growth retardation and eventual fetal demise 
before labor ; and premature labor with expulsion of a 
normally-grown, well oxygenated but unripe infant. 
Maternal placental blood flow is a factor of paramount 
importance with regard to placental exchange. 
The relationship between placental blood flow and preg-
nancy maintenance is less well documented, although a 
relationship has been suggested (Brotanek et al., 
1969a,b). 
It seems useful, therefore, to examine the possible ef-
fects of ß-mimetic agents on blood flow in the pregnant 
uterus. 
2.4.2.2. Animal studies 
Since to date there are no reliable and reproducible 
techniques of measuring uteroplacental flow in women, 
knowledge about effects of ß-mimetics upon hemodynamics in 
the placenta must be gathered from observation and experi-
ments in animal models. 
In the absence of uterine contractions. Cosmi and 
Condorelli (1972) observed in a chronic sheep preparation 
with electromagnetic flow probes, a significant increase 
in uterine blood flow with no significant changes in 
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maternal arterial and uterine pressures when a small dose 
of orciprenaline (0.24 mcg/kg/min) was given. High doses 
(20 mcg/kg/min), on the other hand, produced pronounced 
maternal and fetal tachycardia, a decrease in blood 
pressure and uterine artery blood flow, and fetal 
acidosis, indicating that the effect of β-mimetics on 
placental flow might be dose-dependent. 
It was suggested by Brennan and coworkers (1977) and 
Ehrenkranz et al. (1976, 1977a,b) that there may be only 
an initial depression of uterine blood flow, abating with 
time during continued drug infusion, or that the effects 
of the various ß-mimetics might not be similar. In chron-
ic sheep experiments, Brennan et al. (1977) and Ehrenkranz 
et al. (1976, 1977 a,b) found an initial small decrease of 
uterine blood flow following salbutamol (0.5 mcg/kg/min) 
and a much larger decrease with ritodrine (8 mcg/kg/min), 
but no initial change during fenoterol (0,1 mcg/kg/min) 
all three administered intravenously. 
After 60 - 120 minutes, uterine blood flow, which was 
continuously monitored with an electromagnetic flow trans-
ducer applied to the main uterine artery, began to in-
crease and rose above control levels in the sheep given 
salbutamol and fenoterol. In the sheep which received 
ritodrine, also, uterine blood flow increased after the 
second hour of infusion. But in this case, the uterine 
blood flow returned only to the preinfusion level, and 
this was reached only during the 6th hour of infusion. 
Brennan could also demonstrate an increased resistance in 
the uterine vessels during ritodrine infusion and de-
creased uterine vascular resistance with salbutamol and 
fenoterol. 
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2.4.2.3. Studies in human subjects 
2.4.2.2.1. Aoute experiments 
Brettes and associates (1976) published a double blind 
cross-over study on 29 patients in the third trimester of 
pregnancy. With a low dose of ritodrine (PreparR) given 
by the intravenous route, no statistically significant 
effect could be demonstrated on the blood flow measured 
with a thermister probe inserted into the anterior lip of 
the cervix in women with normal pregnancies. In the group 
of pregnancies complicated by intrauterine growth retarda-
tion or hypertension, however, they observed an increased 
cervical blood flow. 
It must be stressed however, that a thermister probe in-
serted into the cervix at best measures local flow and 
this may not reflect total uterine blood flow or placental 
perfusion. 
The uteroplacental blood flow was measured by Luotola 
and associates (1977) in 26 pregnant women between 36 - 43 
weeks of gestation without complication of pregnancy be-
fore and after administration of isoxsuprine intravenously 
(5 mg i.v. bolus injection or 16 mg i.v. during 30 min-
utes) . Measurements were made by an intravenous 133 
Xe-method and no significant short-term effects of isox-
suprine upon myometrial or placental flow were found. 
Rondinelli and Vangelista (1975) reported on 38 high 
risk pregnant women in the third trimester in whom they 
compared the rate of appearance and intensity of counts 
from 1.5 mCi 113m In, injected intravenously, in the area 
over the placenta under basal conditions and during the 
administration of orciprenaline (10 mcg/min). They found 
a statistically significant increase in radioactivity over 
the placental site during orciprenaline infusion in the 
dose mentioned. An even more marked increase was observed 
in the 5 patients with severe preeclampsia. 
52 
Supportive evidence for all of the experiments mentioned 
above was given by Suonio et al. (1978). Using a radio­
nuclide accumulation method with doses of 0.08 and 0.2 mCi 
of 113m In, he measured no statistically significant dif­
ferences in placental perfusion (p > 0.2) before and one 
hour after an intramuscular dose of 10 mg of ritodrine 
hydrochloride in 11 healthy gravidas between 31 and 41 
weeks of amenorrhea, whereas 10 pregnant women with 
preeclamptic hypertension and 11 with essential hyper­
tension, showed significant increases (p < 0.05 and 
ρ < 0.01 resp.) in placental blood flow. 
Lippert and coworkers (1976) investigated the actions 
of fenoterol (partusisten1*) upon placental and myometrial 
blood flow in 11 patients with various pregnancy compli­
cations during the first stage of labor. the observations 
were made by continuous recording of isotope activity over 
placenta and placenta-free myometrium after injecting 0.5 
mCi of 113m Indium intravenously. The results reported 
show that in the human gravida, fenoterol (60 meg i.v. 
during 5 to 12 minutes) induced an increase in placental 
and myometrial blood pool which was not entirely due to 
cessation of uterine contractions. They suggested that 
the enlarged placental blood pool represented an augmen­
tation of the volume of blood in the intervillous space, 
probably due to a dilatation of the spiral arteries. 
However, enlargement of the intervillous space blood pool 
does not prove that turn-over (flow through) is increased, 
for the same phenomenon can occur as a result of an in­
creased venous resistance to drainage of blood from the 
intervillous space. Furthermore, the possibility must be 
considered that only resting myometrial tension is de­
creased by ß-mimetics, leading to an increase in intervil-
lous space volume with no change in inflow rates or 
pressures. 
Another possibility is that the increased blood volume 
accumulates not in the intervillous space, but in the 
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large veins in the endometrium and myometrium underlying 
the placenta. 
2.4.2.3.2. Chronic experiment 
Janisch and coworkers (1974) studied the influence of 
ritodrine and fenoterol intravenously administered in 
patients with EPH gestosis and an insufficient placental 
blood supply, as assessed by the Y -emissions following 
113m Indium or 99m Tc. The 44 patients were divided into 
three groups of 12, 14 and 18 women, who received ritodri-
ne, fenoterol and "conventional" treatment, respectively. 
After a treatment period of 14 days, a highly significant 
improvement of uteroplacental blood flow was measured in 
the patients treated with 50 mg ritodrine (p < 0.001) or 
0.08 mg fenoterol (p < 0.001) slowly intravenously twice a 
day, whereas the "conventionally" treated patients showed 
a trend toward improvement but no significant difference 
from the initial values. 
2.4.2.4. Disaussion 
The good results in patients with EPH gestosis (Ja-
nisch et al., 1974) and the tendency to a better result in 
"pathological" pregnancies (intrauterine growth retarda-
tion, hypertension) reported by Brettes et al. (1976) and 
Suonio et al. (1978), combined with the absence of 
significant changes in normal gravidas, give support to 
the hypothesis that besides an indirect influence on 
placental blood flow via an increased cardiac output, 
^-sympathomimetics might have a direct effect on the uter-
oplacental arteries by way of spasmolytic action on the 
smooth muscle of the arteriolar wall. The enhanced effect 
might reflect a state of increased vasoconstrictor tone, 
independent of myometrial activity, in these conditions. 
If g-mimetics indeed cause vasodilatation in the 
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uteroplacental vascular bed, the site of this action is 
probably proximal to the spiral arteries, in the radial 
and arcuate arteries and perhaps even in the main uterine 
arteries. Brosens (1964), Ramsey et al. (1976), and 
others have demonstrated that smooth muscle disappears 
from the walls of the spiral arteries during pregnancy in 
man and some other primates, probably as a result of inva-
sion by trophoblast cells. 
Thus, it seems unlikely that these vessels are capable of 
vasomotor activity. Furthermore, the spiral arteries are 
quite widely dilated over most of their length and for 
this reason also are unlikely to be the site of the con-
trolling resistance in the uteroplacental vascular bed. 
This concept is supported by the observation of Moll et 
al. (1978) that pressures within the spiral arteries are 
only slightly greater than the pressure within the 
intervillous space. The physiological advantage of a 
shift in the site of the controlling resistance to more 
proximal, larger vessels during pregnancy has been sug-
gested by Anderson and associates (1977) . According to 
their hypothesis, a greater degree of vascular smooth 
muscle concentration would be necessary in larger than in 
smaller vessels, to produce the same degree of increase in 
vascular resistance. This would have the effect of 
"protecting" the fetus from large changes in placental 
blood flow as a consequence of relatively minor stresses. 
Another important concept with regard to the possible 
site(s) of action of ß-mimetics on the uterine circulation 
is that of differing reactivity between the utero-placen-
tal arteries (those arteries supplying the maternal ex-
change area(s) of the placenta) and the myo-endometrial 
vascular beds. Greiss and coworkers (1976) have demon-
strated that as pregnancy progresses in sheep, the capac-
ity for autoregulation of flow in response to changes in 
perfusion pressure disappears from the uteroplacental 
(cotyledonary) arteries, but remains present in the myo-
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endometrial vessels. Rosenfeld et al. (1976a) and Ander-
son and coworkers (1977) have shown that the degree of 
vasoconstriction induced by adrenaline and noradrenaline, 
respectively, in myoendometrial vessels of the pregnant 
ewe is much greater than that produced in the cotyledonary 
arteries. It would appear that the reactivity of the 
uteroplacental vessels is markedly blunted during preg-
nancy, whereas the myoendometrial vessels retain their 
normal capacity for dilatation and constriction. This 
suggests that a dilator effect of g-adrenergic agents 
would be more likely, and of stronger degree, in the 
non-placental than in the placental portions of the uter-
ine vascular bed during late pregnancy. Caution is there-
fore necessary in interpreting either direct measurements 
of total uterine blood flow (e.g. Brennan et al., 1977 ; 
Ehrenkrantz et al., 1976, 1977a,b) or indirect indices of 
blood flow over the placental site (and overlying myo-
metrium) (Brettes et al., 1976 ; Lippert et al., 1976 ; 
Janisch et al., 1974 ; Suonio et al., 1978) as represent-
ing an increase in maternal flow in the exchange portion 
of the placenta. 
An increase in maternal placental blood flow in re-
sponse to ß-mimetics or other agents remains a real possi-
bility, however. A decrease in the frequency and inten-
sity of uterus contractions would increase average blood 
flow in proportion to the degree in which contractions 
were initially present. That some reserve capacity for 
vasodilatation remains in the uteroplacental vascular bed 
is demonstrated by the observation that estrogens produce 
an increase in cotyledonary blood flow in sheep (Rosenfeld 
et al., 1976b), although the per cent increase in cotyle-
don flow was far less than that observed in myometrium and 
endometrium. 
Still another possible mechanism for increased placen-
tal flow is suggested by the observation that in the rhe-
sus monkey, not all placental lobules are perfused at all 
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times even in the absence of uterine contractions (Martin 
et al., 1964 ; Ramsey et al., 1979). In these radioangio-
graphic studies, some spiral arteries (and the placental 
lobules they supplied) were found to be inconsistently 
visualized in successive radioangiograms made during uter­
ine relaxation, suggesting the presence of intermittent 
vasoconstrictor activity, probably proximal to the spiral 
artery itself (Martin et al., 1964). Recent observations 
with real-time echography have suggested that a similar 
phenomenon occurs in human pregnancy (Hoogland, 1980). 
A vasodilator effect of β-mimetic agents could conceivably 
overcome temporary vasoconstriction in portions of the 
uteroplacental vascular bed, resulting in greater total 
placental perfusion. 
It is, of course, self evident that, in pathologic 
pregnancies, a vasodilator effect of any agent on the 
uteroplacental vascular bed is meaningful only to the 
extent that any reduction in maternal placental blood flow 
present is the result of spasms of the more proximal 
uteroplacental vessels and not the consequence of anatomic 
lesions of the spiral arteries. 
Circulation in the portions of the intervillous space 
downstream from markedly stenotic or occluded spiral ar­
teries will not be improved by vasodilator therapy, 
because of the compartimentalization of the intervillous 
space (Wallenburg, 1971 ; Brame et al., 1969). 
2.4.3. Fetal lung maturation after ЪеЬатітеіъс therapy 
The leading element in reducing the chances for 
healthy neonatal life, or even survival, of prematurely 
born infants is functional immaturity of the lungs. 
A number of drugs including heroin (Glass et al., 
1971) and thyroxine (Redding et al., 1972), are believed 
to have some influence on the incidence of RDS in the 
neonate. 
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Evidence for the role of corticosteroids in the stimula­
tion of fetal lung maturation has been given by several 
authors (Liggens and Howie, 1972 ; Caspi et al., 1976). 
In a retrospective analysis. Boog and associates 
(1975) reported a tendency toward a lower incidence of 
RDS among premature infants whose mothers had been treated 
with ritodrine as compared with a control group of 
untreated subjects. 
From a similarly designed analysis Bergman and Hedner 
(1978) reported a significantly lower proportion of RDS 
among infants from mothers treated with terbutaline com­
pared to control babies (p < 0.05). 
Gamissans et al. (1975) studied the effect of rit­
odrine on the L/S ratio in a prospective, placebo-con­
trolled trial. After 1 week of treatment (10 mg orally 
every б hours), they could only report upon a trend toward 
an improvement of L/S ratio's compared with the untreated 
patients (p < 0.08). 
Recently, the effect of ritodrine (10 mg 4 times per 
day orally), upon amniotic fluid palmitic acid levels was 
investigated by Cabero and coworkers (1979) in a prospec­
tive, randomized, placebo-controlled methodology, in­
cluding 20 normal pregnant women. Treatment was started 
in the 33th week of amenorrhea and lasted for 10 days. A 
significant increase in amniotic fluid palmitic acid 
levels was seen in the treated women (p < 0.001), whereas 
no such increase occurred in the control subjects. Also a 
significant difference was found between the two groups of 
patients in palmitic acid levels after treatment 
(p < 0.05). 
The mechanism of action is not clear. Hypotheses in­
clude an increase of endogenous corticosteroid secretion 
resulting from stimulation of the maternal or fetal pitui­
tary to release ACTH, direct stimulation of adrenal ster­
oidogenesis, and stimulation of surfactant synthesis as a 
result of an increase in fetal pulmonary blood flow. 
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2.4.4. Intrapartum tooolysis with ß-sympathomimetios 
With i n c r e a s i n g c l i n i c a l expe r i ence with ß -mimetic 
agen t s in o b s t e t r i c s , t he se drugs have been used more 
f r e q u e n t l y for i n d i c a t i o n s o ther than the suppress ion of 
e a r l y l a b o r . Important examples of t h i s inc lude t h e i r 
p o s s i b l e b e n e f i c i a l e f f e c t upon p l a c e n t a l blood flow, or 
when a r ap id but s h o r t l a s t i n g r e l a x a t i o n of the u t e r u s i s 
d e s i r e d dur ing l a b o r . Severa l i n d i c a t i o n s for i n t r apa r tum 
t o c o l y s i s have been sugges t ed . These a re summarized in 
Table 2.4 
Table 2.4 INDICATIONS FOR INTRAPARTUM TOCOLYSIS WITH BETAMIMETICS 
I . Intrapartum fetal distress 
- umbilical cord complications 
- excessive uterine activity 
- placental insufficiency 
I I . Impending rupture of the uterus 
I I I . External or internal version 
IV. Before cesarean section to avoid further engagement of a breech 
V. Manual removal of the placenta complicated by a contraction ring 
VI. Manual reposition of an inversion of the uterus 
V I I . "Uterine dystocia" 
Relaxa t ion of the u t e r u s may be a l i f e saving tempor iz ing 
method u n t i l caesa rean s e c t i o n can be performed in case of 
an impending r u p t u r e of the u t e r u s . 
When a f e t o - p e l v i c d i s p r o p o r t i o n i s diagnosed in a 
breech p r e s e n t a t i o n with a high degree of c e r v i c a l d i l a -
t a t i o n , t o c o l y s i s may be he lp fu l whi le awai t ing the abdom-
ina l d e l i v e r y . 
Most impor tant from a q u a n t i t a t i v e p o i n t of view, 
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however, is the administration of 3-mimetics in case of 
intrapartum fetal distress. 
2.4.4.1. Treatment of fetal distress with Q-mimetic agents 
Uterine contractions at any time may reduce or even 
totally arrest blood flow in the pregnant uterus and in-
tervillous space of the placenta by compression of the 
intramyometrial blood vessels (Borell et al., 1964), and 
thus can be an asphyxiai stress for the fetus. 
Because of the recovery time between contractions these 
periodic decreases in uterine blood flow do not neces-
sarily lead to severe fetal hypoxia and acidosis. 
In cases of abnormally intense uterine motility, however, 
the fetomaternal exchange can be diminished to such an 
extent that as a consequence fetal PO- and pH will de-
crease progressively. Even normal uterine activity during 
labor may affect the fetus in the same way when materno-
fetal exchange is hampered, for reasons such as umbilical 
cord complications or placental insufficiency. 
Considering these facts, it seems rational to try to im-
prove deteriorating fetal condition in these circumstances 
by diminishing uterine activity (de Haan et al., 1971). 
The first reports of treatment of intrapartum fetal 
distress with ß-mimetics came from South America when 
Caldeyro-Barcia and associates (1969) described 2 cases of 
fetal distress with normal uterine contractions ; after 
tocolysis (orciprenalin intravenously), late decelerations 
disappeared and the pH of the fetal scalp capillary blood 
rose to normal values, and from Spain (Gamissans et al., 
1971) . 
Schmidt and Hirdes (1974) reported of 60 caesarean 
sections for fetal or mixed fetal-maternal indication. 
Half of the patients were alternatively treated prior to 
the operation with fenoterol (0.08 - 0.1 mg i.V.). A 
significant difference was found between the treated and 
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untreated patients in the pH of umbilical venous blood, 
the fenoterol group being less acidotic (7.29 + 0.08 vs. 
7.22 + 0.08 ; ρ < 0.01) . 
With a considerably lower dose of the same agent, 
K'unzel and Reinecke (1973) found a significant rise in 
fetal POj during normal labor but no alteration in pH of 
mother or fetus. 
Another approach to influence the fetal oxygenation 
and fetal acid-base status in normal labor was made by 
Humphrey and coworkers (1975). They studied 35 women in 
the second stage of labor, specifically excluding patients 
with clinical signs of fetal distress. In a double blind 
controlled study, women were given either a placebo, 1.5 
mcg/kg/min ritodrine i.V., or 3.0 mcg/kg/min ritodrine 
i .v. 
A progressive fall in pH, PO, and oxygen saturation was 
seen in the fetal scalp blood of the control group whereas 
in the ritodrine groups these changes were abolished or 
even reversed. 
In general, the improvements were more pronounced in the 
group of patients treated with the larger dose. 
Kastendieck and associates (1974) found in 14 patients 
with established fetal acidosis in the second stage of 
labor not only a significant rise of pH and base excess 
following a 50 meg bolus of fenoterol i.v. followed by an 
infusion of 2.5 meg/min for 15 minutes, but also a corre­
lation between the severity of the acidosis and the rise 
of pH and base excess. 
Gamissans et al. (1971, 1972) demonstrated a signifi­
cant improvement of fetal acidosis of hypoxic origin after 
intravenous administration of a contraction inhibiting 
dose of ritodrine to women at the end of the first or dur­
ing the second stage of labor. Another report came from 
Lipshitz (1977), who treated six patients with severe 
fetal distress intrapartum with a 10 meg intravenous bolus 
of hexoprenaline (IpradolR) as a temporizing measure 
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before instrumental delivery. In all cases, a rapid 
improvement of the fetal heart rate and a rise in the 
fetal pH was observed, reflecting an improvement in the 
fetal condition probably due to the reversal of the 
aggravating factors which had caused the fetal distress. 
The first trials of intrapartum treatment of fetal 
distress with ß-mimetic agents were carried out with con-
tinuous infusion of the drug. Recently, there has been a 
tendency to the "one shot" therapy, for a bolus injection 
seems to be a convenient and rapid method of stopping 
(excessive) uterine activity for a limited period of time. 
In our department we have modified the bolus treatment by 
injecting the ß-mimetic agent slowly over a period of 
several minutes. 
In our experience such an approach causes prompt cessation 
of uterine activity with less maternal cardiovascular side 
effects than a rapid bolus injection of the same total 
dose. 
Whether intrapartum administration of ß-mimetics in 
cases of fetal distress may be considered as curative 
treatment depends largely upon the nature of the etiolog-
ical factor. Several of the causal factors are revers-
ible. Excessive uterine contractility can be reduced by 
position change of the mother (Caldeyro-Barcia et al., 
1960), or intravenous administration of tocolytic agents, 
continuously if necessary. Although in many instances 
umbilical cord compression can be effectively relieved by 
changes in maternal position, the recovery time for the 
fetus may be shortened by simultaneous complete relaxation 
of the uterus. The same strategy may be applied in the 
correction of fetal hypoxemia due to aortocaval compres-
sion. A true knot in the cord, partial abruption of the 
placenta or severe placental insufficiency as a cause of 
fetal jeopardy, however, will certainly limit the effect 
of uterine inhibiting agents in increasing fetal PO and 
pH. In such cases, the use of these drugs should be re-
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garded as a temporizing measure only and should not lead 
to postponement of delivery. 
Whatever the reasons for fetal asphyxia, and whether 
the etiologic factors are reversible or not, the rate of 
progression of the fetal hypoxia is enhanced by uterine 
contractions. Therefore, rapid deterioration of the fetus 
can be avoided or at least minimized by prompt, complete 
relaxation of the myometrium. 
2.4.4.1.1. Meahanisms of action of ß-mimetic agenta in the treatment 
of fetal distress 
1. Because of the reduction of the blood flow in the uter-
us and intervillous space during contraction of the 
myometrium (Borell et al., 1964), relaxation of this 
muscle must be considered a major contributing factor 
in the process of intrauterine fetal recovery after 
tocolytic treatment. This applies even more when 
excessive uterine motility is present. 
2. The possible influence on uterine and placental blood 
flow has been discussed earlier (2.4.2). 
3. β -mimetic stimulation results in an increased glyco-
genolysis in liver and skeletal muscle and, as a conse­
quence, a raised plasma glucose level both in mother 
and fetus (Unbehaun et al., 1974). This increase in 
blood glucose level could be beneficial to the fetus in 
distress, as long as the fetus maintains a certain 
degree of oxygenation. In more severe fetal hypoxia, 
however, this carbohydrate load can have a deleterious 
effect on fetal brain structures probably as a result 
of the markedly greater extent to which lactic acid 
accumulates in brain tissue in a hyperglycemic state 
(Myers, 1977). Fetal hyperglycemia may also acceler­
ate the rate of fall in pH during fetal hypoxia by 
providing more substrate for anaerobic metabolism to 
lactic acid (Shelley et al., 1975). 
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Even when there is no fetal hypoxia present, adminis-
tration of ß-mimetics can produce a mild degree of mater-
nal and fetal metabolic acidosis. Because of the lack of 
glucose-6-phosphatase in muscle cells, glycogenolysis in 
muscle leads to production of lactic acid, much of which 
diffuses into the blood stream from which it is largely 
removed by the liver and (in the presence of adequate Oj) 
reconverted to glycogen or glucose. 
The net effect is an increase in the maternal plasma level 
of lactic acid. This results in a slight metabolic acido-
sis which, because of the placental transfer of lactate, 
(Weidinger and Mohr, 1973) also affects the fetus. More-
over, the lipolytic action of these agents will also con-
tribute to a fall in maternal pH and base excess. In the 
absence of hypoxemia, however, such a "passive" mild 
metabolic acidosis appears to be innocuous for the fetus. 
2.4.4.1.2. Administration of the drug 
To achieve prompt suppression of unwanted uterine 
activity for a limited period of time, the ß-mimetic agent 
can be given either intravenously or in aerosol form. 
The effect of an intravenous bolus injection of the drug 
is more rapid than that of an equivalent dose administered 
as a timed infusion. Equivalent bolus doses are 25-50 meg 
of fenoterol, 3-6 mg of ritodrine and 100-200 meg of sal-
butamol (Lipshitz et al., 1976). 
Because of compression of pelvic vessels in the supine 
position, bolus injections are preferably administered 
with the patient in the lateral position. 
A precautionary intravenous infusion, and, recording of 
heart rate and blood pressure are recommended and an an-
tagonist should be available. 
The cardiovascular effects of the ß-mimetics may be 
neutralized by the intravenous administration of proprano-
lol, which antagonizes more selectively the cardiovascular 
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effects. Oxytocics antagonize only the tocolytic action 
of ß-mimetics. 
2.4.4.2. Other indications for intrapartum tooolysis 
Zandvoort (1975) described successful regulation of 
hyperactivity, hypertonus and dysregulation of uterine 
contractility in the first stage of labor by infusion of 
fenoterol (0.5 meg per minute). 
Hyperactive labor with excessive amplitude and fre-
quency, hypertonic labor with excessive basal tone, as 
well as incoordinate labor with an irregular sequence of 
multishaped contractions, were reported to be effectively 
regularized by administration of ß-mimetics in a double 
blind, placebo-controlled study (Hüter, 1977). 
Saling and Müller-Holve (1977) reported upon 57 
pregnant women near term in whom 67 attempts at external 
version of a fetus from breech to vertex presentation were 
made. The procedure was carried out after complete re-
laxation of the uterine muscle by intravenous injection of 
fenoterol. In 34 of these patients, the duration of 
pregnancy exceeded 37 weeks, a time beyond which external 
version is frequently unsuccessful. In 25 of these 34 
patients with uterine relaxation, however, version was 
successful. 
In only one case was the attempted version followed by 
severe fetal acidosis. 
In the immediate postpartum period ß-sympathomimetics 
can be employed if contracture of the lower uterine seg-
ment complicates manual removal of the placenta, or in 
cases of acute puerperal inversion of the uterus (Thiery 
et al., 1978). 
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2.4.5. Contraindications 
Contraindications for the inhibi t ion of uter ine con-
t rac t ions with ß-mimetics are summarized in table 2 .5 . 
In hyperthyroid pa t i en t s , administration of ß-adren-
ergic drugs can be dangerous because of the already 
exis t ing greater sympathetic ac t iv i ty in these persons. 
Combination with other drugs such as antihypertensive 
agents or some general anaesthet ics (e .g. fluothane) can 
lead to pronounced hypotension and cardiac arrhythmias or 
asys to le . Monoamine oxidase i nh ib i to r s , used in the 
treatment of some psychiat r ic d isorders , can modify the 
metabolism of ß-agonis ts . Several authors have warned 
against the combined use of ß-adrenergic drugs to inh ib i t 
Table 2.5 RELATIVE CONTRAINDICATIONS FOR THE USE OF BETAMIMETICS 
Thyrotoxicosis 
Heart disease 
Diabetes mell i tus 
Dystrophia myotonia 
Feochromocytoma 
Infections - fever 
Coagulation disorders 
Shock 
Some other drugs 
Preeclampsia * 
Fetal growth retardation * 
Fetal distress (chronic use) 
Severe fetal malformations 
Abruptio placentae 
Ruptured membranes with demonstrated or probable fetal lung 
maturity 
Severe blood loss from the placental site 
According to some authors, these oonditions car. sometimes 
also constitute indications for betammetic therapy. 
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labor and corticosteroids to stimulate fetal lung maturi-
ty. Several cases of maternal death have been attributed 
to this combination, death occurring by pulmonary edema 
and heart failure (section 2.5.1.2). 
Infections with high fever increase the endogenous 
levels of catecholamines. Antibiotic treatment is more 
appropriate than ß-adrenergic drugs. Nevertheless, in 
urinary tract infections with slight temperature eleva-
tions and uterine contractions, the temporary 
administration of ^-adrenergic drugs can be helpful. 
Premature rupture of the membranes forms a separate 
entity because of the risk of intrauterine infection, 
which increases with time after membrane rupture. If the 
fetus has no chance of survival outside of the uterus 
because of the degree of immaturity, inhibition of labor 
seems indicated. 
Dystrophia myotonia (syndrome of Curschmann Steinert) 
is considered a contraindication to the use of ¡3-mimetic 
drugs because of aggravation of the symptoms of myotonia. 
In cases of severe preeclampsia the maternal and/or 
fetal condition can deteriorate rapidly. Termination 
rather than prolongation of pregnancy is often the better 
choice. 
In diabetes mellitus careful control of blood glucose 
levels is needed during ß-mimetic therapy. 
Heart disease and especially disturbances of intra-
cardiac conductance form a relative contraindication. 
Electrocardiograms taken before and during treatment are a 
wise precaution. 
Vaginal bleeding from placenta praevia accompanied by 
uterine contractions is not necessarily a contraindication 
to tocolysis unless blood loss is excessive. In cases of 
placental abruption ß-adrenergic drugs might only be 
indicated when placental reserve guarantees continuing 
fetal well-being. The relationship between uterine activ-
ity and the maternal coagulation defect is not clear. 
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Some believe that a hypertonic and hypercontractile uterus 
forces intrauterine material into the maternal circula­
tion. Others believe that the hypertonus prevents entry 
of thromboplastic material into the maternal circulation 
(Eskes, 1966). This question is presently unresolved. 
Fetal growth retardation, if secondary to a deficient 
uteroplacental circulation, can signify an increased risk 
of intrauterine death, and hence might be regarded as a 
contraindication to β-adrenergic treatment. It might be 
unwise to interfere with the endogenous trigger for labor 
and delivery since this may be a protective mechanism for 
the fetus. On the other hand some authorities advocate 
the use of ß-adrenergics because of their possible bene-
ficial effect on placental perfusion. 
Fetal distress can be regarded as a relative contra-
indication to the chronic use of ß-mimetics because as 
soon as the diagnosis is established by CTG and blood-gas 
analysis, pregnancy or labor should usually be terminated 
promptly. An exception is the rapid temporary inhibition 
of uterine activity during labor by an intravenous bolus 
injection as described above, while preparations for 
operative delivery are being carried out. 
2.5. Side effects of betasympathonrimetios in human obstetrics 
Я.5.1. Extrauterine effects 
2.5.1.1. tfeLabolio effects 
β-sympathomimetic drugs exert an influence on carbohy­
drate metabolism by stimulation of adenylcyclase in liver, 
muscle and probably pancreas cells. 
ß-adrenergic stimulation in liver cells causes an ele-
vation of the serum glucose level as a result of at least 
three mechanisms (Weidinger and Wiest, 1973). 
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1. activation of Phosphorylase, which leads to conversion 
of glycogen to glucose ; 
2. inactivation of glycogen production from glucose ; and 
3. stimulation of gluconeogenesis. 
In muscle cells, glucose-6-phosphatase is lacking. 
Thus, glycogenolysis in striated muscle cells will lead to 
production of lactic acid. After diffusion into the 
bloodstream, the lactate is largely removed by the liver 
and reconverted to glucose. 
In the pancreatic beta cells, there also seems to be a 
direct influence via β-adrenergic receptors, leading to 
increased blood insulin levels (Taylor et al., 1976). 
There may also be an increased insulin resistance secon­
dary to g-mimetic induced lipolytic activity (Weidinger 
and Mohr, 1973). 
Although the exact mechanism of action is not clear, the 
measured net effect of these actions is a transient 
elevation in blood glucose concentration in spite of 
increased insulin secretion. 
When treatment with g-mimetic drugs is continued, a 
new equilibrium within the normal range may be established 
(Unbehaun et al., 1975). 
These observations, and the fact that with respect to 
the tocolytic and cardiovascular effects no or incomplete 
adaptation is seen during long-term treatment have led to 
several speculations including the proposal that there 
might be a separate intracellular receptor system for the 
metabolic effects. 
Another explanation could be compensation of the dia­
betogenic effects of β-mimetics by a correspondingly 
higher level of insulin production, either after indirect 
or direct stimulation of the β-cells of the pancreas 
(Weidinger and Mohr, 1973). 
Adjustment of carbohydrate metabolism as judged from 
normal blood levels of glucose and free fatty acids is no 
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proof of an unaffected carbohydrate metabolism. There-
fore, glucose tolerance during long-term treatment with 
ß-mimetics has been studied by several investigators. 
Blouin and colleagues (1976) studied the effect of 
ritodrine (10 mg orally, 4 times per day) from the 25th 
week of pregnancy until delivery on the carbohydrate 
tolerance of eight pregnant women and their newborn 
infants. They observed no diabetogenic influence on the 
50 gram oral glucose tolerance test or the 24 hour glucose 
profile on the 7th day of treatment, nor after 10 weeks of 
oral ritodrine therapy, as compared with matched control 
women. 
These observations are in agreement with the results of 
Unbehaun et al. (1974), who found a compensation and nor-
malisation of the changes in carbohydrate metabolism 
within 72 hours after the start of treatment. 
Lang and associates (1977) studied the glucose toler-
ance at the end of a 48 hour infusion of 1 meg fenoterol 
per minute in 6 women during the last trimester of 
pregnancy. Comparison of the assimilation constant (Kg) 
of the intravenous glucose tolerance test (i.v. GTT) prior 
to and during fenoterol infusion in the same patients 
demonstrated a slight deterioration in the Kg. A definite 
elevation of glucose levels during fenoterol administra-
tion above control levels, particularly under fasting 
conditions, was also observed. 
When basal glucose values were taken into account, how-
ever, no difference was found between glucose tolerance 
before and during fenoterol administration. The insulin 
profiles during the two glucose tolerance tests were not 
found to be different. 
Because of their effects on carbohydrate metabolism, 
ß-mimetics are contraindicated in patients with unstable 
diabetes mellitus. As to patients in whom no carbohydrate 
intolerance has been detected, frequent assessment of 
glucose homeostasis is advisable. 
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Serum potassium levels can decrease during ß-adrener-
gic treatment because of a shift of potassium from the 
extra- to the intra-cellular compartment. In addition to 
the extracellular to intracellular shift of potassium 
during the first days of ritodrine therapy, Hondros and 
Schaller (1980) also demonstrated an increased urinary 
excretion of potassium. 
These observations could not be confirmed by Grospietsch 
and coworkers (1980) in their trial with fenoterol 
(2 mcg/min intravenously) and verapamil (75 mcg/min intra-
venously) . Indeed, within two hours a marked decrease in 
the serum potassium concentrations was measured, followed 
by a slow increase to preinfusion levels within 24 hours 
of the start of therapy ; the urinary potassium excretion 
per hour (as well as the excretion of sodium), however, 
decreased and did not reach preinfusion levels within the 
first 48 hours following the start of treatment. 
Furthermore, ß-mimetic agents stimulate a specific 
lipase leading to lipolysis, with a rise in free fatty 
acids and free glycerol (Lang et al., 1977). 
This, and the previously mentioned rise in lactic acid 
levels following glycogenolysis in muscle, may lead to a 
transient metabolic acidosis. 
2.5.1.2. Caraiovasoular effects 
Betamimetics have a positive inotropic and chronotrop-
ic effect on the maternal heart, resulting in an increase 
in maternal heart rate. 
Stimulation of the ß-adrenergic receptors in blood 
vessels relaxes vascular smooth muscle, producing a de-
crease in peripheral vascular resistance and a varying 
degree of hypotension with increased pulse pressure. 
Within the therapeutic range of S-2-selective 
ß-mimetics used for long-term tocolysis, the net effect of 
these actions is usually a moderate increase in cardiac 
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output (Bienarz et al., 1974). The increased cardiac 
output with concomitant peripheral vasodilatation could 
increase placental perfusion, if the uteroplacental cir-
culation participates in the vasodilatation (section 
2.4.2). In the treatment of threatening preterm labor, 
however, these cardiovascular effects are unwanted ; for 
especially the resulting maternal tachycardia considerably 
limits the dosage level of 3-mimetics which can be used in 
tocolysis. 
In order to study the possibility of myocardial damage 
during long-term tocolysis, Wellstein and associates 
(1977) and Meinen and coworkers (1978) , analysed the heart 
muscle-specific isoenzyme creatine kinase MB 3 times week-
ly in 50 and 100 women respectively, who were treated with 
fenoterol and verapamil (maximum dose 4 meg and 40 meg per 
minute, respectively, intravenously in both studies). In 
none of their patients could a significant rise in enzyme 
levels in serum be shown. 
Similar results were reported by Steyer and associates 
(1979) , in 128 women receiving long-term tocolysis with 
fenoterol, most of them treated orally (30 - 60 mg daily), 
and by Gerris and colleagues (1980) in 33 gravidas, 
undergoing chronic tocolysis with ritodrine, both studies 
without administration of verapamil. 
However, in the rat (Rona et al., 1959) and in 
cultured human fetal myocardial cells (Hofmann et al., 
1977), morphologic lesions interpreted as myocardial 
necrosis have been reported in connection with the use of 
ß-mimetic agents. 
Jung et al. (1978) studied the maternal and fetal 
electrocardiographic alterations in 18 healthy women in 
labor, during and after infusion of fenoterol. During 
treatment an early ST rise and an increase in the Τ wave 
were observed in the maternal ECG. Similar alterations, 
however, occur during sympathetic stimulation from 
physical stress or emotional excitement as signs of 
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sympathetically altered de- and repolarization of the 
myocardium. Thus, the authors concluded that these 
alterations in maternal ECG were merely functional and not 
a sign of damage to the heart. 
On the other hand, there is a growing number of anec-
dotal reports of maternal morbidity and mortality in 
relation to the combined administration of g-adrenergic 
drugs and corticosteroids (Bender et al., 1977 ; Elliott 
et al., 1978 ; Jonatha et al., 1978 ; Stubblefield, 1978; 
Babenerd and Flehr, 1979 ; Wolff et al., 1979 ; Tinga and 
Aarnoudse, 1979 and Rogge et al., 1979), and in relation 
to a preexisting cardiomyopathy (Eskes et al., 1980), 
leading to severe maternal pulmonary edema within 72 hours 
after the start of therapy. 
Special attention was placed on the role of ergomet-
rine in this situation by Davies and Robertson (1980) , for 
especially after delivery when there is a physiological 
autotransfusion due to uterine contraction, the vaso-
constrictor effect of ergometrine could cause a sudden 
increase in the tonus of both the resistance and capaci-
tance vessels, resulting in a simultaneous overload of 
both the left ventricle and pulmonary circulation. 
As a result of these cardiovascular effects, ß-mimet-
ics are contraindicated in patients with heart disease. 
Also, combination with corticosteroids in order to in-
crease fetal pulmonary maturity can be dangerous. As for 
healthy women, non-invasive examination of the heart is 
recommended to assess the influence of these drugs on 
cardiac function, the more so because of the initial 
decrease in potassium levels (section 2.5.1.1). Special 
attention should be given also to the fluid balance to 
avoid volume overload (section 2.5.1.3) and ergot alkal-
oids should be avoided when there is a short interval 
between the end of treatment and delivery. 
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2.5.1.3. Other extrauterine side effects 
Various subjective side effects are related to β-mi­
metic drugs, especially when these are given in tocolytic 
dosage levels. The most frequent complaints are palpi­
tations, anxiety, tremor, slight headache, constipation, 
nausea, vomiting and sweating. 
Besides the well known influence of 8-mimetics upon 
uterine, pulmonary and cardiovascular smooth muscle, these 
agents also affect other smooth muscle (urinary tract, 
digestive tract) and striated muscle. 
Horowitz and Creasy (1978) reported 2 cases of aller­
gic dermatitis following the administration of isoxsup-
rine. 
Jutting and coworkers (1973) studied the total estro­
gen excretion in ß-mimetic-treated women. 
A significantly lower estrogen excretion compared to 
control patients was found when fenoterol was given intra-
venously. This could, however, be the result of an anti-
diuretic effect of ß-adrenergic agents as postulated by 
Beri et al. (1974), Schrier et al. (1972) and Kords et al. 
(1978a). 
Schrier's (1972) investigations in the dog, suggested that 
the antidiuretic effect of ß-mimetic agents is not the 
result of an alteration of the water permeability of the 
renal tubular epithelium, but rather that the primary 
mechanism involves the integrity of the hypothalamus-neu-
rohypophysical system and the release of ADH. 
Although the antidiuretic effect of ß-mimetic stimulation 
is a transient one according to Grospietsch et al. (1980), 
it may be harmful in cases of EPH gestosis or renal 
insufficiency and may lead in combination with an excess 
of fluid intake and/or corticoid treatment to hypervolemia 
and maternal pulmonary edema (section 2.5.1.2). 
As a result of the water retention within 48 hours 
after the onset of treatment, an increase in weight and a 
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decrease of hemoglobin concentration, hematocrit, and 
serum albumin concentration may also be observed 
(Grospietsch et al., 1980). 
In contrast to the findings of Kords and associates 
(1978a) with fenoterol, Bibby and colleagues (1978) 
demonstrated a fall in peripheral plasma concentrations of 
progesterone and estradiol-17- β when salbutamol was given 
intravenously. 
These values returned to pretreatment levels after discon­
tinuation of therapy. 
No change was seen in plasma human placental lactogen 
concentrations during treatment, which suggests, according 
to the authors, that the fall in steroid hormone levels is 
not likely the result of altered uterine or placental 
blood flow. 
During a 24 hour fenoterol infusion in nine gravidas, 
Kords et al. (1978b) observed a transient fall in plasma 
aldosterone concentration corresponding to the fall in 
plasma potassium concentration, in spite of an elevation 
in plasma renin level. 
The influence of fenoterol upon the platelet aggrega­
tion and the number of platelets in peripheral blood was 
investigated by Ardelt (1978) . As a result of ß-mimetic 
stimulation platelet aggregation was found to decrease and 
a dose-dependent transient reduction in the number of 
platelets was reported. 
However, these observations could not be confirmed by 
Schander et al. (1978), whereas Briel et al. (1978) re-
ported a transient decrease in platelet aggregation after 
intravenous administration of fenoterol but no effect upon 
the peripheral platelet count. As a result of these 
observations of possible alteration in platelet number and 
function, plus the relaxing effect of 3-mimetics upon the 
myometrium, the fear of increased blood loss postpartum 
after prolonged treatment with β-adrenergic drugs or after 
intrapartum tocolysis may be justified. However, our own 
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investigation demonstrated no increase in post partum 
blood loss after long-term B-mimetic treatment (chapter 
5). 
Fenoterol treatment was found to have a significant 
influence upon the oxygen dissociation curve of pregnant 
women with gestational ages between 30 and 35 weeks (Meier 
et al. 1978). Compared to untreated and acetylsalicylic 
acid-treated patients, the actual as well as the standard-
ized partial pressure of oxygen at which hemoglobin was 
50% saturated (Pen) was found to be 1.5 mm Hg higher in 
women with long-term fenoterol treatment. 
2.5.2. Transplacental transfer 
Wiest et al. (1977) using radioisotopically labelled 
fenoterol in 31 cases of legal abortion, proved that 
partusisten crosses the human placental barrier in early 
pregnancy. 
Transplacental transfer of ritodrine was demonstrated 
by Gandar and coauthors (1980), who measured serum levels 
of ritodrine in venous cord blood of neonates born from 
mothers after intravenous infusion of ritodrine at various 
dosage levels. 
However, monoamine oxidase as well as catechol-O-methyl 
transferase have been identified in placental tissues 
(Thompson and Tickner, 1949 ; Morgan et al., 1972), so 
inactivation and protection may be possible to some 
extent. 
2.5.Ó. Effects en fetus and neonate 
The fact that so many different organs including the 
central nervous system are involved in the actions of 
ß-mimetic agonists, plus the ability of these agents to 
cross the placenta, make these drugs potentially dangerous 
to the unborn child. 
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Thus, assessment of the effects on the developing fetal 
organism is essential to judge the appropriateness of 
these drugs for use in human obstetrics. 
Furthermore, the potential effects to be investigated 
include not only short-term actions during the fetal or 
immediate neonatal periods, but also possible long-term 
effects on later physical health and mental development. 
Direct or indirect influence of β-mimetic treatment on the 
fetus is, however, very difficult to measure in man. 
Since transplacental transfer has been proven for some 
drugs in this category (section 2.5.2) and is likely for 
all of them, efforts have been made to measure the influ­
ence upon fetal heart rate and fetal electrocardiogram 
(Stander et al., 1964 ; Junge et al., 1978). Studies of 
the magnitude of acceleration of fetal heart rates have 
not been in agreement. Several authors have reported no 
or only a slight increase in human fetal heart rate even 
during maternal treatment with high doses of ß-mimetics 
(Landesman et al., 1971 ; Bieniarz et al., 1972), whereas 
others have noted significant fetal tachycardias (Stander 
et al., 1964). No satisfactory explanation has thus far 
been offered for this phenomenon, but it may well be due 
to a "first pass" effect of the placenta and/or fetal 
liver, and possibly also a diminished vasodilator-hypo-
tensive response of the fetal systemic circulation. 
Freysz and colleagues (1977) performed a long-term 
evaluation of infants who were exposed to ritodrine while 
in utero. 
Forty-two neonates with intra-uterine exposure of 2 to 93 
days duration (maternal daily dose 60-80 mg) were matched 
with 42 control neonates. 
No statistically significant differences were found in 
psychomotor development (Denver Developmental test), 
clinical examination, electrocardiograms, and other 
investigated parameters between the two groups of infants. 
A negative influence on the body weight gain until the 
77 
fifth day of life was reported by Stormi and colleagues 
(1977) in the newborn who was exposed to ritodrine while 
in utero, compared to control neonates. 
Hofmann et al (1977) reported myocardial necrosis 
following fenoterol exposure in an in vitro study of 
myocardial strips from fetal hearts from legal abortions 
treated in organ cultures. The combination of fenoterol 
with verapamil resulted, according to the investigators, 
in much less injury of the myoplasma. 
Neither Spelger and associates (1980) nor Plieth and 
colleagues (1980) were able to demonstrate pathological 
cardiac findings (CK-MB, electrocardiograms and echocar-
diograms) in newborns following tocolysis with fenoterol 
or isoxsuprine and verapamil, which were related to the 
preceding medication. 
The direct and/or indirect effects of S-mimetics on 
fetal and neonatal carbohydrate metabolism are discussed 
in chapter 4, together with a description of our own 
findings. 
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Chapter 3 
Clinical comparison of ritodrine and fenoterol in their efficacy in 
preventing preterm delivery 
3.1. Introduction 
The use of ß-mimetic drugs for the treatment of 
threatening premature labor has proved to be valid not 
only for the inhibition of uterine activity, but also for 
the delay of the onset of labor (Wesselius-de Casparis et 
al., 1971 ; Ingemarsson, 1976 ; Csapo and Herczeg, 1977 ; 
Christensen et al., 1980). 
Two ß-mimetic drugs were tested for their capacity to 
lengthen the duration of pregnancy after symptoms of 
threatening immature or premature labor had occurred. The 
two drugs were also compared to some side effects. 
3.2. Materials and methods 
3.2.1. Patients 
The original population for this investigation con-
sisted of 319 consecutive patients with threatening prema-
ture labor, for which treatment was started between Janu-
ary, 1974 and January, 1977. 
Further selection criteria applied for inclusion in 
the study were, that the patient had received either rit-
odrine only or fenoterol only as tocolytic agent (28 pa-
tients received both drugs), absence of premature placen-
tal separation (3 ; 3)*, singleton or twin pregnancy (1 ; 
1 triplets)* and that the last menstrual period preceding 
the pregnancy was normal in character and that its dates 
between brackets the number of patients (ritodrine ; fenoterol) 
removed for this reason 
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were known with assurance (23 ; 32)*. Application of 
these criteria resulted in the removal of 91 patients, 
leaving 228 study subjects. Subsequently during data 
analysis, 34 further patients were removed from the final 
comparison groups to achieve acceptably equivalent distri­
butions of background variables between the respective 
subgroups (section 3.2.5). 
The final number of subjects analysed in the compari­
son of the two tocolytic agents was 194 (ritodrine, 94 ; 
fenoterol, 100) . 
3.2.2. Criteria for the diagnosis of threatening early labor 
Threatening early labor was diagnosed clinically by 
judging uterine contractions recorded externally 
(corometrics fetal monitor 101 Β), the status of the fetal 
membranes, the condition of the cervix, and the amount and 
character of vaginal bleeding or discharge (if present). 
Uterine contractions (¡j. one per ten minutes) were 
obligatory to establish the diagnosis of threatening early 
labor. 
In about half of the patients, there were also other symp-
toms to support the diagnosis. Forty-nine patients (rit-
odrine = 23 ; fenoterol = 26) had no other symptoms than 
regular uterine contractions (>, 12 per hour) when therapy 
was begun. 
In 48 patients (ritodrine = 23 ; fenoterol = 25) the only 
symptoms were irregular uterine contractions (6 - 11 per 
hour) without other symptoms. 
Because of the painfulness of their contractions these 
patients were considered to be at high risk for an early 
delivery and therefore treatment was started. 
Inherent in this policy (and, as noted earlier in 
section 1.3 and 1.4, in almost every clinical trial of 
tocolytic drugs) is the possibility that a number of our 
subjects were treated unnecessarily. 
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3.2.3. Treatment schedule 
Ritodrine and fenoterol were given by intravenous 
pump-infusion and/or orally. 
In general treatment was started intravenously. When u-
terine contractions were absent for 24-48 hours, the infu-
sion-rate was decreased, and at levels of 100 meg ritodri-
ne per minute or 0.1 meg fenoterol per minute without de-
tectable uterine activity, oral medication was installed. 
In a number of women these dose-levels could not be 
reached and intravenous medication was continued. 
Several times treatment was started orally and in 
these cases intravenous medication was only given when 
oral treatment failed. 
Mean and standard deviation, median and range of the 
maximum dosage levels during the intravenous treatment 
period of both drugs are given in Table 3.1. 
Table 3.1 
MEANS AND STANDARD DEVIATIONS, MEDIANS AND RANGES OF THE MAXIMAL DOSE 
LEVELS (ug/min) DURING INTRAVENOUS INFUSION OF RITODRINE AND FENOTEROL 
Ritodrine 
Mean + S.D. median range 
311 + 168 300 67 - 732 
Fenoterol 
Mean + S.D. median range 
4.6 + 2.3 4.0 1.3 - 9.3 
During the oral treatment period highest doses were 12 
tablets of ritodrine 10 mg (120 mg) or fenoterol 5 mg 
(60 mg) per 24 hours. 
When the condition of the fetus, assessed by the en-
Si 
largement of the uterus, the urinary excretion of estriol 
and cardiotocograms, remained stable and the fetal mem­
branes were intact, treatment was continued until the end 
of the 37th week of amenorrhea and/or the finding of a 
lecithin / sphingomyelin ratio exceeding 2.0 (according to 
Gluck), or until uterine contractions had been suppressed 
and remained absent during tapering-off of the β-mimetic. 
Mean, median and range of the duration of treatment were 
28, 15, 1 - 125 days and 32, 23, 1 - 120 days for the 
ritodrine and fenoterol treated patients respectively. 
Verapamil (IsoptinR) was not given to prevent circulatory 
side-effects. 
3.2.4. Criteria for the judgement of success 
The difficulties that may arise in comparising the 
efficacy of tocolytic agents are discussed in chapter 2 
(section 2.4.1.2.2). 
Because of the subdivision that has been made accord­
ing to the duration of amenorrhea at the start of treat­
ment (section 3.2.5) it seemed justified to use the 
condition of the neonate as a measure of success. So all 
neonates were scored according to an arbitrarily defined 
Table 3.2 NEONATAL SCORE USED AS A MEASURE OF SUCCESS 
Value : 
0 : healthy mature neonate 
1 : healthy neonate born before the completed 37th week of 
amenorrhea 
2 : neonate with hyperbilirubinemia 
neonate with hypoglycemia 
4 : neonate with respiratory distress syndrome 
10 : perinatal death 
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Table 3.3 NEONATAL SUCCESS SCORES OF TWIN PREGNANCIES 
RITODRim 
Equal suaaese 
patient nr. 6 
49 
151 
209 
250 
Greater success 
inferni 1 
patient nr. 148 
278 
Greater success 
infant 2 
patient nr. 194 
281 
Score 
infant 1 
1 
1 
0 
1 
7 
3 
3 
10 
10 
Score 
infant 2 
1 
1 
0 
1 
7 
7 
7 
5 
1 
FENOTEROL. 
patient nr, 
patient nr. 
patient nr, 
. 52 
57 
58 
253 
, 18 
84 
.177 
279 
Score 
infant 1 
0 
10 
0 
1 
0 
0 
3 
10 
Score 
infant 2 
0 
10 
0 
1 
2 
2 
1 
1 
score in which the variables gestational age, hyperbiliru-
binemia, hypoglycemia, respiratory distress syndrome and 
perinatal death were weighted (Table 3.2). 
In case of a twin pregnancy, the parameters of the 
first infant were used for comparison. This was thought 
to be justified because in most cases a good correlation 
between the condition of the two infants was found (Table 
3.3) . 
Besides in the condition of the neonate, results were 
also expressed in the number of days gained from the first 
day of treatment till the day of delivery, the gain of 
days in relation to the lengthening of pregnancy that was 
aimed at (37th completed week) and the prolongation index 
(Richter, 1977, section 2.4.1.2.2, figure 2.2). 
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Several other variables e.g. gestational age at deliv­
ery, birth weight, Apgar score and pH of the umbilical 
artery blood were compared for the two treatment groups. 
3.2.5. Procedure for the balancing of the two groups of patients 
In studies comparing two groups of patients, it is 
usually required that these groups differ only in the fea­
ture or features being investigated. Other differences, 
however small, may sometimes make it impossible to draw 
valid conclusions. 
This risk may be dealt with by comparing the two 
groups using a prospective randomized, allocated and/or 
double-blind methodology. To reduce the chance of unbal­
anced groups, however, the number of patients has to be 
large and it may be difficult to get these large numbers 
in clinical research. 
When patients are not treated in a prospectively 
randomized way, it is often possible to analyse the data 
by methods which will assure retrospectively that the 
study subpopulations are truly comparable : 
- to select from the total population those patients which 
make up balanced patient groups ; or 
- to include in the data analysis a comparison of the dif­
ferent groups with respect to all of the recognized fac­
tors or variables which might bias the outcome of the 
study. 
Selection of patients for the comparison groups can be 
performed according to several methods. 
Requirements for a good procedure are : 
-the method must lead to a previously defined balance in 
the two groups ; 
-patients with the same features must have the same chance 
of being selected for the definite group ; and 
-not too many patients should be removed. 
Θ4 
3.2.5.1. Possible measures of balance 
Absolute measure 
There are η patients (n, for the first group, n^ for 
the second, ni + n2 = n) a n ^ m discrete variables with k. 
numbers of features (i = 1, 2, ,m) . 
For each patient it is recorded which feature of each of 
the variables is present. The numbers of patients having 
the same feature in each group are called a,· and a.. 
m 
Σ 
ι=1 
ki> (i = If 2, , j, j = 
The absolute measure of balance Τ is defined as 
J 
Τ = Σ 
i=l 'li 
- a 2i 
If there are equal numbers of patients with all features 
in both groups, then Τ equals 0 (complete balance) . With 
a complete nonbalance Τ = η χ m. 
Relative measure 
Instead of wanting a specific feature to appear with 
absolutely equal frequency in both groups, one could also 
desire that the feature occurs in both groups with the 
same relative frequency. 
The relative measure of balance R is defined as : 
J 
Σ 
i=l 
_li 
11 
a2i 
If there are relatively equal numbers of all features in 
both groups, then R equals 0 (complete balance). By a 
complete nonbalance R equals 2 χ m. 
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χ2
 - measure 
For each variable, a 2 χ к. contingency table can be 
made with a classification according to group and feature. 
The X value can be calculated to test the independence of 
both classifications (in case of a 2 χ 2 contingency table 
a correction for continuity is incorporated) . 
Ρ is calculated for X 2 with k· - 1 degrees of freedom. Ρ 
is maximally 1.0 (complete balance) and minimally 0.0 
(complete nonbalance). Since the χ2-test is used here as 
an approximation, the usual conditions for its application 
are not taken into account. Ρ is used only as a measure 
of balance. 
Elimination of patients 
For each woman in the two groups n, and n- the values 
of Τ and R could be calculated with this patients removed 
from the population. The patient with the lowest value of 
Τ or R can be removed. 
This procedure could be repeated until most P's are 
greater than a predetermined value. 
3.2.5.2. The elimination of patients in the present investigation 
As the results of tocolytic treatment might depend up­
on the duration of amenorrhea at the time of administra­
tion, the patients were divided into 4 subgroups (Am 
groups) according to the gestational age at the start of 
treatment (Table 3.4). 
In every Am group the ritodrine and fenoterol treated 
patients were balanced for the variables : uterine con­
tractions (UC), vaginal bleeding (BD), status of the fetal 
membranes (RM), dilatation of the uterine cervix (DI), the 
fundus being (^. 2 weeks) large for dates (FL) and infarcts 
of the placenta (IP) (Table 3.5), following the above de-
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scribed methodology (section 3.2.5.1). 
The ρ value for each of these variables which was aimed at 
was ρ > 0.40. 
Table 3.4 
SUBDIVISION OF THE TREATMENT GROUPS INTO 4 SUBGROUPS ACCORDING TO 
THE DURATION OF AMENORRHEA AT THE START OF TREATMENT 
Amenorrhea at the start of 
treatment 
< 28 weeks 
28 - 31 weeks 
32 - 33 weeks 
Ϊ, 34 weeks 
Am group 
Am group 
Am group 
Am group 
1 
2 
3 
4 
3.2.5.2.1. Balancing of patients of Am group I 
The exclusion of 12 patients led to an increase in the 
probability level ρ of 4 of the 6 variables from minimally 
0.35 to minimally 0.63. The ρ values of the variables : 
dilatation (DI) and uterine contractions (UC) of 0.25 
both, were somewhat dissatisfactory, however, for a 
further increase removal of a considerable number of pa­
tients would be necessary. 
The difference in the mean tocolytic index (Baumgarten and 
Gruber, 1974, section 2.4.1.2.1, table 2.3) for both 
treated groups fell from 0.59 to 0.33 (Table 3.6). 
3.2.5.2.2. Balancing of patients of Am group II 
The basic material of this Am-group was poorly bal-
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Table 3.5 VARIABLES FOR WHICH THE AH GROUPS WERE BALANCED 
VARIABLE CODE FEATUftE 
Uterine contractions UC 0 : none 
1 : i r regular 
2 : regular 
Bloody discharge BD 0 : absent 
1 : present 
Rupture of membranes RM 0 : no 
1 : high 
2 : low 
Di latat ion DI 0 : 0 cm 
1 : 1 cm 
2 : 2 cm 
3 : 3 cm 
4 : 4 cm or greater 
Fundus large for dates, 
e.g. polyhydramnios, mul-
tiple pregnancy, large 
fetus 
FL 0 : no 
1 : yes 
Infarcts of placenta IP 0 : no 
1 : yes 
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Table 3.6 AM GROUP I (balanced) 
ritodrine : η = 26 
fenotevol : π = 27 
mean tooclytio index - 2.77 
mean tocolytic index =2.44 
Variable * Number 
0 1 2 
(Ρ before balancing) 
UC 
BD 
ritodrine 
fenoterol 
ritodrine 
2 
0 
20 
15 
14 
6 
9 
13 
0.25 
0.94 
fenoterol 22 
(0.23) 
(0.39) 
RM 
ri todrine 26 
fenoterol 27 
1.00 (0.35) 
DI 
ri todrine 16 3 
fenoterol 21 
0.25 (0.13) 
FL 
ritodrine 15 11 
fenoterol 16 11 
1.00 (0.78) 
IP 
гг Ьоаггпе 
fenoterol 
24 
25 
1.00 (1.00) 
for explanation see table 3.5 
Distribution of features among the patients in Am group I after being 
balanced, with corresponding probability levels. 
Between brackets probability values before balancing (xz-test) 
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Table 3.7 AM GROUP II (balanced) 
ritodrine : η = 29 
fenoterol : η = 26 
mean tocolytic index = 2.45 
mean tocolytic index = 2.27 
Variable Number 
0 1 
(P before balancing) 
UC 
vitodrine 
fenoterol 
9 
10 
19 
15 
0.84 (0.68) 
BD 
ritodrine 27 
fenoterol 22 4 
0.57 (0.54) 
RM 
ritodrine 29 
fenoterol 26 
1.00 (0.08) 
DI 
ritodrine 19 7 0 
fenoterol 18 б 2 
0.29 (0.29) 
FL 
ritodrine 23 6 
fenoterol 16 10 
0.25 (0.22) 
IP 
ritodrine 27 2 
fenoterol 24 2 
1.00 (1.00) 
for explanation see table 3.5 
Distribution of features among the patients in Am group II after being 
balanced, with corresponding probability levels. 
Between brackets probability values before balancing (x2-test) 
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Table 3.8 AM GROUP I I I (balanced) 
ritodrine : η = 18 
fenoterol : η = 27 
mean tocolytic index = 3.06 
mean tocolytic index = 3.11 
Variable Number 
0 1 2 3 4 
Ρ (Ρ before balancing) 
UC 
ritodrine 0 7 11 
fenoterol 4 8 15 
0.22 ( 0 . 1 1 ) 
BD 
ritodrine 17 1 
fenoterol 22 5 
0.42 (0.09) 
ritodrine 
RM 
14 1 
fenoterol 20 
0.81 ( 0 . 6 7 ) 
ritodrine 
DI 
14 
fenoterol 21 
0.99 (0.42) 
ritodrine 
FL 
14 
fenoterol 22 
1.00 (1.00) 
ritodrine 
IP 
15 
fenoterol 21 
0.94 (0.63) 
for explanation see table 3.5 
Distribution of features among the patients in Am group III after being 
balanced, with corresponding probability levels. 
Between brackets probability values before balancing (x2-test) 
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Table 3.9 AM GROUP IV (balanced) 
ritodrine : η = 21 
fenotevol : η = 20 
mean tocolytic index = 2.86 
mean tocolytic index - 2.50 
Variable Number 
0 1 2 
(P before balancing) 
UC 
ritodrine 
fenoterol 
12 
11 
1.00 (1.00) 
ritodrine 
BD 
18 
fenoterol 15 5 
0.64 (0.54) 
RM 
DI 
ritodrine 
fenoterol 
ritodrine 
fenoterol 
20 
20 
13 
14 
1 
0 
4 
4 
2 
0 
2 
1 
0 
1 
1.00 
0.50 
(0.40) 
(0.39) 
FL 
ritodrine 17 4 
fenoterol 17 3 
1.00 (1.00) 
ritodrine 20 1 
IP 
fenoterol 20 
1.00 (1.00) 
for explanation see table 3.5 
Distribution of features among the patients in Am group IV after being 
balanced, with corresponding probability levels. 
Between brackets probability values before balancing (x2-test) 
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anced for the variable : ruptured fetal membranes (RM). 
After excluding 10 patients among whom all patients with 
high and low ruptured fetal membranes, probability levels 
ρ were still < 0.40 for the variables DI and FL, being 
0.29 and 0.25 respectively. This was accepted for only 
after removal of another 7 patients all probability levels 
ρ would exceed 0.42. The difference in the mean tocolytic 
index decreased from 0.34 to 0.16 (Table 3.7). 
3.2.5.2.3. Balancing of patients of Am group III 
Probability values ρ of 0.11 and 0.09 were measured 
for UC and BD in the basic material. 
Removal of 9 patients led to satisfactory ρ levels except 
for UC (0.22). The difference in the mean tocolytic index 
fell from 0.15 to 0.05 (Table 3.8). 
3.2.5.2.4. Balancing of patients of Am group IV 
With the elimination of 2 patients balance of all 
variables was reached, ρ values exceeding 0.50. 
The difference of the mean tocolytic index decreased from 
0.40 to 0.26 (Table 3.9). 
3.2.5.3. Comparison of the two treatment groups with respect to other 
factors which might influence the outcome of the experiment 
The two treatment groups were compared with respect to 
several variables which might bias the results of the 
trial. The incidence of the fundus being {>, 2 weeks) 
small for dates was judged and proved to be balanced for 
the two populations ; ρ values for the separate Am groups 
and the whole population being al more than 0.50. A dif­
ference was seen in the route of administration for the 
two groups (Table 3.10). 
A frequency histogram of the maternal ages of the patients 
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Table 3.10 ROUTE OF ADMINISTRATION OF RITODRINE AND FiNOTEROL 
AM GROUP I 
% rit. % fen. 
I.V. 31 30 
Oral 19 26 
I.V. and oral 50 44 
Ρ " 0.84 
AM GROUP II 
% rit. % fen. 
28 23 
24 46 
48 31 
0.21 
AM GROUP III 
% rit. X fen. 
44 26 
23 48 
33 26 
0.20 
AM GROUP IV 
% rit. % fen. 
42 25 
29 45 
29 30 
0.42 
ALL PATIENTS 
% rit. % fen. 
35 26 
24 41 
41 33 
0.03 
" chi square test 
is given in figure 3.1. 
The reproductive history revealed a trend towards a 
greater number of previous abortions and live born term 
neonates among fenoterol treated women (table 3.11). 
Maternal age (years) 
12-1 
10 20 30 40 SO 10 20 30 40 50 
Median 27 
Mean 27 
SO 4 
Mm-ma« 19-39 
Figure 3.1 
Median 28 
Mean 2Θ 
SD 4 
Mm -max 20 - 43 
p - 0 11 (Iwo-lailed) 
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Table 3.11 REPRODUCTIVE HISTORY OF WOMEN IN THE TWO GROUPS 
Number : 0 
1 
2 
3 
4 
5 
Ρ " 
PARITY 
pit. 
50 
33 
9 
2 
0 
0 
94 
0. 
" х
г
 - test 
"" In this 
of amene 
"""in this 
of amene 
fen. 
43 
32 
15 
7 
0 
3 
100 
11 
table premature 
irrhea. 
ABORTION 
rit. fen. 
74 62 
11 23 
4 10 
2 4 
3 1 
94 100 
0.05 
delivery is 
IMMATURE 
STILLBIRTHS 
pit. fen. 
88 94 
6 6 
94 100 
0.91 
defined as del' 
table term delivery is defined as delivery 
irrhea. 
IMMATURE 
ALIVE 
Ht. fen. 
87 91 
6 6 
1 2 
0 1 
94 100 
0.74 
i very after 
after 38 о 
PREMATURE** 
STILLBIRTHS 
rit. fen. 
92 96 
2 2 
0 2 
94 100 
0.39 
28 completed weeks 
ompleted weeks and 
PREMATURE 
ALIVE 
vit. fen. 
77 77 
15 16 
2 5 
0 2 
94 100 
0.37 
χ* TERMXxx 
STILLBIRTHS 
rit. fen. 
91 100 
2 0 
1 0 
94 100 
0.20 
TERM"»"« 
ALIVE 
rit. fen. 
77 67 
16 30 
1 0 
0 2 
0 1 
94 100 
0.07 
and before 38 completed weeks 
before 42 completed weeks 
Table 3.12 
FACTORS TO INFLUENCE THE DURATIi 
Twi ns 
Polyhydramnios 
Congenital malformation 
of uterus 
Fibroids in uterus 
Scar in uterus 
Diabetes mellitus 
Prediabetes 
E.P.H. gestosis 
Placenta circumvallata 
Placenta praevia 
Low-lying placenta 
Marginal sinus rupture 
Total of mentioned abnorma­
lities of placenta 
Vaginal bloodloss during 
pregnancy 
- first half of pregnancy 
- second half of pregnancy 
Diastolic bloodpressure 
> 90 turn Hg 
- before pregnancy 
- developed during 
pregnancy 
Smoking 
- mild (1 -10 sig/24 hrs) 
- severe (> 10 sig/24 hrs) 
ON OF PREGNANCY 
Ritodrine 
η 
9 
5 
7 
3 
3 
0 
12 
5 
4 
0 
4 
2 
10 
18 
5 
3 
22 
22 
9 
IN THE 
Fenoterol 
η 
8 
8 
8 
3 
4 
3 
24 
6 
7 
1 
4 
4 
16 
9 
10 
4 
12 
17 
9 
TWO GROUPS OF 
x
2 
0.02 
0.21 
-
-
-
1.23 
3.34 
-
0.27 
-
-
0.11 
1.49 
3.36 
0.94 
-
3.61 
-
~ 
PATIENTS 
Ρ 
0.89 
0.65 
-
-
-
0.27 
0.07 
-
0.61 
-
-
0.74 
0.48 
0.07 
0.34 
-
0.06 
-
~ 
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Several factors which might influence the duration of 
pregnancy are filed up for the two groups in table 3.12. 
Fig. 3.2 gives the comparison of the tocolytic index ac-
cording to Baumgarten and Grüber (1974) for the ritodrine 
and fenoterol treated patients. 
Tocolytic index 
Ritodrine Fenolerol 
Median 2 Median 2 
Μ |
- · Ί " 2 7
 M e a n 2 6 
S D 1 6 S D 1 6 
Mm max 1 7 Mm
 m a x ι β 
y _ - HOBS ρ 0 4 4 (Iwo tailed) 
Figure 3.2 
3.2.6. Statistical evaluation 
Balancing for some background variables was done in 
advance for the distinct Am groups as described in section 
3.2.5. When several features of a variable were involved, 
comparability of the treatment groups was assessed with 
the χ2 - test in contingency tables with correction of 
continuity. 
With the other variables, comparability of the two groups, 
and differences in efficacy and side effects were tested 
with the so called distribution free (non-parametric) Mann 
and Whitney U-test. 
When Am groups were tested separately as well, a combined 
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g Table 3.13 
MEANS + SD OF NEONATAL SUCCESS SCORE, PROLONGATION INDEX, DAYS GAINED AND RELATIVE GAIN FOR THE TWO GROUPS OF PATIENTS 
NEONATAL χ 
SUCCESS SCORE Ρ 
PROLONGATION κ 
INDEX Ρ 
DAYS GAINED χ 
Ρ 
RELATIVE GAIN к 
Ρ 
ritodrine 
AM GROUP I 
fenotevol 
4.12 
3.51 
0.59 
38 + 31 
43 + 28 
0.40 
62 + 47 
72 + 42 
0.42 
61 % + 41 
74 % + 39 
0.14 
AM GROUP II 
rttodrine 
fenotevol 
1.52 
2.15 
0.58 
21 + 12 
22 + 9 
0.99 
46 + 24 
48 + 18 
0.89 
79 t + 34 
87 % + 23 
0.60 
ritodvine 
AM GROUP III 
fenotevol 
2.22 
1.93 
0.53 
9 + 7 
10 + 7 
0.87 
22 + 16 
24 + 17 
0.86 
63 % + 39 
66 % + 37 
0.88 
vitodrine 
AM GROUP IV 
fenotevol 
1.33 
0.75 
0.10 
6 + 6 
< 0.05 
9 + 5 
16 + 14 
23 + 11 
< 0.05 
76 % + 28 
95 % + 16 
< 0.01 
vi todrine 
ALL PATIENTS 
fenotevol 
0.48 0.12 
71 % + 36 
0.13 < 0.03 
79 % + 33 
- Mann and Whitney U test (2-tailed) for the distinct Am-groups 
- combined Mann and Whitney U test for the total population 
Mann and Whitney ü two sample t e s t was employed for the 
whole populat ion. Results are presented in frequency 
h i s tograms and as medians + s tandard d e v i a t i o n s and 
ranges. 
3. 3. Results 
3.3.1. Efficacy of treatment 
Perinatal outcome as measured by the neonatal success 
score described in section 3.2.4 was not significantly 
different for the patients in Am groups I, II and III or 
the total population. Only with respect to Am group IV 
{>, 34 weeks), a trend was seen toward better results among 
the fenoterol treated patients (p = 0.10) (table 3.13). 
Differences were more evident for the other 
success-variables. Although results seemed on the average 
better in the fenoterol groups, statistical significance 
was only evident in Am group IV. 
When the results of the 4 AID groups were combined, there 
was a significant difference in only one parameter : the 
fenoterol-treated women exhibited a greater relative gain 
after the start of treatment (p < 0.03 ; table 3.13). 
The birth weights of the children born to mothers 
treated with ritodrine did not differ significantly from 
those treated with fenoterol (p = 0.12 ; fig. 3.3), nor 
was a statistically significant difference seen in the 
percentiles of birth weights (Kloosterman, 1977) of both 
groups (p = 0.38). 
Means, medians and standard deviations of the placen-
tal weights were 433, 435 and 131 grams and 449, 450 and 
129 grams respectively (p = 0.47) when twin pregnancies 
were excluded. The mean duration of amenorrhea at 
delivery was 251 + 30 days for the women treated with 
ritodrine and 254 + 28 days for those treated with fenote-
rol (fig.3.4). 
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Birth weights (grams) (twins excl.) 
Ritodrme Fenolerol 
1 2 -
e-
4 
1 
•J iJ \JÊ 0 1000 2000 
Median 
Mean 
S D 
Mm max 
> 2 5 0 0 
2000 2499 
< 2 0 0 0 
Hi jure 3 
2740 
2613 
831 
250 4000 
56% 
20°o 
2 4 % 
3 
J | d • 
3000 
I L 
4000 5000 
12 
В 
4 
0 
• 1 . и шШ 
Ι ι 
0 1000 20« 
Median 
Mean 
S D 
Mm max 
> 2 5 0 0 
2000 2499 
< 2 0 0 0 
3000 
2760 
81β 
390 4150 
6 5 % 
IS-o 
2 0 % 
As far as the pH of the umbilical artery blood (p = 0.99 ; 
fig. 3.5) and 5 minutes Apgar scores (p = 0.76) were con­
cerned, no statistically significant differences were 
found. 
Other relevant factors regarding the fetal outcome in 
the two treatment groups are listed in table 3.14. 
Amenorrhea at delivery (days) 
Rilodrme Fenolerol 
100 ISO 200 250 300 350 100 150 200 250 300 350 
Median 255 
Mean 251 
S O 30 
Mm max 137 293 
Median 261 
Mean 254 
S D 2β 
Mm max 150 290 
U 4 4 1 8 5 ρ 0 4 7 [Iwo lailed) 
Figure 3.4 
100 
pH umbilical artery blood 
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 T 
5 
β.70 6.90 7.10 7.30 7.50 
Median 7 24 
Mean 7 23 
S D 0 08 
Mm -max 6 87-7 36 
A 
6.70 6.90 7.10 7.30 7.50 
Median 7 24 
Mean 7 23 
S D 0 09 
Mm -max 7 00-7 42 
U 2611 ρ 0 99 (two tailed) 
Figure 3. S 
In the group of patients treated with ritodrine there were 
three intrauterine deaths and 7 neonatal deaths. 
Among the fenoterol treatment women one stillbirth and 8 
neonatal deaths occurred. 
The details of the cases of perinatal (between 28 weeks 
amenorrhea and the end of the 7th day after delivery) 
Table 3.14 FETAL OUTCOME 
Stillbirth 
Neonatal death 
Hyperbilirubinemia 
Hypoglycemia 
(diabetes mellitus and 
pregnancy diabetes ex­
cluded) 
Congenital malformation 
IRDS 
IN THE TWO 
ritodrine 
3 
7 
25 
4 
1 
6 
GROUPS OF PATIENTS 
fenoterol 
1 
8 
26 
9 
3 
6 
Ρ 
0.57 
-
-
0.16 
0.66 
-
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Table 3.15 DETAILS OF THE PERINATAL DEATHS 
Patient nr. 
3 
63 
74 
154 
194 
216 
243 
Death within 
stillbirth 
24 hrs 
48 hrs 
24 hrs 
24 hrs 
24 hrs 
intrapartum 
24 hrs 
Amenorrhea 
34 wks 
2 days 
28 wks 
5 days 
28 wks 
2 days 
32 wks 
4 days 
29 wks 
2 days 
29 wks 
2 days 
28 wks 
3 days 
37 wks 
3 days 
Treatment 
ritodrine 
ritodrine 
ritodrine 
fenoterol 
ritodrine 
ritodrine 
fenoterol 
fenoterol 
placental insufficiency 
asphyxia RDS 
breech - extraction 
hemorrhagia cerebri RDS 
asphyxia RDS 
f i r s t chi ld of twin 
hemorrhagia cerebri 
asphyxia RDS 
second chi ld of twin 
hemorrhagia cerebri 
asphyxia RDS 
intrauterine asphyxia 
severe congenital 
malformations 
deaths are given in table 3 .15 . 
3.3.2. Side effects 
Prior to the s t a r t of treatment, maternal heart rates 
were s imilar for both groups of women, ( f i g . 3 . 6 ) . 
During t r e a t m e n t , r i t o d r i n e as w e l l as f e n o t e r o l 
caused an increase of the maternal heart frequency ; the 
f i r s t drug, however, showed a more pronounced e f f e c t 
(p < 0 . 0 2 ) . The means, medians and standard dev ia t ions of 
the maximal maternal heart frequenc ies , measured af ter the 
second day of treatment when adaptation to the medication 
had taken p l a c e , are given in a frequency histogram in 
f i g . 3 . 7 . 
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Initial maternal heart frequency (b.p.m.) 
Ritodnne Fenolerol 
7 0 90 110 130 70 90 110 130 
Medtan BO 
Mean Θ2 
S D 7 
Mm -max 6 5 - 1 0 0 
Median 80 
Mean 82 
S D 7 
Mm -max 64 -105 
U = 2416 5 ρ - 0 79 (two-tailetl) 
Figure 3.6 
The mean increase in maternal heart rate was 48 % 
(mean + SD) for the ritodrine treated women and 41% 
when fenoterol was given (p < 0.02). 
Maternal heart frequency during treatment 
(b.p.m.) 
30-1 
80 100 120 140 160 180 
Median 120 
Mean 120 
S D 11 
M m - m a x 9 2 - 1 6 0 
Θ0 100 120 140 160 180 
Median 118 
Mean 115 
S D 12 
Mm -max 85 -140 
U = 2700 5 p < 0 02 {two tailed) 
Figure 3. 7 
3.4. Discussion 
3.4.1. Comparability of study groups 
Balancing of the separate Am groups for the 6 charac­
teristics given in table 3.5 (section 3.2.5.2) led to good 
comparability of the two treatment groups in all param­
eters (table 3.16) . 
Table 3.16 PROBABILITY LEVELS*BEFORE AND AFTER BALANCING OF THE AH GROUPS 
AM GROUP I AM GROUP II AM GROUP III AM GROUP IV ALL PATIENTS 
UB В UB В UB В UB В UB* В* 
0.23 
0.39 
0.35 
0.13 
0.78 
1.00 
0.25 
0.94 
1.00 
0.25 
1.00 
1.00 
0.68 
0.54 
0.08 
0.29 
0.22 
1.00 
0.84 
0.57 
1.00 
0.29 
0.25 
1.00 
0.11 
0 09 
0.67 
0.42 
1.00 
0.63 
0.22 
0 42 
0.81 
0.99 
1.00 
0.94 
1.00 
0.54 
0.40 
0.39 
1.00 
1.00 
1.00 
0.64 
1.00 
0.50 
1.00 
1.00 
0.98 
0.27 
0.22 
0.12 
0.34 
0.55 
0.81 
0.Э2 
0.88 
0.49 
0.83 
0.91 
= χ
2
 measure 
κ
 UB = probability levels before balancing 
В - probabil ity levels after balancing 
Other characteristics which might influence the dura­
tion of pregnancy, including the tocolytic index which, in 
previous investigations (Baumgarten and Grüber, 1974 ; 
Richter, 1977 ; Eskes and Essed, 1979) was found to be a 
suitable test of threatening premature labor, were reason-
ably similar between the two study populations. The route 
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of administration, however, was found to be different for 
the two groups, for which finding no clear explanation was 
visible. 
Reproductive history revealed a greater number of both 
previous first trimester abortions and liveborn term neo-
nates among fenoterol-treated patients. 
The incidence of spontaneous preterm labor was related to 
previous abortions and previous preterm deliveries in a 
retrospective study of 8404 consecutive patients by Keirse 
and colleagues (1978). 
The incidence of preterm labor in subsequent pregnancies 
was not found to be increased if reproductive history 
included only first trimester abortions. Patients with 
previous mid-trimester abortions and third trimester 
preterm labor were at significantly higher risk for sub-
sequent preterm delivery than the remainder of the popula-
tion. 
3.4.2. Effioacy of therapy 
Richter and Hinselmann (1979) reported a lower success 
rate with ritodrine alone (n = 35) (p < 0.05) than with 
ritodrine plus verapamil or with fenoterol with or without 
verapamil. The patients in their investigation treated 
with ritodrine alone, however, possessed more pronounced 
features of impending premature labor, as evident in a 
difference in tocolytic index (p < 0.05), than the pa-
tients in the other 3 groups. 
The present study revealed a trend towards differences 
with respect to the efficacy of treatment for the total 
populations, but not for all of the separate Am groups. 
This suggests that differences between these two drugs are 
subtle, and that large numbers of patients will be needed 
to demonstrate conclusively any difference in efficacy. 
105 
3.4.3. Side effects 
Because of the difficulties encountered in studying 
subjective side effects, an objective cardiovascular side 
effect was measured in this study, specifically, the 
change in maternal heart rate. Although blood pressure 
might also be considered such an objective parameter, the 
difficulties in accurate indirect measurement of blood 
pressure (van Dongen, 1979) , and the marked effect of 
position on blood pressure mitigated against inclusion of 
this measurement in the analysis. 
The differences in degree of acceleration of the 
maternal heart rate observed between the two treatment 
groups are in agreement with those reported in the liter-
ature (Hüter et al., 1972 ; Richter and Hinseimann, 1979). 
Of the 28 patients who developed tachycardia and/or 
palpitations requiring a change of tocolytic agent, 19 
initially received ritodrine ; 9 subjects could not toler-
ate fenoterol in the dosage required to obtain tocolysis 
and did better with ritodrine. 
So there seem to be individual differences in acceptabil-
ity for these two drugs. 
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Chapter 4 
Plasma glucose levels in the neonate after antenatal exposure to 
betamimetic agents 
4.1. Introduction 
Betasympathomimetic drugs exert an influence on 
carbohydrate metabolism by stimulation of adenylcyclase in 
liver, muscle and probably pancreas cells (section 
2.5.1.1.). 
In liver cells β-adrenergic stimulation causes an 
elevation of the serum glucose level as a result of at 
least three mechanisms (Weidinger and Wiest, 1973) . 
-Activation of Phosphorylase, which leads to conversion 
of glycogen to glucose ; 
-Inactivation of glycogen production from glucose ; and 
-Stimulation of gluconeogenesis. 
In muscle cells glucose-6-phosphatase is lacking. 
Thus, glycogenolysis in striated muscle cells will lead to 
production of lactic acid. After diffusion into the 
bloodstream, the lactate is largely removed by the liver 
and reconverted to glucose. 
In the pancreatic β-cells, there also seems to be a 
direct influence via ß-adrenergic receptors, leading to 
increased insulin blood levels (Taylor et al., 1976). 
The net effect of these actions will be a transient ele-
vation in blood glucose concentration even in spite of an 
increased insulin secretion. 
The maternal carbohydrate intolerance which is induced 
by these drugs and the fact that ß-mimetics do cross the 
placental barrier (Weidinger et al., 1975) give support to 
the suggestion that long-term B-mimetic medication, as 
used in the suppression of premature labor, could result 
in fetal hyperinsulinism. 
For the same reason, the assumption has been made that 
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fetal macrosomia might result from the diabetogenic effect 
of these drugs. Indeed, Sivasamboo (1972) reported a 
higher birth weight of children born from mothers treated 
with ritodrine, compared to a control group. However, 
these observations could not be confirmed by Seidl and 
colleagues (1972) and Brettes and associates (1976). 
Blouin and colleagues (1976) studied the effect of 
ritodrine (10 mg orally, 4 times per day) from the 25th 
week of pregnancy on the carbohydrate tolerance of eight 
pregnant women and their newborn infants. They observed 
no diabetogenic influence on the 50 gram oral glucose 
tolerance test or the 24 hours glucose profile on the 7th 
day of treatment and neither after 10 weeks of oral 
ritodrine therapy. 
These observations are in agreement with the results of 
Unbehaun and coworkers (1975), who found a compensation 
and normalisation of the changes in carbohydrate metabo-
lism within 72 hours after the start of treatment. 
As to the carbohydrate metabolism of the neonates, 
Blouin et al. (1976) could not demonstrate a significant 
difference between the glucose and insulin values for 
ritodrine-treated and control patients, in a study group 
of 8 patients and 6 controls. Samples were taken from the 
umbilical vein and by a heel prick 2 hours after delivery 
and before the first feeding. 
Epstein and co-workers (1979) studied umbilical cord blood 
insulin levels and neonatal blood glucose values at 30, 60 
and 90 minutes after birth in 12 infants whose mothers had 
received ß-mimetic therapy (fenoterol and terbutaline). 
In 5 of the 6 cases where the interval from termination of 
ß-mimetic therapy to delivery was 2 days or less, the in-
fants exhibited sustained hypoglycemia. This was not 
observed in any case where the interval exceeded 2 days. 
The mean cord blood insulin levels in the 6 infants with a 
short termination-delivery time was 50 % greater than in 
the larger interval group. 
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Umbilical cord glucose levels were not significantly dif-
ferent. No comparison was made with untreated neonates. 
In retrospect, Brazy and Pupkin (1979) found a signif-
icantly higher incidence of hypoglycemia in premature 
neonates (gestational ages at birth 26 - 35 weeks) whose 
mothers were treated with isoxsuprine within 48 hours of 
delivery (n = 43) in comparison with a reference popula-
tion of 107 untreated infants. 
As diabetogenic influences upon the fetus, as far as 
the risk of hypoglycemia is concerned, have more pro-
nounced effects on the newborn in the first extra uterine 
hour than at birth, the present investigation was under-
taken to assess the possible influence of prenatal expo-
sure to ß-adrenergics upon the neonatal glucose levels in 
the first 30 minutes after delivery. 
4.2. Materials and methods 
From January 1976 until January 1979, plasma glucose 
levels were measured in the first 30 minutes of extra-
uterine life in neonates from mothers treated with β-mi­
metic drugs (fenoterol and/or ritodrine) for the preven­
tion of premature birth. 
In general, these tocolytic agents were administered 
intravenously for at least 2 days at the minimum dose 
necessary to stop labor successfully (dose i.v. 67 - 700 
mcg/min ritodrine, 1.0 - 9.3 mcg/min fenoterol). 
The dosage was then decreased ; and if uterine contrac­
tions did not return, oral treatment with 5 mg fenoterol 
or 10 mg ritodrine 6 to 12 times daily, was substituted. 
With several patients, however, it was possible to avoid 
parenteral medication and to start with oral ß-mimetic 
therapy. 
In general, medication was continued until the end of the 
37th week of gestation. 
Treatment was started prior to the 28th week of ges-
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ta t ion in 27 p a t i e n t s . Gestational age at the s t a r t of 
treatment was 28 weeks or more in 114 p a t i e n t s (range : 
17-36 weeks) . Intravenous therapy alone was used in 61 
p a t i e n t s , oral therapy only in 35 p a t i e n t s and 45 p a t i e n t s 
were t reated both intravenously and o r a l l y . 
Ritodrine was given to 83 p a t i e n t s ; and fenoterol , to 
43 p a t i e n t s . Fifteen women were t reated with both β-ago­
n i s t s . The duration of medication is given in table 4 . 1 . 
Table 4.1 DURATION OF MEDICATION IN THE TREATED PATIENTS 
< 24 hrs 8 patients 6 % 
24 - 48 hrs 4 patients 3 % 
2 - 7 days 23 patients 16 % 
·}! days 106 patients 75 1 
The interva l s between the end of treatment and delivery 
(t - d interval) are presented in table 4.2. 
Table 4.2 
TIME INTERVAL BETWEEN THE END OF TREATMENT AND DELIVERY (T - D INTERVAL) 
t - d interval number of patients % 
< 24 hrs 45 32 % 
24 - 48 hrs 18 13 % 
48 - 72 hrs 3 2 % 
>, 3 days 75 53 1 
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For every patient in the treatment group who gave 
birth in 1976 and 1977, the next subsequent patient who 
delivered with the same duration of amenorrhea (+ 4 days) 
was taken as a control. Mean +_ SD and range of gestation­
al age at delivery were 257 + 19 days (203-294) for the 
treated neonates and 259 + 15 days (206 - 290) for the 
control infants. Only patients who delivered vaginally 
were included in the study. There were 12 twin pregnan­
cies (Θ %) in the treatment group, whereas the control 
patients included 7 sets of twins (6 % ) . 
In these cases, only the first infant was included in the 
study. Children of patients with diabetes mellitus, 
gestational diabetes, severe dysmaturity (below 2.3th per­
centile of birth weight for gestational age) and congeni­
tal malformations were not included or removed afterwards, 
because of the influence that these factors may have upon 
the serum glucose level. For the same reason neonates 
with pH values of the umbilical artery blood under 7.10 
and neonates whose body temperature, measured exactly at 
30 minutes after delivery, had dropped below 35.0 degrees 
Celsius, were excluded. 
Mean + SD of the pH of the umbilical artery blood were 
7.26 + 0.07 for the treated neonates and 7.25 + 0.07 for 
the control infants (p = 0.29). 
Body temperatures 30 minutes after birth, were 35.7 + 
0.4 (35.2 - 36.6) and 35.9 + 0.5 (35.0 - 36.8) respective­
ly. 
After exclusion of patients according to the mentioned 
criteria, 141 treated patients and 110 control babies were 
left for comparison. The blood samples were taken at var­
ious times (one sample per patient) in the first 30 min­
utes after delivery and before the first feeding, by means 
of a heel stick (table 4.3). 
Plasma true glucose concentration were determined en-
zymatically (glucose-oxidase method) within 10 minutes of 
sampling in a BeekmanR glucose analyser. 
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Table 4.3 TIME INTERVAL BETWEEN DELIVERY AND PLASMA GLUCOSE SAMPLE 
(D - S INTERVAL) IN 141 TREATED NEONATES AND 110 UNTREATED INFANTS 
d - s interval 
0 - 5 min 
6 - 1 0 min 
11 - 15 min 
16 - 20 min 
21 - 25 min 
26 - 30 min 
number of treated 
neonates 
29 
31 
28 
32 
12 
9 
141 
21 
22 
19 
23 
9 
6 
100 
% 
% 
t 
% 
0/ 
г 
% 
number of 
neonates 
27 
18 
30 
19 
8 
8 
ПО 
untre; 
25 % 
16 t 
27 % 
17 % 
8 % 
7 t 
100 % 
The d i f f e r e n c e s in the s e v e r a l p a r a m e t e r s were t e s t e d 
by means of the Mann-Whitney U - t e s t (Wilcoxon) ( t w o - t a i l ­
ed) and by means of the Kruskal-Wal l i s one-way a n a l y s i s of 
v a r i a n c e by r a n k s . R e s u l t s a r e expressed in means + s t a n ­
dard d e v i a t i o n s . 
4.3 . Results 
After exclusion of twin pregnancies, the birth weights 
of the treated and control babies were similar : mean + SD 
and range being 2728 + 614 grams (1300 - 4220) and 2837 + 
696 grams (1386 - 4450), respectively. 
To analyse the influence of the time interval between 
delivery and sampling, comparison was made of glucose 
concentrations measured 1-10, 11-20 and 21-30 minutes 
after delivery. This was done separately for the control 
patients and for the treatment group (Table 4.4). 
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Table 4.4 MEAN + SD OF PLASMA GLUCOSE LEVELS OF UNTREATED AND TREATED NEONATES 
ACCORDING TO DIFFERENT DELIVERY - SAMPLING (D - S) INTERVALS 
plasma 
glucose (A) 
d - s interval mmol/l 
plasma 
glucose (B) 
mmol/l 
1 - 10 min 
11 - 20 min 
21 - 30 min 
3.1 + 0.7 
3.1 + 1.0 
2.8 + 0.4 
ρ
 x
 = 0.59 
23 
19 
7 
3.5 + 0.8 
3.4 + 0.9 
3.3 + 0.9 
ρ * = 0.72 
22 
30 
9 
d -
1 
11 
21 
s interval 
- 10 min 
- 20 min 
- 30 min 
plasma 
glucose (С) 
mmol/l 
2.5 + 0.5 
2.9 + 0.9 
2.4 + 0.5 
„ * _ η IO 
η 
34 
28 
9 
plasma 
glucose (D) 
mmol/l 
3.1 + 0.7 
3.2 + 0.7 
3.5 + 1.2 
η 
26 
32 
12 
plasma 
glucose (E) 
mmol/l 
2.6 + 0.5 
2.7 + 0.8 
2.2 + 0.4 
η 
24 
19 
7 
= 0.61 = 0.15 
A = untreated neonates gestational age < 37 wks 
В = untreated neonates gestational age 5. 37 wks 
С = treated neonates < 37 wks 
D = treated neonates > 37 wks 
E = treated neonates gestational age < 37 wks 
treatment - delivery interval < 48 hrs 
Kruskal-Wallis 
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No s igni f icant differences were found in glucose values of 
the control neonates with respect to the delivery - sample 
(d - s) i n t e r v a l . This was true for both premature (< 37 
weeks gestat ion) infants and the term neonates. 
Nor did the t reated pat ients differ in t h i s regard, a l ­
though prematurely born neonates in the treatment group 
had s l i g h t l y lower plasma glucose concentrations when 
sampled 21-30 minutes after b i r t h (2.4 + 0.5 mmol/1) than 
when the d - s interval was 1 - 1 0 minutes (2.5 + 0.5 
mmol/1), especial ly when the time interval between the 
cessation of treatment and delivery had been less than 48 
hours ; however, these differences were not s t a t i s t i c a l l y 
s igni f icant according to Kruskal-Wallis. 
No re la t ionship was found between the duration of the 
second stage and the blood glucose levels of the treated 
neonates (p > 0.10 ; Table 4 .5) . 
Table 4.5 MEAN + SD OF PLASMA GLUCOSE LEVELS OF TREATED NEONATES WITH 
DIFFERENT DURATION OF THE SECOND STAGE OF LABOR 
Durat ion 2nd 1 - 1 0 1 1 - 2 0 21 - 30 31 - 60 
stage minutes minutes minutes minutes 
Plasma glucose 2 . 9 + 0 . 7 2 . 8 + 0 . 8 3 . 0 + 0 . 7 3 . 2 + 0 . 9 
l e v e l s (mmol/1) η = 48 η = 45 η = 24 η = 21 
Ρ = NS (Kruskal - W a l l i s ) 
There was a s t a t i s t i c a l l y s i g n i f i c a n t d i f f e r e n c e 
between the plasma glucose values of premature and term 
infants in the control group (p < 0.05 ; Table 4 .6) . 
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Plasma glucose concentrations (MMOL/L) 
treated (π -141) untrealedfn 110) 
О 2.0 4.0 6.0 Θ.Ο 
median 2 θ 
Mean 2 9 
SD 0Θ 
Min -Max 1 6 - 6 5 
Ρ < 0 001 (two-tailed) 
0 2 0 4.0 6.0 8 0 
Median 31 
Mean 3 3 
SD OB 
Mm -Max 1 6-5 6 
Figure 4.1 
This difference was more pronounced (p < 0.0001) when 
treatment was given, probably as a result of the fact that 
far more premature (70 %) than term neonates (19 %) were 
born with a t - d interval of less than 48 hours. 
The plasma glucose levels of the treated and control 
neonates are presented in figure 4.1 and table 4.6. 
Table 4.6 MEAN + SD OF PLASMA GLUCOSE LEVELS (MMOL/L) OF TREATED AND 
CONTROL NEONATES 
treated patients 
control patients 
MEASURED WITHIN 
all patients 
2.9 + 0.8 
Ρ 
3 
ι = 141 
< 0.001 
.3 + 0.8 
η = 110 
30 MINUTES AFTER 
patients < 
I 
2.7 + 0.7 
r 
Ρ 
3 
= 71 
< 0.001 
1 + 0.8 
η = 49 
37 
- Ρ 
— η 
DELIVERY 
wks 
< 0 
* η 
0001 -
пч 
patients > 37 wks 
| 
3.2 + 0.8 
Ρ 
3 
τ = 70 
= 0.14 
4 + 0.9 
η = 61 
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Significantly lower plasma glucose concentrations were 
measured in babies from treated mothers than were found in 
the control group : 2.9 + 0.8 versus 3.3 + 0.8 mmol/1 
(p < 0.001). After subdivision, these differences were 
evident in prematurely born infants (2.7 + 0.7 versus 
3.1 + 0.8 mmol/1 ; ρ < 0.001), whereas the glucose values 
of the treated infants born after the 37th week of amenor­
rhea did not differ significantly from control neonates of 
the same gestational age. As mentioned above, it must be 
stressed that the mothers of 70 % of the prematurely born 
infants were still being treated 48 hours before delivery, 
in comparison to only 19 % when delivery occured after the 
completed 37th week of gestation. 
To assess the influence of the route of administration 
of the β-mimetic agent, plasma glucose levels were com­
pared for the neonates whose mothers were treated intra­
venously and orally (Table 4.7). 
Table 4.7 MEAN + SD OF PLASMA GLUCOSE LEVELS FOR DIFFERENT ROUTES OF ADMINISTRATION 
A = TREATED INTRAVENOUSLY 
В = TREATED ORALLY 
A В 
intravenous treatment η oral treatment η ρ 
All patients 2.7+0.7 61 3.1+0.8 35 < 0.03 
t - d interval < 48 hrs 2.5 + 0.5 39 2.9 + 0.5 8 0.05 
Lower plasma glucose levels were found in the intravenous­
ly treated patients in comparison to the group that re­
ceived tablets (p < 0.03). This difference may be influ­
enced by the fact that a larger proportion of the i.v. 
group was treated until within 48 hours before delivery, 
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for the time interval between termination of treatment and 
delivery was < 48 hours in 39 of 61 intravenously t reated 
p a t i e n t s (64 %) and in 8 of 35 (23 %) women who got only 
oral medication. 
When the analysis was r e s t r i c t e d to neonates with t - d 
in terva l s less than 48 hours, the difference was numeri­
cal ly the same (p = 0.05). 
In t h i s invest igat ion, no corre la t ion was found be­
tween the number of days treatment was given and the p l a s ­
ma glucose levels after delivery (Table 4 .8) . 
Table 4 . 8 MEAN + SD OF PLASMA GLUCOSE LEVELS (MMOL/L) OF NEONATES FROM WOMEN 
STILL TREATED WITHIN 48 HOURS BEFORE DELIVERY WITH DIFFERENT TREATMENT PERIODS 
treatment < 2 days 2.7 + 0.5 (n = 12) 
ρ = 0.53 
treatment » 3 days 2.6 + 0.7 (n = 51) 
A strong influence could, however, be measured accord­
ing to the number of days treatment had been stopped be­
fore a premature baby was born. Neonates born before the 
37th week of gestation had lower plasma glucose levels 
when treatment was continued to within 72 hours of deliv­
ery (2.6 +0.6 mmol/1) than with an interval of 3 or more 
days (3.0 + 0.8 mmol/1) (p < 0.05 ; table 4.9). 
In the comparison of premature infants of the treated 
patients subdivided in different treatment-delivery inter­
vals and untreated women, a statistically significant dif­
ference was found according to Kruskal-Wallis (p = 0.003). 
Tested with the two-tailed Mann Whitney U test plasma glu­
cose levels of treated infants were significantly lower 
when the t - d interval was 0 or 1 day (p < 0.001 for 
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Table 4.9 MEAN + SD OF PLASMA GLUCOSE LEVELS (MMOL/L) OF PREMATURE 
NEONATES IN RELATION TO THE TIME INTERVAL BETWEEN THE END OF 
TREATMENT AND DELIVERY (T - D INTERVAL) 
t - d interval < 72 hrs 2.6 +0.6 η = 52 
ρ < 0.05 
t - d interval >, 3 days 3.0 + 0.8 η = 19 
both) , compared to untreated chi ldren, whereas plasma 
glucose levels of t reated neonates with t - d interva l s of 
3 or more days did not differ s igni f icant ly from control 
neonates (Table 4.10). 
Table 4.10 MEANS + SD OF PLASMA GLUCOSE CONCENTRATIONS (MMOL/L) OF TREATED 
PREMATURE NEONATES WITH DIFFERENT TIME INTERVALS BETWEEN TERMINATION OF 
TREATMENT AND DELIVERY (T - D INTERVAL) AND UNTREATED PREMATURE NEONATES 
treated 
t - d interval of prematurely born treated neonates 
< 24 hrs 2.6 + 0.7 (38) 
24 - 48 hrs 2.4 + 0.3 (12) 
3 - 7 days 2.9 + 0.7 ( 8) 
» 7 days 2.9 + 0.9 (13) p 
untveated 
ρ = 0.003 (Kruskal-Wallis) 
3.1+0.8 (49) 
Mann Whitney U test (two tailed) 
0.001 0.001 
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Comparison between patients according to the tocolytic 
agent used revealed no differences in age, gestational age 
at the start of treatment, the time interval between the 
cessation of drug administration and delivery, gestational 
age at delivery, birth weights, duration of second stage, 
the time interval between delivery and blood sample, the 
pH values of the umbilical artery blood and the neonatal 
body temperature measured at 30 minutes after delivery 
(Table 4.11) . Intravenous treatment was given in 85 % of 
the ritodrine- and 70 % of the fenoterol-treated patients. 
The tocolytic indices (Baumgarten and Gr'uber, 1974), were 
somewhat higher in the fenoterol treated patients : 
3.1 + 1.6 versus 2.6 + 1.3 (p = 0.10). 
Among the patients treated with ritodrine, there were 11 
twin pregnancies and none in the fenoterol group. 
During the intravenous treatment period, the means + SD of 
the maximum dose used were 254 + 21 mcg/min when ritodrine 
was used and 3.1 + 0.5 mcg/min for fenoterol (range 67 -
700 mcg/min and 1.0 - 9.3 mcg/min). 
A significant difference was found between the plasma 
glucose concentrations of neonates exposed to ritodrine 
and fenoterol, with the fenoterol group having the lower 
plasma glucose values in the first 30 minutes after deliv-
ery (p < 0.05). 
When analysis was restricted to the preterm neonates, a 
trend towards lower plasma glucose values of fenoterol-
treated babies compared to ritodrine-treated infants was 
seen when treatment was still given 48 hours or less 
before delivery (p = 0.09). 
Also, term neonates had lower plasma glucose levels when 
exposed in utero to fenoterol than to ritodrine 
(p < 0.02). After exclusion of twin pregnancies, this 
difference was even more pronounced (p < 0.01). When 
patients with t - d intervals of more than 2 days were 
compared, plasma glucose concentrations of the fenoterol 
group were still lower than those after exposure to rit-
odrine (p = 0.05 ; Table 4.12). 
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Table 4.11 
Age 
Gestational age 
start of treatment 
t-d interval 
< 48 hours 
Gestational age 
at delivery 
< 37 weeks 
:> 37 weeks 
Birth weights 
twins excl. 
Duration of second 
stage 
1 - 10 min 
11 - 20 min 
21 - 30 min 
> 30 min 
D-S interval 
1 - 10 min 
11 - 20 min 
21 - 30 min 
PH umb. art. blood 
Body temperature 
30 min p.p. 
Toc. index 
Ritodrine (n 
MEAN + SD 
27 + 4 
years 
216 + 28 
days 
11 + 18 
days 
46 % 
257 + 19 
days 
56 % 
44 % 
2700 + 614 
gr 
19 + 14 
minutes 
39 % 
30 % 
13 % 
18 % 
13 + 7 
minutes 
44 % 
42 % 
14 % 
7.25 + 0.08 
35.7 + 0.4 
2.6 + 1.3 
- 82) 
RANGE 
18-37 
125-256 
0-91 
203-294 
1650-4220 
3-80 
1-30 
1-6 
Fenoterol (n 
MEAN + SD 
27 + 5 
years 
219 + 26 
days 
15 + 26 
days 
48 % 
258 + 19 
days 
43 % 
57 % 
2672 + 658 
19 + 16 
minutes 
34 % 
32 % 
20 % 
14 % 
14 + 8 
minutes 
34 % 
46 % 
20 % 
7.27 + 0.07 
35.8 + 0.4 
3.1 + 1.6 
= 4¿) 
RANGE 
18-42 
140-258 
0-116 
210-290 
1300-4030 
3-90 
2-29 
1-7 
Ρ 
0.83 
0.66 
0.85 
0.56 
0.89 
0.76 
0.51 
0.16 
NS 
0.10 
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Table 4.12 
MEAN + SD OF PLASMA GLUCOSE LEVELS (MMOL/L), DETERMINED 1 - 30 MINUTES AFTER 
DELIVERY, OF NEONATES EXPOSED EITHER TO RITODRINE OR FENOTEROL 
Ritodrine 
3.0 + 0.8 
2.8 + 0.8 
3.4 + 0.8 
2.7 + 0.7 
3.3 + 0.9 
N 
83 
46 
37 
38 
45 
Fenoterol 
2.7 + 0.7 
2.4 + 0.6 
2.9 + 0.7 
2.5 + 0.6 
2.9 + 0.7 
N 
43 
18 
25 
21 
22 
Ρ 
< 0.05 
0.13 
< 0.02 
0.25 
0.05 
All patients 
Gestational age < 37 wks 
Gestational age > 37 wks 
t - d interval < 48 hrs 
t - d interval 5. 48 hrs _
Gestational age < 37 wks 
t - d interval < 48 hrs 2.7 + 0.7 32 2.4 + 0.6 14 0.09 
Gestational age £ 37 wks 
t - d interval > 48 hrs 3.5 + 0.9 31 2.9 + 0.8 18 < 0.03 
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4.4. Discussion 
Several clinical conditions are known to affect the 
blood glucose level of the neonate. 
The mode of delivery exerts a strong influence upon 
the glucose concentration in venous cord blood at delivery 
and in capillary blood of the neonate during the first 
hours of life (Cornblath et al., 1961). For this reason, 
patients who delivered by a caesarean section were not 
included in this study. 
In their study of the effect of several factors (such 
as pretreatment of the mother, mode of delivery and 
exposure to labor) on the course of the blood glucose 
concentration during the first hours of life and on the 
ability of the normal infant to regulate his level of 
glucose, Cornblath and associates (1961) also showed that 
the maternal blood glucose level had a significant in-
fluence upon the glucose concentration of fetal venous 
cord blood, but not on the glucose levels of the newborn 
in the first hour after delivery. Although umbilical cord 
glucose concentrations were 49.4 % higher in infants from 
vaginally delivered mothers who received glucose prior to 
delivery than when no intravenous fluids or only saline 
solution had been given (127 mg/100 ml versus 85 mg/lOO 
ml respectively), the capillary blood glucose levels 30 
minutes after delivery were strikingly similar in the two 
groups (54 + 8.4 mg/100 mg and 55 + 5.8 mg/100 ml). 
Also for this reason, in the current study comparisons 
were made between the plasma glucose levels during the 
first half hour of extrauterine life. 
Gestational age proved to be a relevant factor in re-
gard to neonatal blood glucose levels (Table 4.6), so 
separate comparisons were made for preterm and term 
infants. 
As pointed out previously, the control patients were 
carefully matched with the treated ones for gestational 
122 
age at delivery. 
The duration of the second stage of labor was inves­
tigated and did not turn out to be an important element in 
respect to the plasma glucose levels of the neonates in 
the present trial (table 4.5). 
The similarity in birth weights of the exposed and 
control neonates was in disagreement with the higher birth 
weights of children born from treated mothers reported by 
Sivasamboo (1972). 
Although Unbehaun and co-workers (1975) concluded that 
a balancing out of the initial β-stimulated metabolic 
changes occurs in the maternal metabolism, the hypoglyce­
mic response of the fetal organism after delivery was not 
diminished when tocolytic treatment had been given for a 
longer period of time (table 4.8). 
In disagreement with Blouin and associates (1976), 
strong evidence was found in this study for a fall in 
neonatal plasma glucose levels soon after birth as a 
result of antenatal exposure to a ß-mimetic agent. 
A highly significant difference was measured between 
the plasma glucose concentrations of infants whose mothers 
were treated within 48 hours before delivery and control 
neonates of the same gestational ages. This difference 
was not seen when treatment had been stopped for three 
days or more before delivery. 
Moreover, when the treated infants were compared according 
to whether the treatment - delivery interval was 2 days or 
less, or 3 days or more, infants with shorter intervals 
between exposure and delivery were found to have lower 
plasma glucose concentrations than those with the larger 
t - d intervals. These findings are in line with the 
greater incidence of hypoglycemia reported by Brazy and 
Pupkin (1979) and Epstein and associates (1979) in 
neonates from patients who received ß-mimetic substances 
shortly before delivery. So adequate time to recover from 
exposure to the ß-adrenergic influence seems to be of 
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importance in the infant's ability to maintain a certain 
blood glucose level directly after birth. 
There was no significant correlation between the 
delivery-measurement interval and the plasma glucose 
concentration which was found in either the control or 
treated patients on the whole. When analysis was re-
stricted to preterm infants who were still exposed to 
3-mimetics 48 hours before delivery, however, a downward 
trend in the mean plasma glucose levels was seen within 
the first 30 minutes of life. This could be the result of 
a synergism between two hypoglycemic threats : 
prematurity, and recent exposure to a ß-mimetic agent. 
With relation to the metabolic alterations in the 
fetal organism after ß-mimetic treatment of the mother, 
there are principally two levels to consider : 
A. Indirect, via ß-mimetic drug influence upon the mater-
nal organism 
The drug-induced increase in maternal glucose concen-
trations may alter the maternal-fetal transfer of carbo-
hydrate, fat metabolites and minerals during and after the 
establishment of a new maternal metabolic homeostasis. 
Because of the prompt transport across the placenta, this 
may lead to an elevation in fetal blood glucose concentra-
tion. It has been shown that repeated or continuous fetal 
hyperglycemia can trigger the fetal pancreatic ß-cell to 
increase its secretion of insulin. 
Alteration of the uteroplacental circulation as a re-
sult of the changed maternal cardiac output and also pos-
sible direct effects of the ß-mimetic agent upon the 
uteroplacental vascular bed may influence the amount of 
substrate available to the fetal carbohydrate metabolism. 
These alterations which can effect either an increase or 
decrease in the uteroplacental blood flow, have been shown 
to be drug, dose and duration dependent in animals 
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(Brennan et al., 1977). 
В. Direct ß-stimulated responses of the fetus itself 
Recent evidence indicates that increased fetal blood 
glucose levels after B-mimetic treatment of the mother 
could partially be attributed to ß-stimulated effects 
within the fetal organism. In a chronic sheep prepara-
tion, Ehrenkranz and associates (1976) found a significant 
rise in fetal blood glucose concentration after infusion 
of ritodrine directly into the fetus, without changes in 
the maternal blood glucose level. 
In human pregnancy, Esteban-Altirriba and colleagues 
(1974) noted an elevation in fetal blood glucose concen-
tration, independent of maternal blood glucose changes and 
thus probably as a direct effect of ritodrine on the 
fetus, after simultaneously infusing ritodrine and practo-
lol. The resulting hyperglycemia could stimulate insulin 
secretion by the fetal pancreas. 
As mentioned before, there also seems to be a direct in-
fluence on the pancreatic ß-adrenergic receptors, leading 
to increased insulin secretion (Taylor et al., 1976). 
Indeed, Epstein and coworkers (1979) measured increased 
insulin levels in umbilical cord serum when fenoterol or 
terbutaline had been administered shortly (< 48 hours) 
before delivery. 
The potential mechanisms predisposing to a neonatal fall 
in glucose concentration after direct ß-mimetic influence 
upon the fetal organism are twofold ; for not only may 
this lead to an elevation in fetal blood insulin concen-
tration at delivery secondary to the elevated glucose 
level or via a possible direct effect on the fetal pan-
creas, but also ß-mimetic stimulation could lead to de-
pletion of fetal glycogen stores as a result of ß-stim-
ulated glycogenolysis in the fetal liver. 
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An unexpected difference was found between the neo-
natal plasma glucose levels with respect to the specific 
drug that was used. Children exposed in utero to fenote-
rol had lower plasma glucose levels than those whose 
mothers were treated with ritodrine. These differences 
were found whether or not twin pregnancies had been ex-
cluded and also after subdivision according to gestational 
age and t - d interval. 
Even more suprising was the finding of the same difference 
in plasma glucose levels in full term infants with t - d 
intervals of more than 2 days. Among ritodrine treated 
patients, differences in neonatal plasma glucose levels 
were found to disappear with increasing t - d intervals 
whereas among infants whose mothers received fenoterol, 
this "recovery" was not observed. 
No bias factor could be found in the patient populations 
to account for these differences (Table 4.11), thus the 
possibility of qualitative as well as quantitative differ-
ences in the effects of these two agents on carbohydrate 
metabolism must be considered. A comparison of these two 
drugs in their capacity to lengthen the duration of 
pregnancy after symptoms of imminent preterm delivery, and 
cardiovascular side effects has previously been published 
(Essed et al., 1978) . 
Certainly this subject deserves further investigation. 
One additional point of clinical relevance is evident 
from the data relating neonatal glucose values to the in-
terval between delivery and sampling. That is, that in the 
premature infants recently exposed to ß-mimetics a hypo-
glycemic tendency may already be established within 30 
minutes after birth. 
Therefore, monitoring of glucose values should be started 
very early in these infants in order to recognize and 
correct promptly neonatal hypoglycemia. Furthermore, when 
fenoterol has been employed, the early hypoglycemic effect 
may persist even when the interval from last dose to de-
livery has been several days. 
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Chapter 5 
Influence of long-term betamimetic drug administration during pregnancy 
on the early post partum blood loss 
5.1. Introduction 
Among the factors responsible for post partum hemor-
rhage one has to consider the incomplete contraction and 
retraction of the myometrium. Beta-adrenergic drugs are 
known to inhibit uterine contractions. Therefore the in-
fluence of these drugs on post partum blood loss was 
studied. 
If there is any influence of ß-mimetic drugs on the 
blood loss after delivery, this could be expected mainly 
in those patients who were treated until the day of deliv-
ery. The current study was therefore confined to patients 
delivered before the 38th week of amenorrhea, for only 
among prematurely delivering mothers were a substantial 
proportion of the patients still being treated until 
within 24 hours of delivery. 
5.2. Materials and methods 
Blood loss was measured during the 45 minutes after 
delivery of the fetus in all patients treated with ß-mi-
metic drugs for the prevention of premature birth who 
delivered vaginally from January, 1975 until January, 
1979, with amenorrheas at delivery between 29 and 38 weeks 
(n = 129). Beginning immediately after clamping and 
division of the umbilical cord, fluid blood and clots were 
collected in a basin placed beneath the patient's hips. 
The volume of this blood loss was measured directly. The 
amount of blood absorbed by sponges and drapes was obtain-
ed by weighing. 
For comparison with the treated patients the amount of 
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blood loss post partum was measured in the same way in all 
other (not treated) patients who delivered vaginally after 
an amenorrhea between 29 and 38 weeks (n = 176) , from 
January 1975 until January 1977. 
Patients with polyhydramnios, myomas of the uterus, pa­
thology of the placenta, manual removal of the placenta, 
forceps- or vacuum-assisted delivery, laceration of cervix 
or vagina, third-degree perineal laceration or multiple 
pregnancy were not included in the study, because of the 
influence that these factors may have upon the blood loss 
post partum. 
The treated patients had received fenoterol and/or 
ritodrine. In general, these tocolytic agents were admin­
istered intravenously for at least 2 days at the minimum 
dosage necessary to stop labor. The mean of the maximum 
i.v. dosages were 300 + 199 mcg/min, range : 67 - 800 
mcg/min for ritodrine, and 4.3 + 2.4 mcg/min, range : 1.0 
-8.0 mcg/min for fenoterol. 
The dosage was then decreased ; and if uterine contrac­
tions did not return, oral treatment with 5 mg fenoterol 
or 10 mg ritodrine, 6 to 12 times daily, was substituted. 
With several patients, however, treatment was started 
orally. In general, medication was continued until the 
end of the 37th week of gestation. Intravenous therapy 
only was used in 56 patients, oral therapy only in 23 
patients, and 50 patients were treated both intravenously 
and orally. 
Ritodrine was given to 61 patients ; and fenoterol, to 58 
patients. Ten women were treated with both β-agonists. 
The duration of medication was less than 7 days in 35 
patients (27 % ) . Ninety-four patients were treated for 
one week or more. The intervals between the end of treat­
ment and delivery (t-d interval) are presented in table 
5.1. 
Management of the third stage of labor was similar in 
all deliveries and did not change during the 4 year study 
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Table 5.1 TIME INTERVAL BETWEEN THE END OF 
TREATMENT AND DELIVERY (T - D INTERVAL) 
< 24 hrs 64 patients (50 %) 
24 - 48 hrs 19 patients (14 %) 
Ì. 48 hrs 46 patients (36 %) 
period : after watchful waiting until the placenta had 
separated, which was indicated by the umbilical cord pro-
truding farther out of the vagina, and ascertaining that 
the uterus was contracted, the patient was asked to bear 
down, while at the same time the muscles of the abdominal 
wall were supported manually without touching the fundus 
(Baer method). During this manoeuvre, the umbilical cord 
was kept slightly taut. After removal of the placenta, 
the uterus was watched constantly for at least 45 minutes 
during which time repair of the episiotomy, if performed, 
was carried out. if at any time excessive or brisk 
bleeding was observed, uterine contractility was assessed 
and the cervical, vaginal and perineal regions were 
promptly inspected to identify the source of the bleeding. 
Five units of oxytocin was injected intramuscularly after 
the delivery of the infant in 31 % of the treated and also 
in 31 % of the control patients. 
Fundal pressure to hasten delivery at the end of the 
second stage was applied in 20 % of the treated patients 
and in 23 % of the controls. 
A mediolateral episiotomy mainly to protect the head 
of the premature infant was performed in 57 % of the β-mi­
metic treated patients and in 51 % of the control women. 
The mean duration of the second stage of labor was 
similar for both groups of patients : 17 + 14 min when 
treated with a 6-agonist and 19 + 13 min for the control 
patients (P = 0.40). 
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In 15 % of the treated patients, labor was induced by 
intravenous administration of oxytocin, mostly following 
spontaneous rupture of the membranes without effective 
contractions. For the controls, this percentage was 28 %. 
Birth weights were similar in both groups : 2453 + 577 
grams versus 2462 + 676 grams, for treated and control 
infants respectively (P = 0.52), altnough a difference was 
found in the placental weights ; mean + SD of the placen-
tal weights in the group of treated women were 438 + 122 
grams, compared to 394 + 118 grams among the untreated 
patients (p < 0.002). All placentas were prepared in the 
same way before weighing : membranes and umbilical cord 
were removed and a period of at least 10 minutes was 
allowed for drainage of liquid blood from the intervillous 
space and major fetal vessels. 
The gestational ages of the groups were not the same, 
the ß-mimetic treated patients being more premature : 247 
+ 14 days versus 251 + 14 days in the control group 
(P < 0.001). 
Table 5.2 COMPARISON OF PARITY IN THE TREATED AND 
UNTREATED PATIENTS * 
(previous pan 
0 
1 
2 
3 and more 
ty) 
treated 
58 (45 %) 
43 (33 %) 
15 (12 %) 
13 (10 %) 
untrem ed 
101 (57 %) 
48 (23 %) 
21 (12 %) 
6(3·.) 
129 176 
* ρ < 0.05 Mann-Whitney U-test 
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The distribution of parities is given in table 5.2. 
Parities were higher among the treated patients 
(P < 0.05). 
The significance of differences in the several parame-
ters was tested by means of the Mann Whitney U-test (two 
tailed) and the Kruskal-Wallis one-way analysis of 
variance by ranks. 
Results are expressed as means + standard deviations. 
5.3. Results 
In the control group, post partum blood loss was found 
to be significantly affected by the presence of an episio-
tomy, and by placental weight. In the treated patients, 
also, blood loss was increased with episiotomy ; however, 
the relationship with placental weight was less profound. 
Comparison between ß-mimetic treated and non-treated sub-
jects demonstrated no increase in postpartum blood loss 
after 0-mimetic treatment. In some categories, blood loss 
was significantly less in the treated than in the un-
treated patients. 
In the control group the average post partum blood 
loss was found to be about 100 ml higher for patients with 
an episiotomy than for those without (mean + SD : 417 + 
342 ml, η = 89, versus 308 + 315 ml, η = 87 ; ρ < 0.002). 
The difference in placental weights between patients with 
an episiotomy and patients without was not significant 
Op = 0.82), but a tendency was found towards higher birth 
weights in the patients with episiotomy (2585 + 552 grams 
versus 2336 + 766 grams ; ρ = 0.07). 
When comparison was restricted to patients with babies 
weighing over 2500 grams at birth, the mean increase of 
blood loss after episiotomy was 117 ml. 
Among the treated patients, the amount of post partum 
blood loss in the women who had an episiotomy was in aver­
age about 125 ml greater than when no episiotomy was 
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performed. No differences between the placental weights 
of these two subgroups were found (p • 0.94), but here the 
birth weights of the infants born from mothers who had an 
episiotomy were lower than birth weights of infants of 
mothers who had no episiotomy (2348 + 603 grams versus 
2594 + 511 grams ; ρ < 0.01). In the case of treated 
mothers whose infants had birth weights over 2500 grams, 
the extra blood loss after an episiotomy was 199 ml (438 + 
293 ml as compared to 239 + 179 ml ; ρ < 0.002). 
Table 5.3 MEAN + SD OF THE AMOUNT OF EARLY POST PARTUM BLOOD LOSS OF UNTREATED AND 
TREATED PATIENTS IN RELATION TO THE DURATION OF THE SECOND STAGE OF LABOR 
Not treated 
Duration of second stage 1 - 10 mm 11 - 20 mm 21 - 60 min 
al l patients 
% episiotomy 
without episiotomy 
placental weight 
350 - 600 gr 
322 + 298 ml (61) 380 + 354 ml (57) 398 + 349 ml (56) 
33 % 54 % 64 % 
335 + 289 ml (26) 420 + 507 ml (16) 311 + 198 ml (15) 
I Ρ = 0.67 — I I Ρ = NS 
Ρ = 0.92 
Treated 
Duration of second stage 1 - 10 m m 11 - 20 mm 21 - 60 mm 
al l patients 
% episiotomy 
without episiotomy 
placental weight 
350 - 600 gr 
271 + 233 ml (50) 348 + 257 ml (44) 364 + 298 ml (34) 
46 % 6 8 % 59 % 
179 + 108 ml (18) 248 + 164 ml (11) 253 + 203 ml (11) 
I Ρ = NS 1 I Ρ = NS 1 I 
Ρ = NS 1 
Table 5.3 gives the means and S.D. of the post partum 
blood loss of treated and untreated women in relation to 
the duration of the second stage of labor with considera-
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Table 5.4 MEAN + SD OF THE AMOUNT OF EARLY POST PARTUM BLOOD LOSS OF UNTREATED 
AND TREATED PATIENTS ACCORDING TO THE WEIGHT OF THE PLACENTA 
Not treated 
All patients 
Birth weights 
2500 - 3500 gr 
Placental weight 
^ 400 gr 
282 + 271 ml (105) 
264 + 216 ml ( 34) 
Without episiotomy 247 + 318 ml ( 56) 
Gestational age : 
Placental weight 
> 400 gr 
483 + 379 ml (71) 
497 + 382 ml (52) 
419 + 282 ml (31) 
< 0.0001 
< 0.002 
< 0.0005 
36 - 37 weeks 303 + 210 ml ( 62) 456 + 362 ml (50) < 0.05 
Treated 
All patients 
Birth weights 
2500 - 3500 gr 
Placental weight 
< 400 gr 
254 + 191 ml (SO)" 
345 + 265 ml (12) 
Without episiotomy 219 + 184 ml (23) 
Gestational age : 
- 37 weeks 276 + 244 ml (18) 
Placental weight Ρ 
> 400 gr 
363 + 290 ml (76) < 0.05 
338 + 272 ml (42) 0.82 
255 + 177 ml (31) 0.22 
357 + 295 ml (39) 0.32 
3 missing values 
tion of placental weights and episiotomy. Among the 
untreated patients, the duration of the second stage was 
found to be of little influence upon the blood loss after 
delivery. In the treated group the differences in post 
partum blood loss between shorter and longer durations of 
the second stage of labor seemed to be more pronounced, 
but these data were biased by a higher episiotomy rate in 
the patients who had longer expulsion times. 
Moreover, treated patients with episiotomy who delivered 
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after a second stage of more than 15 minutes were found to 
have higher birth weights and placental weights. 
When the comparison was standardized according to placen-
tal weights, no significant difference in the amount of 
post partum blood loss with respect to the duration of the 
second stage of labor was found. 
A highly significant difference in the amount of blood 
loss after delivery was found according to the weight of 
the placenta in the untreated patients. With the smaller 
placentas (•£ 400 grams) a significantly lower blood loss 
was measured than when the placental weight was over 400 
grams (p < 0.0001). These differences were also found 
after standardizing for birth weight, gestational age and 
episiotomy. Among treated patients, a dissimilarity in 
the amount of post partum blood loss was only evident for 
the entire group of patients, and this difference disap-
peared after standardizing for birth weights, episiotomy, 
or gestational age (table 5.4). 
Fundal pressure was not found to increase the quantity 
of post partum blood loss to a significant degree either 
among treated patients or in the control group. 
Nor was the intramuscular injection of 5 units of 
oxytocin after the delivery of the child of significant 
influence upon the total blood loss. 
Table 5.5 and 5.6. summarize the data with respect to 
the effect of birth weight and gestational age on the 
amount of blood loss after delivery ; when the patients 
were grouped according to equivalent placental weights, no 
significant differences in early post partum blood loss 
were seen among either the treated or non-treated women. 
When treated patients (as a whole) were compared to 
non-treated patients, the mean amount of blood loss after 
delivery seemed quite similar in the treated and control 
groups : 321 + 261 ml (n = 129) versus 363 + 333 ml 
(n = 176) (p = 0.37 ; table 5.7). However, when the pa-
tients were compared after subdivision according to pla-
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Table 5.5 MEAN + SD OF THE AMOUNT OF EARLY POST PARTUM BLOOD LOSS ACCORDING 
TO THE BIRTH WEIGHTS 
Not treated 
All patients 
Patients with 
placental weights 
350 - 600 gr 
Patients without 
episiotomy 
Treated 
All patients 
Patients with 
placental weights 
350 - 600 gr 
Patients without 
episiotomy 
Birth weights 
4 2500 gr 
306 + 296 ml (84) 
376 + 367 ml (38) 
274 + 335 ml (46) 
Birth weights 
ΐ 2500 gr 
311 + 264 ml (72) 
335 + 301 ml (47) 
260 + 205 ml (26) 
Birth weights 
> 2500 gr 
415 + 356 ml (92) 
428 + 377 ml (74) 
346 + 290 ml (41) 
Birth weights 
> 2500 gr 
332 + 258 ml (57) 
307 + 250 ml (43) 
239 + 179 ml (29) 
Ρ 
< 0.03 
0.74 
0.11 
Ρ 
0.45 
0.91 
0.90 
cental weight, duration of the second stage of labor, or 
presence of episiotomy, differences were found between the 
treated and non-treated women : patients with placental 
weights of over 400 gr (p < 0.05) as well as patients with 
a short duration (1 - 10 min) of the second stage of labor 
(p = 0.09), and women without episiotomy had lower blood 
loss after delivery when they were treated with ß-mimetic 
drugs during pregnancy compared to those who were not 
treated (table 5.7). 
A tendency to an increase in post partum blood loss 
was seen in patients who were treated until within 24 
hours before delivery in comparison to the women in whom 
treatment had been stopped for several days (p = 0.10), 
and, moreover, when these subgroups were compared sépa-
las 
Table 5.6 EFFECTS OF GESTATIONAL AGE UPON THE EARLY POST PARTUM BLOOD LOSS 
.Vot treated 
All patients 
Patients with 
placental wei 
350 - 600 gr 
Treated 
All patients 
Patients with 
placental wei 
350 - 600 gr 
ghts 
ghts 
Amenorrhea 
23 - 36 weeks 
350 + 390 ml (64) 
475 + 473 ml (34) 
Amenorrhea 
29 - 36 weeks 
313 + 247 ml (71) 
329 + 270 ml (46) 
Amenorrhea 
36 - 37 weeks 
371 + 296 ml (112) 
382 + 318 ml ( 78) 
Amenorrhea 
36 - 37 weeks 
330 + 278 ml (58) 
314 + 287 ml (44) 
Ρ 
0.07 
0.70 
Ρ 
0.91 
0.47 
Presented are the mean values and standard deviations. 
rately with the control patients, only the patients in 
whom treatment had been terminated more than 24 hours 
before delivery were found to have significantly lower 
post partum blood loss than the untreated women (p < 0.01; 
table 5.7). 
The duration of treatment was not found to effect the 
amount of blood loss after delivery. 
No difference in post partum blood loss was found with 
respect to the specific drug which was used (table 5.8). 
The ritodrine-treated patients and the fenoterol-treated 
women were comparable according to the relevant factors 
including incidence of episiotomy, placental weight and 
duration of pregnancy. However, a significant difference 
was found with relation to the duration of the second 
stage of labor, with the ritodrine-treated women having a 
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Table 5.7 
MEAN + SD OF THE EARLY POST PARTUM BLOOD LOSS OF UNTREATED AND TREATED PATIENTS 
Untreated Treated 
I. All patients 363 + 333 ml (176) 321 + 261 ml (129) 0.37 
II. According to placental weight *x 
ΐ 400 gr 282 + 271 ml (105) 254 + 191 ml 
> 400 gr 483 + 379 ml ( 71) 363 + 290 ml 
III. According to episiotomy * 
with episiotomy 470 + 394 ml ( 55) 404 + 323 ml 
without episiotomy 352 + 343 ml ( 57) 218 + 155 ml 
IV. According to duration of second stage 
1 - 10 min 363 + 324 ml ( 37) 
11- 20 min 438 + 453 ml ( 30) 
21- 60 min 434 + 358 ml ( 44) 
V. According to treatment-delivery interval 
< 24 hours 410 + 372 ml (112) 366 + 297 ml 
Ï. 24 hours 410 + 372 ml (112) 281 + 253 ml 
255 + 239 ml 
334 + 256 ml 
408 + 332 ml 
( 35) 
( 29) 
( 25) 
0.09 
0.54 
0.72 
50) 0.72 
76) < 0.05 
50) 0.37 
40) < 0.05 
43) 0.69 
47) < 0.01 
to unbias the comparison from the larger placental weights in the treated patients, 
comparisons under III, IV and V are restricted to patients with placental weights 
350 - 600 gr 
3 missing values among the treated patients 
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Table 5.8 MEAN + SD OF THE AMOUNT OF EARLY POST PARTUM BLOOD LOSS OF PATIENTS 
EITHER TREATED WITH RITODRINE OR FENOTEROL 
Ritodrine (n) Fenoterol (η) Ρ 
All patients 324 + 294 ml (61) 295 + 212 ml (58) 0.83 
Without episiotomy 250 + 199 ml (27) 236 + 165 ml (25) 0.92 
With episiotomy 382 + 344 ml (34) 340 + 235 ml (33) 0.88 
Placenta « 400 gr 254 + 188 ml (25) 258 + 205 ml (23) 0.91 
Placenta > 400 gr 385 + 349 ml (34) 319 + 216 ml (35) 0.94 
Duration second stage 
« 15 min 299 + 280 ml (41) 267 + 185 ml (32) 0.91 
Duration second stage 
> 15 min 389 + 325 ml (19) 329 + 241 ml (26) 0.76 
t-d interval < 24 hrs 352 + 310 ml (37) 296 + 169 ml (24) 0.94 
t-d interval > 24 hrs 280 + 269 ml (24) 294 + 241 ml (34) 0.61 
greater proportion of short expulsion phases than the 
fenoterol patients (Table 5.9). 
Table 5.9 COMPARISON OF DELIVERY PARAMETERS 
AND FENOTEROL TREATED PATIENTS 
Amenorrhea at delivery 
Parity 
Birth weight 
Placental weight 
% episiotomy 
Duration second stage 
* mean + SD ** 
Ritodrine (n -
246 + 14 days * 
0.5 ** 
2358 + 497 g * 
427 + 116 g * 
56 % 
10.3 min *м 
median 
BETWEEN RITODRINE-
61) Fenoterol (n -
248 + 14 days 
0.8 
2516 + 650 g 
443 + 135 g 
57 % 
15.0 min 
S8) Ρ 
0.31 
0.17 
0.25 
0.52 
< 0.05 
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5.4. Discussion 
δ. 4.1. Comparability of subject groups 
As stated in the materials and methods section, the 
3-mimetic-treated patients in this investigation were 
collected over a 4-year period, whereas untreated subjects 
from only the first 2 years of this 4-year period were 
included in the control group. Comparison of patient 
groups collected over non-identical time periods was felt 
to be justifiable in this study for several reasons. 
First, these time limits resulted in treatment and control 
groups of approximately equivalent size for statistical 
comparison, while permitting exactly the same selection / 
exclusion criteria to be applied for both the treated sub­
jects and the potentially much more numerous control pa­
tients. In both cases, all patients delivered during the 
stated periods and meeting the stated criteria with regard 
to duration of pregnancy, singleton fetus, and route of 
delivery were included in the study. Second, there were 
no differences in age, parity, pregnancy duration at de­
livery, placental weight or average blood loss between the 
treated patients in the 3rd and 4th project years and 
those in the first 2 years of the study, suggesting that 
there was no significant change in patient population in 
the second half of the study period. Finally, there were 
no changes during the entire 4 year period in the manage­
ment of the third stage of labor, in the indications for 
operative delivery or episiotomy, or in the indications or 
techniques for stimulation of labor in this clinic. Thus, 
there is no reason to suspect that the dissimilar intake 
periods for treated and control patients introduced any 
bias into the results of the study, and simultaneously 
there are positive reasons to assert that patients and 
policies were similar during the first and second halves 
of the project period. 
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5.4.2. Factors affecting blood loss at delivery 
In the control group, blood loss at delivery was 
increased as the placental weight and, presumably, also 
the size of the placental site increased. This finding 
was not unexpected, although the relationship between size 
of the placental site and the amount of early post partum 
blood loss has not been stressed in the literature. In 
most textbooks, the tendency towards increased blood loss 
with fetal macrosomia or multiple gestation has been 
ascribed chiefly to impaired contraction and retraction of 
the previously overdistended uterus - as stated by Davis 
and Russell (1966), the amount of blood loss is "directly 
proportional to the size of the intrauterine mass". The 
finding in this study of increased blood loss with in-
creased placental size in prematurely ending singleton 
pregnancies suggests that the larger size of the placental 
site may also play a role in increasing the post partum 
blood loss with very large babies, multiple pregnancies, 
or indeed other conditions where the area of the placental 
site is increased. 
Also as expected, early post partum blood loss was 
increased in patients who had an episiotomy. 
Duration of the second stage of labor up to one hour 
did not consistently affect total blood loss. Perhaps an 
effect of uterine fatigue in promoting hypocontractile 
uterine bleeding might have become apparent had patients 
with prolonged second stage durations been included j 
however, prolongation of the second stage beyond 1 hour 
was considered an indication for operative delivery (for-
ceps, vacuum extraction). These patients therefore fell 
under the exclusion criteria for the present study. 
5.4.3. Effect of ß-mimetic treatment on early post partum blood loss 
Because of the demonstrated effects of placental size 
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and episiotomy on early post partum blood loss in the 
control group, these factors were taken into account in 
comparing blood loss between treated and untreated pa­
tients. When treated and untreated patients were grouped 
according to similar placental weights and episiotomy 
status, there was clearly no increased blood loss in the 
treated patients. In some categories, moreover, blood 
loss was less in the β -mimetic treated than in the un­
treated controls. This was the case when the placenta was 
relatively large (> 400 grams), for patients with com­
parable placental weights who had no episiotomy, and a 
tendency towards such a difference was found when the 2nd 
stage of labor was short (10 minutes or less). Further, 
the difference in blood loss between patients with large 
(> 400 grams) or smaller placentas seemed less in the 
treated than in the control group, and was not significant 
for treated patients without episiotomy. These obser­
vations indicate that control of placental site bleeding 
was not only unimpaired by chronic 3-mimetic treatment, 
but may have been even more efficient than usual in this 
group. 
There are several possible explanations for these 
findings of no increase, or even a decrease, in early post 
partum bleeding after chronic 3-mimetic treatment. It 
should be noted first that decreased blood loss, in the 
cases where it was observed, reflected decreased bleeding 
from the placental site, for extra blood loss contributed 
by episiotomy was similar in treated and in untreated 
patients. Since the major mechanism for control of pla­
cental site bleeding is contraction and retraction of the 
myometrium, the findings with regard to placental site 
bleeding of the ß-mimetic treated patients must be related 
to uterine contractility. One clear index that effective 
uterine contractility had been restored in the treated 
patients was that in 85 %, parturition began spontaneously 
and all patients had spontaneous deliveries. Thus the 
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tocolytic activity of the ß-mimetic drug had, in every 
case, either disappeared as a result of cessation of 
therapy and subsequent inactivation of the drug, or had 
been overwhelmed by whatever contraction-stimulating 
factors were responsible for the premature labor (when 
effective contractions occurred despite continuing treat-
ment) . 
The observation that, in some comparison categories, 
treated patients lost less blood at delivery than the 
untreated patients, together with the fact that these 
patients had been treated on the indication of clinically 
increased uterine activity, suggests that there may have 
been a quantitative difference in uterine contractility 
between the treated and untreated patients. Both groups 
delivered prematurely, but the amenorrhea at delivery was 
significantly shorter in the treated than untreated pa-
tients. To that must be added the fact that treatment was 
begun an average of 35 days before delivery. Thus, clini-
cally significant increased uterine activity had appeared 
earlier in pregnancy in the group of treated patients than 
in the control group. 
The decrease in blood loss was statistically signifi-
cant only in those patients where the t - d interval ex-
ceeded 24 hours. In these patients, presumably, the myo-
metrium had regained its full contractile potential. With 
a shorter t - d interval, the difference in the average 
blood loss between the treated and control patients was 
not significant. It is possible that this finding may 
reflect some small degree of persisting tocolytic effect 
of the ß-mimetics when the t - d interval was relatively 
short ; however, as stated above, the effect was insuf-
ficient to interfere with delivery or hemostasis at the 
placental site. 
These findings do not negate the fear of increased 
post partum blood loss after intrapartum application of 
ß-mimetics in term deliveries, for not only is there no 
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selection towards higher contractility characteristics of 
the myometrium in those cases, but also some degree of 
persisting tocolytic effect could interfere with hemo-
stasis at the placental site. Thus it seems reasonable to 
employ oxytocics (not ermetrine ; section 2.5.1.2) during 
the third stage of labor as a prophylactic measure when 
ß-mimetics (with half-lives similar to fenoterol and rit-
odrine) have been given during labor. 
143 
Table 6.1 
SUMMARY OF OBSTETRICAL STATISTICS FROM THE DEPARTMENT IN WHICH THIS RESEARCH WAS 
CARRIED OUT, FOR THE YEARS 1974 THROUGH 1978 
partus ì 16 weeks 
children £ 16 weeks 
immature partus 
% 
premature partus 
% 
partus ^ 28 weeks 
children 5. 28 weeks 
% perinatal mortality ^ 28 weeks 
% fetal death 
% neonatal death 
% CS. 
% forceps or vacuum 
1974 
1634 
1657 
25 
0.5 
114 
7.0 
1609 
1628 
2.2 
1.4 
0.8 
6.4 
11.5 
1975 
1649 
1672 
11 
0.7 
109 
6.6 
1638 
1660 
1.1 
0.6 
0.5 
7.4 
14.3 
1976 
1736 
1766 
13 
0.7 
162 
9.3 
1723 
1753 
2.1 
1.2 
0.9 
7.4 
13.7 
1977 
1827 
1872 
21 
1.2 
157 
8.6 
1806 
1849 
1.8 
1.1 
0.7 
8.5 
15.5 
1978 
1919 
1953 
28 
1.6 
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7.7 
1891 
1922 
1.4 
0.5 
0.9 
10.9 
11.7 
Chapter 6 
Appendix 
This study describes the influence of ß-mimetic drugs 
used for the inhibition of uterine contractions and the 
lengthening of pregnancy. Furthermore two ß-mimetic 
agents (ritodrine and fenoterol) were compared in their 
effects and side-effects. 
Perinatal mortality and morbidity data of the immature 
and premature infants mentioned in this study must be ap-
preciated in the context of the total perinatal services 
given in the years 1974 - 1978 (Table 6.1). 
The policy of the department concerning preterm labor in 
the years studied can be described as follows : when labor 
had to be accepted fetal monitoring was instituted using 
scalp-electrodes and also microblood investigations when 
indicated. Fetal scalp blood pH was not permitted to de-
crease below 7.10 before caesarean section, forceps 
delivery or vacuumextraction was performed. Episiotomies 
were preferable in vaginal deliveries, especially in nul-
liparous women with a longer duration of the second stage. 
In case of a breech presentation, caesarean section was 
favoured in the stage of early prematurity (28 - 34 
weeks) . 
When premature rupture of the fetal membranes was 
diagnosed, labor was induced in case of suspected intra-
uterine contamination or infection, as soon as L/S deter-
mination suggested fetal lung maturity, and, when no 
reliable sample of amniotic fluid could be obtained, after 
34 weeks of amenorrhea if the estimated fetal weight 
exceeded 2000 grams. 
Neonatal intensive care could be given immediately 
after birth, when necessary, by neonatologists who were 
available around the clock and were usually alerted before 
the delivery. 
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During pregnancy, labor or post partum the mother was 
evaluated for contributing factors for premature delivery; 
i.e., infections, metabolic disturbances, congenital uter-
ine anomalies, etc. Because these features were not 
studied prospectively and therefore were incomplete they 
were not included in detail in this chapter. It must be 
said, however, that apart from the self-evident causes as 
mentioned above and twins, these maternal investigations 
are disappointing, leaving too many "unknowns". This 
stresses the need for further investigations on the initi-
ation of labor (Eskes, 1979). 
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SUMMARY 
Chapter 1 
This chapter deals with the obstetrical involvement in 
by far the most important factor in the incidence of 
neonatal mortality : premature birth. Some aspects of the 
etiology, diagnosis, and prevention of preterm labor are 
reviewed from the literature and some theories about the 
initiation of labor are summarized. 
Chapter 2 
This chapter presents a review of present knowledge 
about the applications of β-adrenergic agents in human 
obstetrics. 
Clinical pharmacological aspects, indications for use 
and contraindications as well as some major side effects 
are discussed. 
A section of this chapter deals with some methods for 
the evaluation of success of different treatment regimens 
for the prevention of preterm labor. 
Also the possible usefulness of ß-mimetic therapy in 
chronic placental insufficiency, the probable beneficial 
effect upon fetal lung maturation, and the intrapartum use 
of these drugs are discussed. 
Chapter 3 
Chapter 3 presents the results of a clinical compar-
ison of ritodrine and fenoterol in their ability to 
lengthen the duration of pregnancy after the occurrence of 
threatening preterm labor. 
The patient groups were subdivided according to gesta-
tional age at the start of treatment and balanced accord-
ing to a procedure described in section 3.2.5. 
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Only subtle differences in the efficacy of therapy 
were found between the two drugs. In general the increase 
in maternal heartrate was more pronounced in the ritodri-
ne-treated patients. 
However, there seemed to be individual differences in 
acceptability of these drugs. 
Chapter 4 
The effect of long-term intrauterine exposure to 
ß-sympathomimetic tocolytic therapy (fenoterol or ritodri-
ne) on plasma glucose concentrations in the first 30 
minutes after delivery was examined in 251 infants. 
Significantly lower plasma glucose concentrations were 
measured in the first 30 minutes of neonatal life in 
children born from mothers who were treated with ß-mimet-
ics until within 48 hours before delivery, compared with 
babies from untreated mothers. 
These effects were more pronounced in premature in-
fants. 
The total period of time treatment has been given was 
not found to be of much influence. 
Infants whose mothers were treated with fenoterol had 
lower plasma glucose values in the first 30 minutes after 
delivery than those infants who were exposed to ritodrine. 
A recommendation is made to start monitoring blood 
glucose concentrations of the neonates immediately after 
delivery when ß-mimetic tocolytic treatment has been given 
to the mother, and especially if delivery occurs within 48 
hours after the termination of therapy. 
Chapter S 
During a 4 year period, early post partum blood loss 
was measured for all patients who had been treated with 
ß-mimetics for the prevention of preterm labor. 
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For comparison, post partum blood loss was measured in 
the same way in all other (not treated) patients who 
delivered with the same gestational ages during the first 
two years of the investigation. 
Only vaginal deliveries were included and some pa-
tient-categories were excluded from both groups. 
Placental weight and episiotomy status were found to 
affect the amount of early post partum blood loss at a 
statistically significant level. 
The blood loss after delivery was not found to be 
increased by long-term ß-mimetic treatment, even when this 
treatment ended less than 24 hours before delivery. 
Moreover, when the treatment - delivery interval exceeded 
24 hours, the average amount of blood lost by treated 
patients was less than that of the untreated patients in 
some comparison categories. A possible explanation for 
these findings is discussed. 
No differences in the amount of blood loss was found 
according to the specific drug that had been used. 
Appendix 
The appendix presents some information about the inci-
dence and management of preterm deliveries in the depart-
ment in which the study was done. 
149 
SJATU KONTENTI 
Kapitel 1 
A kapitel disi e taki fu a obstetrisi sey fu a moro 
principali orsaki fu dede ini a fosi wiki baka na gebortu: 
data na te na gebortu kon turnsi fruku. 
A e tjari kon na fesi, san buku skrifi fu na etiologi, fu 
a fasi fa a diagnosu musu roeki nanga fa wi kan tapu na 
fruku meki, so srefi leki sonwan teori fu fa a gebortu fu 
na pikin e bigin. 
Kapitel 2 
Na ini a kapitel disi wi e luku na bradi san wi sabi 
nojaso fu oten bere-uma musu kisi ß-adrenergica. 
Baka makandra den klinis-pharmakologisi sey, den indikasi, 
den kontra-indikasi, nanga den sey-efekti e kon na fesi. 
Moro farà prakseri e kenki na tapu sonwan fu den 
wrokofasi, fu tjari den resultati kon na doro fu den 
difrenti fasi fu tapu fruku meki. 
Fu kaba, wi sa taki, fa den β-mimetica kan kobroiki na 
te a placenta no man fu du a wroko so bun moro, fa na fasi 
e seti fu meki na logo-logo fu berepkin kon lepi, en a 
fasi fa den dresi disi musu kobroiki na den juru fu a 
gebortu fu a pikin. 
Kapitel 3 
A kapitel disi e presenter! den resultati fu wan marki 
makandra fu atoso-ondrosuku, fu kan sabi, fa ritodrine 
nanga fenoterol kan meki a marna hori bere moro langa, te 
na ten kisi, efu te fruku meki e sori en srefi. 
Den pasjenti di kobroiki ritodrine noso fenoterol wi prati 
na ini fo grupu na a bigin fu na kisi dresi, en wi poti 
den na ini balans nanga makandra na a maniri fa paragraf 
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3.2.5. sor i. 
Den tu dresi no e sori bigi difrenti na ini a hori-bere-
moro-langa-wroko. 
A ati fu a mama ben e naki moro esi nanga ritodrine. Toku 
a sori, leki ibri wan suma e piki en eygi fasi na tapu den 
dresi disi. 
Kapitel 4 
Wan ondrosuku ben meki ondro 251 pikin fu luku san e pasa 
nanga a konsentreri fu glucose na ini na brudu-plasma te a 
pikin ben ondrofeni langa ten na ini na muru a wroko fu 
den dresi san e wroko wan ß-adrenerge tocolytisi fasi. 
A ondrosuku disi ben meki ondro den pikin na ini na ten fu 
wan afu juru baka di den ben gebore. 
Efu wi poti den pikin disi na wan sey, nanga wan grupu 
pikin fu marna di no ben kisi den dresi dati na tra sey, 
dan den pikin fu na fosi grupu, sobun fu den mama di ben 
kisi g-mimetica te na 48 juru befosi den meki a pikin, ben 
sori wan krin-krin moro lagi warde glucose na ini den 
brudu, na fosi afu juru baka di den gebore, leki a kriboi 
grupu, di den mama no ben kisi dresi. 
A piki disi ben de fu si moro krin, na fruku-meki pikin. 
A glucose konsentreri fu na plasma fu den pikin na ini na 
fosi afu juru baka di den gebore, ben de moro lagi, efu 
den mama ben kisi fenoterol prefu ritodrine. Fu gi wan 
bun rai : bigin wantron-wantron baka di a pikin gebore fu 
marki omeni glucose de na ini na brudu, efu na marna ben 
kisi ß-mimetica, funamku efu a meki na pikin befosi 48 
juru pasa, baka di a tapu nanga a dresi. 
Kapitel S 
Fo jari langa, na ala den urna di ben kisi ß-mimetica, fu 
hori bere, a brudu san lasi na baka di na pikin gebore, 
ben marki. 
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Den urna disi ben poti na sey wan grupu urna, di no ben kisi 
na dresi en di ben hor i bere net so langa leki na fosi 
grupu. 
Tu jari langa den urna disi, di no ben gebroiki ß-mimetica 
dresi, ben ondrosuku. 
Soso den, di текi den pikin sondro fu den bere ben musu fu 
koti opo, ben teki prati na ini a ondrosuku disi. 
Ά brudu san lasi, ben marki na srefi fasi na ala den marna. 
A hebi fu na placenta, nanga te wan episiotomi ben de 
fanowdu, den tu sani disi ben gi wan tru-tru kenki na ini 
brudu san lasi, wantron na baka di na pikin gebore. 
Awinsi den urna ben kisi na dresi langa ten di den ben bori 
bere, toku den no ben lasi moro furu brudu, awinsi na ten 
no ben kisi 24 juru srefi di na dresi tapu, befosi na 
pikin gebore. 
Efu na dresi ben tapu moro langa leki 24 juru befosi na 
pikin ben gebore, sonwan fu den urna di ben kisi na dresi, 
no ben lasi so meni brudu srefi leki den urna di no ben 
kisi na dresi. 
A disertasi srefi e ferteri moro krin, fa dat du kon. 
Awinsi sortu wan fu den dresi ben kobroiki, den urna no ben 
sori difrinti na ini brudu san ben lasi. 
Bakapisi 
A bakapisi e gi den reglement! fu na atoso, pe na 
ondrosuku ben meki. 
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SAMENVATTING 
Hoofdstuk 1 
Dit hoofdstuk behandelt de obstetrische aspecten van 
de belangrijkste oorzaak van neonatale mortaliteit : de 
premature geboorte. Etiologische aspecten, diagnose-
stelling en preventie van de vroeggeboorte, alsmede enige 
theorieën omtrent het begin van de baring worden belicht 
vanuit de literatuur. 
Hoofdstuk 2 
In dit hoofdstuk wordt een overzicht gegeven van de 
huidige inzichten in de toepassing van ß-adrenergica in de 
humane verloskunde. Klinisch-pharmacologische aspecten, 
indicaties, contraindicaties en bijwerkingen worden 
achtereenvolgens besproken. 
Verder wordt aandacht besteed aan enkele methoden ter eva-
luatie van het resultaat der verschillende wijzen van be-
handeling ter voorkoming van vroeggeboorte. 
Tot slot volgt een beschouwing over de toepasbaarheid van 
^-mimetica bij chronische "placentaire insufficiëntie", de 
invloed op de foetale longrijping en het gebruik van deze 
medicamenten tijdens de baring. 
Hoofdstuk 3 
Hierin worden de resultaten van een vergelijkend kli-
nisch onderzoek naar de zwangerschapsverlengende werking 
van ritodrine en fenoterol bij een dreigende vroeggeboorte 
gepresenteerd. De met ritodrine en fenoterol behandelde 
patiënten werden naar amenorrhoeduur bij de aanvang van de 
behandeling in 4 klassen onderverdeeld en met elkaar in 
evenwicht gebracht volgens een in paragraaf 3.2.5. be-
schreven procedure. De zwangerschapsverlengende werking 
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toonde slechts geringe verschillen voor beide middelen. 
De gemiddelde toename in hartfreguentie was groter bij de 
met ritodrine behandelde patiënten. Er lijken echter 
individuele verschillen in tolerantie voor deze geneesmid-
delen te bestaan. 
Hoofdstuk 4 
De gevolgen van langdurige intrauteriene blootstelling 
aan ß-adrenerge tocolytische medicatie op de plasma 
glucose concentratie gedurende de eerste 30 minuten na de 
geboorte werden bestudeerd bij 251 kinderen. 
Vergeleken met kinderen van niet behandelde moeders, wer-
den in de eerst 30 minuten post partum, significant lage-
re glucose spiegels gemeten in het plasma van neonaten 
wier moeders tot 48 uur voor de bevalling behandeld werden 
met ß-mimetica. 
Dit effect was het duidelijkst waarneembaar bij prematuur 
geboren kinderen. 
Kinderen waarvan de moeders met fenoterol behandeld wer-
den, hadden in de eerste 30 minuten post partum gemiddeld 
een lagere plasma glucose concentratie dan zij bij wie 
ritodrine was toegediend. 
Aanbevolen wordt onmiddellijk na de geboorte de plasma 
glucose spiegel van de neonaat te bepalen, wanneer de 
moeder behandeld werd met β-mimetica, zeker indien de be­
valling plaatsvindt binnen 48 uur na het staken van de 
therapie. 
Hoofdstuk 5 
Gedurende een onderzoeksperiode van 4 jaar werd het 
direct na de bevalling optredend bloedverlies bepaald bij 
alle patiënten die ter preventie van een vroeggeboorte met 
ß-mimetica werden behandeld. Een controle groep werd 
gevormd uit alle andere (niet behandelde) patiënten die 
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bij dezelfde amenorrhoeduur bevielen in de 2 eerste jaren 
van het onderzoek en waarbij het bloedverlies post partum 
op dezelfde wijze gemeten werd. 
Alleen patiënten die vaginaal bevielen, werden onderzocht 
en in beide groepen werden diverse categorieën patiënten 
uitgesloten van het onderzoek. Het placentagewicht en een 
episiotomie bleken een significante invloed op het bloed-
verlies direct na de bevalling te hebben. 
Het bloedverlies bleek niet verhoogd te zijn na langdurige 
behandeling met S-mimetica tijdens de graviditeit, zelfs 
niet wanneer deze minder dan 24 uur ante partum nog 
plaatsvond. 
Indien de behandeling meer dan 24 uur voor de bevalling 
gestaakt werd, was in enkele subgroepen het bloedverlies 
na de bevalling bij de behandelde vrouwen gemiddeld zelfs 
geringer dan bij de onbehandelde patiënten. Een mogelijke 
verklaring hiervoor wordt besproken. 
Met betrekking tot het middel waarmee werd geremd, werden 
er bij de behandelde patiënten geen verschillen in bloed-
verlies gevonden. 
Appendix 
De appendix bevat enige informatie over de incidentie 
van, en het beleid bij, de voortijdige bevalling in het 
instituut waar het onderzoek werd verricht. 
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Stellingen behorend bij het proefschrift: 
"Aspects of human tocolysis with adrenergic agents" 
G. G. M. ESSED, 20 februari 1981 
I 
Bij pasgeborenen die intra-uterien aan ß-adrenergica zijn bloot-
gesteld, dient binnen 30 minuten post partum de glucose concen-
tratie in het plasma gecontroleerd te worden. 
Dit proefschrift. 
II 
Zwangerschapsverlenging uitgedrukt als percentage van de na-
gestreefde therapieduur is een betere maat voor de potentie van 
een tocolyticum dan de zwangerschapsverlenging op zich. 
Ill 
Bij een aanzienlijk deel van de vrouwen die wegens een dreigende 
vroeggeboorte met bedrust en tocolytica worden behandeld, is 
bedrust alléén als therapie voldoende. 
IV 
Gezien de invloed van ß-adrenergica op de bloedstolling dient bij 
langdurig intraveneus gebruik, thrombose profylaxe te worden toe-
gepast. 
Göser, R. et al. (1980) 
Arch. Gynecol. 230, 89. 
V 
De ligging van Puddicombe vormt een waardevolle bijdrage aan de 
preventie van een occipito-posteriore achterhoofdsligging in de 
uitdrijvingsperiode. 
Puddicombe, J. F. 11955) 
J. int. coll. surg. 23, 73. 
VI 
Fluor genitalis is een juistere benaming voor het symptoom dat 
thans nog te vaak met fluor vaginalis wordt aangeduid. 
VII 
Het gebruik van jodiumtinctuur in de nabijheid van elektrische ap-
paratuur is niet zonder risico. 
Vili 
Het risico ten aanzien van het herhaald optreden van een vroegge-
boorte bij een partus praematurus in de voorgeschiedenis kan ver-
kleind worden door specialistische prenatale zorg. 
Smits F. (1981) 
Academisch Proefschrift, Nijmegen. 
IX 
De trage verandering van de attitude ten aanzien van het roken, 
van sociale activiteit tot asociaal gedrag, is voor menig roker nau-
welijks bij te houden. 
X 
Het effect van door rokers geproduceerde luchtvervuiling op niet-
rokers dient in wetenschappelijk onderzoek naar de gevolgen van 
tabaksgebruik betrokken te worden. 
White, J. R. en Froeb, H. F. (1980) 
N. Eng. J. Med. 302, 720. 
XI 
Echoscopisch onderzoek draagt bij tot de betrouwbaarheid van een 
LU .CD. als contraceptivum. 
Schmidt, E. H. et al. (1979) 
Geburtsh. u. Frauenheilk., 39, 138. 
XII 
Staande blijven op het hellend vlak dat ontstaat wanneer de demo-
cratische principes in een land wegvallen, vereist een hoge graad 
van acrobatisch vermogen. 
XIII 
De nauwelijks ontwikkelde afscheidingsgedachte in Limburg ge-
tuigt van een hoge mate van zelfbeheersing in deze provincie. 


